10-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K

(X) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the Fiscal Year Ended September 30, 2013

OR

( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the transition period from N/A to N/A

Commission File Number: 000-28745

Cloud Medical Doctor Software Corporation

(Name of small business issuer as specified in its charter)

(Formerly National Scientific Corporation)

Texas	86-0837077
State of Incorporation	IRS Employer Identification No.

1291 Galleria Drive, Suite 200

Henderson, NV 89014

(Address of principal executive offices)

(702) 818-9011

(Issuer’s telephone number)

Securities registered under Section 12(b) of the Exchange Act:

None

Securities registered under Section 12(g) of the Exchange Act:

Common Stock, $0.01 par value per share

(Title of Class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. [ ] Yes [x] No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. [ ] Yes [x] No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [ ] Yes [x] No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). [ ] Yes [x] No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [x]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	[ ]	Accelerated filer	[ ]
Non–Accelerated filer	[ ]	Small reporting company	[x]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b–2 of the Exchange Act). [ ] Yes [x] No

Aggregate market value of the voting stock held by non-affiliates: $5,219,871 as based on the closing price of the stock on March 30, 2013 (the last business day of the Registrant’s prior second fiscal quarter). The voting stock held by non-affiliates on that date consisted of 173,995,712 shares of common stock.

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date. As of January 31, 2014, there were 215,159,216 shares of common stock, par value $0.01, issued and outstanding 4,000,000 shares of preferred stock, par value $0.01.

Documents Incorporated by Reference: None 

Cloud Medical Doctor Software Corporation

FORM 10-K ANNUAL REPORT

FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2013 and 2012

TABLE OF CONTENTS

PART I
ITEM 1.	BUSINESS	2
ITEM 1A.	RISK FACTORS	10
ITEM 1B.	UNRESOLVED STAFF COMMENTS	16
ITEM 2.	PROPERTIES	16
ITEM 3.	LEGAL PROCEEDINGS	16
ITEM 4.	REMOVED AND RESERVED	17
PART II
ITEM 5.	MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES	18
ITEM 6.	SELECTED FINANCIAL DATA	22
ITEM 7.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	22
ITEM 7A.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	27
ITEM 8.	CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA	27
ITEM 9.	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE	48
ITEM 9A.	CONTROLS AND PROCEDURES	48
ITEM 9B.	OTHER INFORMATION	49
PART III
ITEM 10.	DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE	50
ITEM 11.	EXECUTIVE COMPENSATION	52
ITEM 12.	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS	54
ITEM 13.	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE	56
ITEM 14.	PRINCIPAL ACCOUNTANT FEES AND SERVICES	56
PART IV
ITEM 15.	EXHIBITS AND FINANCIAL STATEMENT SCHEDULES	58
	SIGNATURES	59
CERTIFICATIONS
Exhibit 31	Management Certifications
Exhibit 32	Sarbanes-Oxley Act

Special Note Regarding Forward-Looking Statements

Some of our statements under "Business," "Properties," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations,"" the Notes to Financial Statements and elsewhere in this report constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are subject to certain events, risks and uncertainties that may be outside our control. Some of these forward-looking statements include statements of:

· management's plans, objectives and budgets for its future operations and future economic performance;

· capital budget and future capital requirements;

· meeting future capital needs;

· realization of any deferred tax assets;

· the level of future expenditures;

· impact of recent accounting pronouncements;

· the outcome of regulatory and litigation matters;

· the assumptions described in this report underlying such forward-looking statements; and

· Actual results and developments may materially differ from those expressed in or implied by such statements due to a number of factors, including:

o those described in the context of such forward-looking statements;

o future service costs;

o changes in our incentive plans;

o the markets of our domestic operations;

o the impact of competitive products and pricing;

o the political, social and economic climate in which we conduct operations; and

o the risk factors described in other documents and reports filed with the Securities and Exchange Commission.

In some cases, forward-looking statements are identified by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "approximates," "predicts," "potential" or "continue" or the negative of such terms and other comparable terminology.

Although we believe that the expectations reflected in these forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither we nor anyone else assumes responsibility for the accuracy and completeness of such statements and is under no duty to update any of the forward-looking statements after the date of this report.

Table of Contents -1-

PART I

ITEM 1. BUSINESS.

General

The financial statements presented in this report are of Cloud Medical Doctor Software Corporation, a Texas corporation. When the terms “Cloud”, the “Company,” “we,” “us” or “our” are used in this document, those terms refer to Cloud Medical Doctor Software Corporation.

Our Company

The Company was incorporated in Texas on June 22, 1953 as American Mortgage Company. On May 16, 1996, the Company changed its name to National Scientific Corporation. On April 3, 2012, the Company changed its name to Cloud Medical Doctor Software Corporation (“Cloud-MD”). During 1996, the Company acquired the operations of Eden Systems, Inc. (“Eden”) as a wholly owned subsidiary. Eden was engaged in water treatment and the retailing of cleaning products. Eden’s operations were sold on October 1, 1997. From September 30, 1997 through the year ended September 30, 2001, we aimed our efforts in the research and development of semiconductor proprietary technology and processes and in raising capital to fund its operations and research.

Beginning in calendar 2002, we focused our efforts on the development, acquisition, enhancement and marketing of location device technologies. Our revenue was derived from sales of electronic devices.

On February 4, 2010, the prior Board members, Mr. Michael Grollman and Mr. Greg Szabo, voted to discontinue and wind down the operation of the Company's Mobile DVR and Location Products business. These Company assets were transferred to a Limited Liability Company named NSC Labs, LLC controlled and owned by Mr. Grollman. Mr. Grollman and NSC Labs, LLC agreed to pay the Company 2% of future revenues and $100,000. However, neither Mr. Grollman nor NSC Labs, LLC have paid any consideration for this transaction. The Company discontinued these operations in 2011.

On November 19, 2010, the prior management of the Company was terminated and a new management team began working on operations related to the Company’s medical billing software. In fiscal 2011, the year of termination of prior management, the new management team deemed that the above transaction transferring prior operations to NSC Labs, LLC was transacted in full and final settlement of the liabilities owed to the former management. Since the transaction was related to the former management team, who had the ability to affect the terms and outcomes of the liabilities, the settlement of the liabilities has been subsequently recorded as an increase to additional paid in capital.

Item 1. Description of Business

Cloud Doctor Medical Software Corporation

In 2011, Cloud introduced the Cloud-MD Office, a “Cloud Based”, 5010 ready and ICD-10 compliant, fully integrated and interoperable suite of medical software and services, designed by experienced healthcare analysts and programmers for healthcare providers, that produces “Actionable Information” to help Independent Physician Practices, New Care Delivery Models (ACO), Healthcare Systems and Billing Services optimize a wide range of business processes resulting in Increased Profits, Higher Quality, Greater Efficiency, Noticeable Cost Reductions and Better Patient Care. Current software product offerings include Practice Management, Electronic Medical Records, Revenue Management, Patient Financial Solutions, Medical and Pharmaceutical Supply Management, Claims Management and PHI Exchange.

In 2012, Cloud launched Cloud-MD Billing Services which provides management of medical claims from posting physician charges and payments into our medical billing software. The software uses a continuous insurance claim follow-up system to track and research all rejected or denied medical claims; a Comprehensive Reporting module that includes monthly financial statements sent to our clients so they can see how their practice is performing and a variety of detailed reports giving our clients the necessary information and tools used to assist in the increased production which leads to more profit; and patient account inquiries & support to assist patients with their billing and insurance questions.

Table of Contents -2-

Products and Services

Cloud-MD™ Software Products

Our applications and platforms provide real value to the individual clinician making their job easier, while at the same time benefiting other players in the health care system continuum. Cloud-MD™ has differentiated itself by using the Software as a Service (“SaaS”) Cloud Computing based business model in order to:

• Lower software and hardware startup cost for providers

· Lower per patient visit cost

· Lower IT maintenance and support cost for providers

· Lower days in account receivable

· Increase practice revenue per patient

· Lower costs for Cloud-MD™ while preserving high-value, high-margin aspects of the acquisition models for CloudMD™

· Provide a solution that makes it extremely unlikely that customers will leave for other software systems or billing services

· Offer data mining of the extremely valuable data that is captured by Cloud-MD™ software

· Offer a software solution suitable for both independent medical providers or medical billing companies desiring a Meaningful Use certified product with a feature set designed for billing companies

· Build a business model designed for fast growth and high profitability

Physician financial and clinical systems are rapidly evolving and are the main driving force to meet a heightened demand for a growing need to increase efficiencies so physicians can make better patient care and profitability decisions. Cloud-MD™’s interoperable systems optimize the physician’s ability to increase revenues, increase efficiencies, lower costs, and increase profitability.   This business process management within healthcare is better known as Revenue Cycle Management (RCM) and has the following major components:  

Cloud-MD™ Office is a fully INTEGRATED and INTEROPERABLE suite of SaaS products and medical practice services that provide the flexibility to address the ever changing business and production requirements within a medical practice setting. Physicians and their management teams prefer to have interoperable systems and services delivered by one company that also provides the installation, training, and support of those systems.

By combining an interoperable suite of systems, billing management and other services, Cloud-MD™ Office can help to increase the physician’s profitability and office efficiency by electronically: (1) documenting patient encounters; (2) automatically coding those encounters with a billing logic that is designed to maximize income; (3) analyzing the financial and clinical performance of the practice; (4) notifying the physician. By reducing paper based errors, increasing speed and accuracy of collections, and improving operational decision making, Cloud-MD™ enables the physician to improve their performance and their financial position.

Table of Contents -3-

Physicians use a multitude of products and services in their daily operations. Cloud-MD™ Office offers products and services to physicians that meet HIPAA, 5010, ICD-10 and Meaningful Use criteria and include, but are not limited to, the following:

1.	Cloud-MD™ Electronic Medical Records (“EMR”) Cloud-MD™’s EMR software can also help streamline coding and billing, appointment scheduling, prescription writing – and ultimately patient safety.
2.	Cloud-MD™’ Business Intelligence (“BI”) dashboard tool for physician practices is being developed internally for both clinical and financial applications. Business Intelligence is used to analyze the financial health of the practice and proactively address trends. Cloud-MD™’s BI has been in development for the past two years and is currently in Beta testing. The product utilizes dashboards to provide a visual display of the practice’s business health, with over 20 Key Performance Indicators (“KPI”). By streamlining these functions, the physician can better focus on having a more profitable practice. Test markets have widely applauded the product. It is anticipated that the product will be ready to market in mid-2014.
3.	Practice Management (“PM”) Software, out of all of the different kinds of medical software available, PM is the system that is most useful to every physician on a daily basis. The main reason: it is the only system that generates income from the medical services provided to patients. In addition, while some programs are designed to facilitate surgical procedures or help doctors make more accurate diagnoses, practice management programs deal with organizing the ins and outs of the daily occurrences in a medical office.
4.	Revenue Cycle Management (“RCM”) Software consists of a suite of capabilities that will help a physician’s practice identify and prevent revenue cycle losses. RCM facilitates the efficient performance of the complex financial and administrative transaction processes that healthcare groups face every day. The Cloud-MD™ solution is EHNAC, HDX, ANSI HL 7, EDI and ASP/Cloud Computing model compliant and delivered through a HIPAA secure, high-performance, high-volume web portal. Components of the Revenue Cycle Management solution include:

a.	Cloud-MD™ Claims Manager provides the most advanced and efficient Claim Lifecycle Management Solutions for all of a practice’s insurance claims during every step of the processing cycle, ensuring you receive every dollar to which you are entitled. The Claims Manager significantly improves the way physicians communicate with payers, optimize revenue capture, shorten payment cycle time, improve operational efficiencies, collectadditional revenue and better manage their revenue stream and resources.
b.	Cloud-MD™ Real-Time Insurance Eligibility Verification improves practice profitability by solving the problems with eligibility verification, the cause of three out of four insurance denials. With real-time access to approximately all electronically accessible plans, the Cloud-MD™ Eligibility Verification and Benefit Inquiry permits a provider to determine if a patient is currently eligible for coverage from a payer.
c.	Cloud-MD™ Patient Credit is a totally new concept in patient collections for the HealthCare Provider - it shifts the burden of lost revenue from the provider to the patient. It utilizes a proven system for managing the collection process from the moment of creation of the debt through the final payment, all without costing the provider any money or resources. It fully automates the payment process and benefits include: Increased Collections; Reduced A/R; Reduced Patient Bad Debt; Reduced Patient Billing Expenses; No Collection Calls; Expedites Cash Flow.
d.	Cloud-MD™ e-Payment Solution offers multiple ways to process Credit, Debit and Check transactions. It offers the lowest rates for merchant processing through either a credit card point of sale terminal or through our Virtual e-terminal. It will accept all of the major Credit and Debit cards so that you can provide more payment options to your patients.
e.	Cloud-MD™ Billing Services stands out from the crowd of medical billing companies. Cloud-MD™ Billing Services offers a complete medical billing solution, offers best-of-breed technology, an air tight medical billing process, actionable reporting and broad experience and can work its clients' medical billing systems. Cloud-MD™ Billing Services is a major component of Revenue Cycle Management and will assist physicians in maximizing their revenues as they see patients. Physicians typically pay more than they should for billing – either internal or outside services. Because Cloud-MD™ can combine the Company systems and processes within the billing company; we can quickly reduce expenses of the operation and increase profitability of the physician’s practice.

5. Patient Health Information Exchange (“PHI”) offers a new concept in referrals management, physician-to-physician communications and physician-to-patient communications. With complete HIPAA compliant security and use of already familiar electronic tools such as an Electronic Medical Records (“EMR”)/Electronic Health Records (“EHR”), email or a FAX machine, Patient Health Information can be easily and securely transmitted and retrieved by only the intended parties.

Table of Contents -4-

6.	Information Security (“IS”) offers CipherLoc™, the most comprehensive security coverage available and easily complies with HIPAA guidelines. CipherLoc™ is a patent pending, state-of-the-art Polymorphic Cipher Engine that was created as an advance Polymorphic Key Progression Algorithm (“PKPA”) cipher engine. CipherLoc™ is an industry changing, ground breaking and innovative solution for making all digital communications virtually impenetrable, thus, giving any corporation or individual the capability to achieve virtually the same security offered by a One Time Pad (OTP), the most secure cipher solution known, without all of the disadvantages. The CipherLoc™
7.	Healthcare Inventory Management (“IM”) is a sophisticated, yet easy-to-use, solution for inventory management and product acquisition as well as a resource for accessing detailed, actionable information about specific product usage in order to help streamline current processes and procedures to manage the costs and complexities of the internal inventory cycle of a healthcare business.
8.	Practice Optimization Consulting is an audit based service performed on the individual practice in order to make recommendations on ways to improve efficiencies and increase revenues. Our team of experts will analyze how your practice functions and looks at your specific systems and needs. Based on our findings, we will help you develop a program that will improve the efficiency of your practice, leading to higher profits.
9.	Cloud MD Cross Border Verticals provides ancillary income to its members and will provide physician members the opportunity to increase their personal revenue by receiving dividends from the Company for buying goods and services they are required to have. As mentioned earlier, physicians indirectly control 50 – 60% of all healthcare spending. Cloud MD Cross Border Verticals gives the physician the opportunity to benefit financially from this type of spending.
10.	Company Owned Services offers opportunities for physicians to potentially share in the revenue generated by the various divisions of the company.
11.	Recurring Income Opportunities from various third party vendors like insurance purchases or group supply purchases will be negotiated and made available to share among the Cloud MD members.

Cloud-MD™ software products are fully integrated, designed as cloud based computing solutionsdeployed using the following architectural and physical models:

We have already attracted physician investors and have already begun the process of developing our “Cross Border Verticals” initiative which includes services such as Inventory Management of medical supplies and pharmaceuticals as well as program development for a Concierge Medicine initiative.

In addition, we are in negotiations with several major healthcare and healthcare solution providers, cumulatively representing several thousand medical providers, to offer a variety of products and services.

Table of Contents -5-

CipherLoc™ “To Defeat the Attacker” Software Product

CipherLoc™ is the first truly Polymorphic Cipher Engine that can be used in commercial, security sensitive applications and is far more secure than any cipher by itself. This PKPA Engine eliminates replay attacks because the cipher morphs quickly over time. It also rejects data access and injection, false commands, and data alteration. All such methods are keys to cyber intrusion, spoofing, and electronic attacks. CipherLoc™ is one facet of a layered defense in depth protection plan for any organization. Cost effective and easy to use, the CipherLoc™ Polymorphic Cipher Engine provides an electronic gate that restricts access to vital assets, production facilities, and distribution systems that comprise the backbone of today’s electronics based organizations.

This morphing cipher engine features low latency, minimal memory requirements, and small size. It is able to morph, or change at least 3,000 times per second. This is a cipher that gets stronger as technology improves rather than easier to break. While no measure cures all problems, CipherLoc™ will protect communications, networks and electronic assets better than any other cipher currently available, and just as well as the One Time Pad (OTP) without the prohibitive expense and time latency associated with the OTP.  

What is a “Polymorphic Cipher”?

A polymorphic cipher has the ability to change an encryption to another method of encryption or key on the fly and is more commonly known as a “mutating” cipher. Polymorphic ciphers are a revolutionary idea based on the information content in a message rather than the difficulty of the key. Using advanced set theory and information theory, this encryption method does not rely exclusively on large keys and complicated permutation/obscuring techniques. This makes the algorithm faster, thus, allowing cipher changes to occur VERY quickly, and requires less memory than other encryptions. Polymorphic changes take place at a rate no slower than the effective “unicity distance” (that certain amount of information needed in order to decrypt an encrypted message) of the cipher, more frequently than enough information can be collected to break the code. Most other ciphers are easily broken as hardware gets faster because it is easier to check all possible keys in the cipher key space. However, if a polymorphic cipher is implemented properly, the speed of the encryption will increase as the hardware gets faster. Thus, unlike other ciphers, this type of software becomes safer as computers get faster.

Table of Contents -6-

CipherLoc™ - Key Facts:

1.	CipherLoc™ was created as an advance Polymorphic Key Progression Algorithm (“PKPA”) cipher engine that achieves essentially the same security as a One Time Pad (“OTP”), the most secure cipher known, without all of the disadvantages.
2.	CipherLoc™ will eliminate dependence on a single type of cipher.
3.	The estimated number of keys is greater than 2.5x101500 per second. Even then the person breaking the cipher must know EVERY bit that crosses the network during the transmission period. At 100 Mbps transmission rates, this means recording a GB of information to analyze every 10 seconds.
4.	CipherLoc™ works on all operating systems and for all computing environments. More than just an obscuring algorithm, CipherLoc™ extends security without expending additional resources. It is the pinnacle of cipher technology.
5.	CipherLoc™ works using the information content of the message.
6.	CipherLoc™ prevents a cryptographer from getting enough information to recover data.
7.	CipherLoc™ keys are randomized from network traffic.
8.	CipherLoc™ prevents replay attacks because improperly encrypted messages are rejected.
9.	CipherLoc™ can use any (and all) ciphers that are peer reviewed and judged to be strong.
10.	CipherLoc™ changes block size randomly.
11.	Keys change at over 3,000 changes per second (“cps”).
12.	CipherLoc™ gets stronger with hardware and software advances.
13.	CipherLoc™ can be keyed to local or global entropy for additional security.
14.	CipherLoc™ has no need for key distribution (like an OTP) since keys are electronically determined.
15.	CipherLoc™ messages are always different. Repeating messages does not result in the same encrypted text and the same letters in different slots encrypt differently.

  16.  CipherLoc™ can be used at Layers 2-7 of the OSI Protocol Stack or within user applications. It can be run as an independent program and added as a module to the program it secures. Operation is transparent to the end user. No new transmission protocol is needed because CipherLoc™ works on the contents of the packets and does not provide a “chosen plaintext” scenario for analysis. 17.  CipherLoc™ is achievable in hardware, software, or a mix of the two. 18.   CipherLoc™ is ideal for internet and private networks. 19. CipherLoc™ works extremely well for Real Time Operating Systems and control systems.  

20.	CipherLoc™ automated key generation from a randomized source means that even if the first key is compromised the next key is not formed until the network provides the data. This prevents the so-called “rubber hose” attack.
21.	CipherLoc™ is infinitely configurable and mathematically provably secure. It allows you to have security as good as a government without the same cost and vast array of equipment.

Table of Contents -7-

CipherLoc™ - Development

CipherLoc™ is not a static product and because of its very nature will always be a “work-in-progress” so that it can always be one step ahead of contemporary hacking approaches. The CipherLoc™ initial proof-of-concept was done in conjunction with a major U.S. university recognized for its excellence in security instruction and research by the US Government. Today’s CipherLoc™ team consists of several PhD’s (math, computer science, electrical engineering and statistics), elite professors, one of whom is a Fulbright Scholar, graduate students and commercial software developers specializing in operating systems, networking and security. Collectively the development team has specialties and experience in computer science, information theory, ciphers, cryptography, set theory, tactical and strategic electronic warfare, wireless communications, networking, control systems, communications electronics, commercial telecommunications and military telecommunications. Members of the team have worked for some of the largest and most admired engineering companies in existence, have military security expertise, have designed security programs, audited utilities and other infrastructure facilities, designed legal chain of custody applications, created anti-piracy and HIPAA (defined below) programs, protected credit card information, and worked in defense industries. Cooperative research takes place at several different universities with innovative cyber security programs. Each professor leads research teams composed of specially selected researchers specializing in cutting edge mathematics and cryptography techniques for randomization and decryption. Both are used to simplify encryption algorithms and proactively “attack the hack.” The goal is to make hackers react to attacking methods in the cipher rather than to react to new attack methodologies used by the hackers. Members of the research and development team have published papers and books on cryptography and set theory, are Critical Infrastructure Protection (“CIP”) certified, are developing university programs in cyber security, and are considered experts in the field of cryptography.

The Market and Industry

Cloud-MD™ Marketing

CloudMD participates in the rapidly growing US Healthcare industry, which is expected to grow from nearly $2.0 trillion today to approximately $2.9 trillion in the next 2-5 years. Research by The American Medical Association, The Gartner Group, Datamonitor and Forrester Research and others makes it clear that healthcare provider spending has been growing annually since 2005 and is expected to continue growing through 2016, led by the IT services segment, whose annual growth rate is expected to be 6.6% compound annual growth rate.

Recent industry changes have added many challenges and complexities to the business of the medical practice (EHR transition, Patient Protection and Affordable Care Act (“PPACA”), HIPAA revisions, Accountable Care Organizations (“ACO”), ICD-10, Electronic Prescribing “eRX”, Physician Quality Reporting Solutions “PQRS”, declining reimbursement rates, increased patient payment responsibility, etc.). As such, many practices have started to reevaluate the idea of partnering with a professional medical billing or revenue cycle management firm as a possible resource for addressing some of the challenges.

As medical practices evaluate the option of outsourcing the medical billing functions verses performing the process internally, the related cost of each option should be considered. The analysis involves more than simply comparing the billing firm fee to the salary of internal billing staff. A proper analysis can illustrate a substantial price difference between the two options.

When evaluating the cost of performing billing and reimbursement functions internally, a practice should quantify: 1) Salary and Wages; 2) Benefits; 3) Training Costs; 4) Space / Real Estate / Opportunity Costs; 5) EDI Costs; 6) Patient Statement Costs; 7) Office equipment; 8) Office Supplies; 9) Communication Costs; 10) Theft/Embezzlement; 11) Billing Errors.

The fees for outsourcing are typically in the 6% - 9% range - less than the fees the practice may incur to perform billing in house. Furthermore, the cost of medical billing errors can be very expensive to the average medical practice.

If a medical billing firm can cause even a slight increase in the quality of the medical billing process, the practice may realize a double benefit in the form of increased revenue as well as decreased total overhead expenses.

Table of Contents -8-

Billing firms (i.e. Cloud-MD) can afford to charge less because of economies of scale.

Furthermore, if the billing firm is able to collect more for the practice, the cost as a percentage of total collections can be less because total collections have increased.

Given the recent increase in industry complexities, the partner billing firm can also be used as an additional resource helpful for addressing or assisting with new rules and regulations.

Cloud-MD™ has products and services that participate in this ever expanding market and the size of the market is growing as other expenses incurred by healthcare providers rise over time.

CipherLoc™ Marketing

A new concentration of risks in the cloud is driving the creation of new threat vectors. These new threats, in turn, create uncertainty about the Internet-fueled growth plans of Intel, Google, Microsoft, Yahoo, Apple, Facebook, AT&T, Verizon and just about any tech hardware, software or services company you care to name.

The market for CipherLoc™ spans the entire spectrum of digital communications and covers every industry across the globe. Potential licenses for the CipherLoc™ family of encryption technology are in the 100’s of millions of client licenses.

REGULATIONS

HIPAA - General Information

The Administrative Simplification provisions of the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”, Title II) require the Department of Health and Human Services (HHS) to adopt national standards for electronic health care transactions and national identifiers for providers, health plans, and employers. To date, the implementation of HIPAA standards has increased the use of electronic data interchange. Provisions under the Affordable Care Act of 2010 will further these increases and include requirements to adopt:

· operating rules for each of the HIPAA covered transactions

· a unique, standard Health Plan Identifier (“HPID”)

· a standard and operating rules for electronic funds transfer (“EFT”) and electronic remittance advice (“RA”) and claims attachments.

In addition, health plans will be required to certify their compliance. The Act provides for substantial penalties for failures to certify or comply with the new standards and operating rules.

For more information regarding HIPAA including additional provisions under the Patient Protections and Affordable Care Act (Affordable Care Act or “ACA”) of 2010, go to the "Related Links Outside CMS".

Related LinksPrivate and Community Cloud IaaS and PaaS Infrastructure v1.0, Published February 1, 2013

Private and Community Cloud IaaS and PaaS Infrastructure Supplement defines the enterprise-wide standard architecture for building, configuring, and deploying Infrastructure-as-a-Service (“IaaS”) and Platform-as-a-Service (“PaaS”) Cloud Infrastructure. An effective cloud infrastructure enhances productivity by providing a standards-based platform to securely manage the full system life cycle from initial provisioning through eventual retirement and de-provisioning of virtual resources, including virtual machines, storage, and networks.

This TRA supplement defines terminology and presents the business rules for use of IaaS and PaaS in private and community clouds at Center for Medicare and Medicaid Services (“CMS”). The document describes the essential characteristics of Cloud services, including on-demand service, resource pooling, rapid elasticity, and measured services, and how these services operate within the CMS multi-zone architecture. This supplement also presents guidance about planning for and deploying IaaS and PaaS-based applications that meet the expectations of CMS and its stakeholders.

Table of Contents -9-

Release Management Supplement, v1.0, Published June 28, 2013

This CMS Technical Reference Architecture – Release Management Supplement, Version 1.0 complements the CMS TRA by providing rules and engineering guidance for developing, testing, and hosting CMS distributed systems and business applications within the agency’s data center Development, Test, Implementation, and Production Processing environments.

This supplement provides the rules governing the support and use of CMS data center environments for the conduct of pre-approved, scheduled Development, Validation Testing, and Implementation Testing of distributed CMS systems, infrastructure, and business applications.

The CMS Chief Technology Officer authorizes and approves the publication of the Release Management Supplement and its contents. This supplement augments and aligns with the CMS TRA Foundation 3.0, and CMS will update it on an as-needed basis.

Personnel

As of the date of this report, we have fifteen full-time employees.

WHERE YOU CAN FIND MORE INFORMATION

You are advised to read this Form 10-K in conjunction with other reports and documents that we file from time to time with the SEC. In particular, please read our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that we file from time to time. You may obtain copies of these reports directly from us or from the SEC at the SEC’s Public Reference Room at 100 F. Street, N.E. Washington, D.C. 20549, and you may obtain information about obtaining access to the Reference Room by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains information for electronic filers at its website http://www.sec.gov.

In an effort to keep our stockholders and the public informed about our business, we may make “forward-looking statements.” Forward-looking statements usually relate to future events and anticipated revenues, earnings, cash flows or other aspects of our operations or operating results. As indicated previously, forward-looking statements are often identified by words, “will”, “may”, “should”, “continue”, “anticipate”, “believe”, “expect”, “plan”, “forecast”, “project”, “estimate”, “intend” and words of similar nature. Forward-looking statements generally include statements containing:

• projections about accounting and finances;

• plans and objectives for the future;

• projections or estimates about assumptions relating to our performance; or

• our opinions, views or beliefs about the effects of current or future events, circumstances or performance.

You should view those statements with caution. Those statements are not guarantees of future performance, circumstances or events. They are based on facts and circumstances known to us as of the date the statements are made. All phases of our business are subject to uncertainties, risks and other influences, many of which we do not control. Any of these factors either alone or taken together, could have a material adverse effect on us and could change whether any forward-looking statement ultimately turns out to be true. Additionally, we assume no obligation to update any forward-looking statement as a result of future events, circumstances or developments.

ITEM 1A. RISK FACTORS

Outlined below are some of the risks that we believe could affect our business and financial statements. An investment in our common stock involves a high degree of risk. You should carefully consider the following information about these risks, together with the other information contained in this Annual Report on Form 10-K, before investing in our common stock. If any of the events anticipated by the risks described below occur, our results of operations and financial condition could be adversely affected which could result in a decline in the market price of our common stock, causing you to lose all or part of your investment.

Table of Contents -10-

The report of our independent registered public accounting firm contains explanatory language that substantial doubt exists about our ability to continue as a going concern.

The independent auditor’s report on our financial statements for the year ended September 30, 2013 contains explanatory language that substantial doubt exists about our ability to continue as a going concern. We have an accumulated deficit at September 30, 2013 of $26,542,265 and need additional cash flows to maintain our operations. We depend on the continued contributions of our executive officers to finance our operations and need to obtain additional funding sources to explore potential strategic relationships and to provide capital and other resources for the further development and marketing of our products and business. If we are unable to obtain sufficient financing in the near term or achieve profitability, then we would, in all likelihood, experience severe liquidity problems and may have to curtail or cease our operations altogether. If we curtail our operations or cease our operations, we may be placed into bankruptcy or undergo liquidation, the result of which will adversely affect the value of our common shares.

Because we are quoted on the OTC Marketsformerly known as “Pinks Sheets” instead of an exchange or national quotation system, our investors may have a tougher time selling their stock or experience negative volatility on the market price of our stock.

Our common stock is traded on the OTCBB “OTC Markets”. The OTCBB “OTC Markets” is often highly illiquid, in part because it does not have a national quotation system by which potential investors can follow the market price of shares except through information received and generated by a limited number of broker-dealers that make markets in particular stocks. There is a greater chance of volatility for securities that trade on the OTCBB “OTC Markets” as compared to a national exchange or quotation system. This volatility may be caused by a variety of factors, including the lack of readily available price quotations, the absence of consistent administrative supervision of bid and ask quotations, lower trading volume, and market conditions. Investors in our common stock may experience high fluctuations in the market price and volume of the trading market for our securities. These fluctuations, when they occur, have a negative effect on the market price for our securities. Accordingly, our stockholders may not be able to realize a fair price from their shares when they determine to sell them or may have to hold them for a substantial period of time until the market for our common stock improves.

We depend significantly upon the continued involvement of our present management.

The Company’s success depends significantly upon the involvement of our present management, who is in charge of our strategic planning and operations. We may need to attract and retain additional talented individuals in order to carry out our business objectives. The competition for individuals with expertise in this industry could be intense and there are no assurances that these individuals will be available to us.

Our common stock is subject to penny stock regulation.

Our shares are subject to the provisions of Section 15(g) and Rule 15g-9 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), commonly referred to as the "penny stock" rule. Section 15(g) sets forth certain requirements for transactions in penny stocks and Rule 15g-9(d)(1) incorporates the definition of penny stock as that used in Rule 3a51-1 of the Exchange Act. The Commission generally defines penny stock to be any equity security that has a market price less than $5.00 per share, subject to certain exceptions. Rule 3a51-1 provides that any equity security is considered to be penny stock unless that security is: registered and traded on a national securities exchange meeting specified criteria set by the Commission; authorized for quotation on the NASDAQ Stock Market; issued by a registered investment company; excluded from the definition on the basis of price (at least $5.00 per share) or the registrant's net tangible assets; or exempted from the definition by the Commission. Since our shares are deemed to be "penny stock", trading in the shares will be subject to additional sales practice requirements on broker/dealers who sell penny stock to persons other than established customers and accredited investors.

Table of Contents -11-

Compliance with changing regulation of corporate governance and public disclosure will result in additional expenses and pose challenges for our management.

Changing laws, regulations and standards relating to corporate governance and public disclosure, including the Dodd-Frank Wall Street Reform and Consumer Protection Act and the rules and regulations promulgated there under, the Sarbanes-Oxley Act and SEC regulations, have created uncertainty for public companies and significantly increased the costs and risks associated with accessing the U.S. public markets. Our management team will need to devote significant time and financial resources to comply with both existing and evolving standards for public companies, which will lead to increased general and administrative expenses and a diversion of management time and attention from revenue generating activities to compliance activities.

The Company’s directors and officers may control the outcome of most matters submitted to a vote of shareholders.

Our directors and officers control 21.21% of the issued and outstanding common shares of the Company. They also control 100% of the supermajority convertible preferred Series A shares which allows the officers and directors to vote 150 common shares for one preferred shares they holds which is 600,000,000 common shares. The Series Preferred shareholders may also have the right to convert those shares to common shares once they have sent notice to the Board of Directors.

Also the officers and directors have change in control provisions that allows for the full payment of salary and stock in case the company is taken over by a third party. In addition to the ability of these directors and officers of the Company to vote shares representing a significant majority of the total voting power of the Company’s common shares.  (See the officers’ employment agreements).

Under Texas law, common shares of the Company owned by the officers and directors may be voted in a manner in which those votes are determined by the two directors Michael De La Garza and Pamela J. Thompson. Those directors, should they choose to act together, will be able to control substantially all matters affecting the Company, and to block a number of matters relating to any potential change of control of the Company.  See Item 12–Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

Risks Relating To Our Industry

There are substantial inherent risks in attempting to commercialize new technological applications, and, as a result, we may not be able to successfully develop products or technology for commercial use.

Our company conducts ongoing development on our medical billing software. Our product development team is working on developing technology and products in various stages. Software development requires significant amounts of capital and takes an extremely long time to reach commercial viability, if at all. During the development of our software, we may experience technological barriers that we may be unable to overcome. Because of these uncertainties, it is possible that none of our product candidates will be successfully developed.

The cloud-based computing model presents execution and competitive risks.

Our competitors are rapidly developing and deploying cloud-based services for consumers and business customers. Pricing and delivery models are evolving. Devices and form factors influence how users access services in the cloud. We are devoting significant resources to develop our own competing cloud-based software plus services strategies. While we believe our expertise, investments in infrastructure, and the breadth of our cloud-based services provides us with a strong foundation to compete, it is uncertain whether our strategies will attract the users or generate the revenue required to be successful. In addition to software development costs, we are incurring costs to build and maintain infrastructure to support cloud computing services. These costs may reduce the operating margins we have previously achieved. Whether we are successful in this new business model depends on our execution in a number of areas, including:

Table of Contents -12-

• continuing to innovate and bring to market compelling cloud-based experiences that generate increasing traffic and market share;

• maintaining the utility, compatibility and performance of our cloud-based services on the growing array of computing devices, including smartphones, handheld computers, netbooks, tablets and television set top devices; and

• continuing to enhance the attractiveness of our cloud platforms to third-party developers.

We face intense competition.

We continue to experience intense competition across all markets for our products and services. Our competitors range in size from Fortune 100 companies to small, specialized single-product businesses and open source community-based projects. Although we believe the breadth of our businesses and product portfolio is a competitive advantage, our competitors that are focused on narrower product lines may be more effective in devoting technical, marketing, and financial resources to compete with us. In addition, barriers to entry in our businesses generally are low and products, once developed, can be distributed broadly and quickly at relatively low cost. Open source software vendors are devoting considerable efforts to developing software that mimics the features and functionality of our products. In response to competition, we continue to develop versions of our products with basic functionality that are sold at lower prices than the standard versions. These competitive pressures may result in decreased sales volumes, price reductions, and/or increased operating costs, such as for marketing and sales incentives, resulting in lower revenue, gross margins, and operating income.

We may not be able to protect our source code from copying if there is an unauthorized disclosure of source code.

Source code, the detailed program commands for our operating systems and other software programs, is critical to our business. Although we license portions of our application and operating system source code to a number of licensees, we take significant measures to protect the secrecy of large portions of our source code. If an unauthorized disclosure of a significant portion of our source code occurs, we could potentially lose future trade secret protection for that source code. This could make it easier for third parties to compete with our products by copying functionality, which could adversely affect our revenue and operating margins. Unauthorized disclosure of source code also could increase the security risks described in the next paragraph.

Security vulnerabilities in our products and services could lead to reduced revenues or to liability claims. Maintaining the security of computers and computer networks is a critical issue for us and our customers. Hackers develop and deploy viruses, worms, and other malicious software programs that attack our products and gain access to our networks and data centers. Although this is an industry-wide problem that affects computers across all platforms, it affects our products in particular because hackers tend to focus their efforts on the most popular operating systems and programs and we expect them to continue to do so. We devote significant resources to address security vulnerabilities through:

• engineering more secure products and services;

• enhancing security and reliability features in our products and services;

• helping our customers make the best use of our products and services to protect against computer viruses and other attacks;

• improving the deployment of software updates to address security vulnerabilities;

• investing in mitigation technologies that help to secure customers from attacks even when such software updates are not deployed; and

• providing customers online automated security tools, published security guidance, and security software such as firewalls and anti-virus software.

The cost of these steps could reduce our operating margins. Despite these efforts, actual or perceived security vulnerabilities in our products could lead some customers to seek to return products, to reduce or delay future purchases, or to use competing products. Customers may also increase their expenditures on protecting their existing computer systems from attack, which could delay adoption of new technologies. Any of these actions by customers could adversely affect our revenue. In addition, if third parties gain access to our networks or data centers they could obtain and exploit confidential business information and harm our competitive position.

Table of Contents -13-

Our business depends on our ability to attract and retain talented employees.

Our business is based on successfully attracting and retaining talented employees. The market for highly skilled workers and leaders in our industry is extremely competitive. We are limited in our ability to recruit internationally by restrictive domestic immigration laws. If we are less successful in our recruiting efforts, or if we are unable to retain key employees, our ability to develop and deliver successful products and services may be adversely affected. Effective succession planning is also important to our long-term success. Failure to ensure effective transfer of knowledge and smooth transitions involving key employees could hinder our strategic planning and execution.

Delays in product development schedules may adversely affect our revenues.

The development of software products is a complex and time-consuming process. New products and enhancements to existing products can require long development and testing periods. Our increasing focus on cloud-based software plus services also presents new and complex development issues. Significant delays in new product or service releases or significant problems in creating new products or services could adversely affect our revenue.

Acquisitions and joint ventures may have an adverse effect on our business.

We expect to continue making acquisitions or entering into joint ventures as part of our long-term business strategy. These transactions involve significant challenges and risks including that the transaction does not advance our business strategy, that we don't realize a satisfactory return on our investment, or that we experience difficulty in the integration of new employees, business systems, and technology, or diversion of management's attention from our other businesses. These events could harm our operating results or financial condition.

Risks Related to our Securities

The market price for our common stock may be volatile, and you may not be able to sell our stock at a favorable price or at all.

Many factors could cause the market price of our common stock to rise and fall, including:

• actual or anticipated variations in our quarterly results of operations;

• changes in market valuations of companies in our industry;

• changes in expectations of future financial performance;

• fluctuations in stock market prices and volumes;

• issuances of dilutive common stock or other securities in the future;

• the addition or departure of key personnel;

• announcements by us or our competitors of acquisitions, investments or strategic alliances; and

• it is possible that the proceeds from sales of our common stock may not equal or exceed the prices you paid for the shares after including the costs and fees of making the sales

Substantial sales of our common stock, or the perception that such sales might occur, could depress the market price of our common stock.

We cannot predict whether future issuances of our common stock or resale in the open market will decrease the market price of our common stock. The consequence of any such issuances or resale of our common stock on our market price may be increased as a result of the fact that our common stock is thinly, or infrequently, traded. The exercise of any options, or the vesting of any restricted stock that we may grant to directors, executive officers and other employees in the future, the issuance of common stock in connection with acquisitions and other issuances of our common stock may decrease the market price of our common stock.

Table of Contents -14-

Holders of our common stock have a risk of potential dilution if we issue additional shares of common stock in the future.

Although our Board of Directors intends to utilize its reasonable business judgment to fulfill its fiduciary obligations to our then existing stockholders in connection with any future issuance of our common stock, the future issuance of additional shares of our common stock would cause immediate, and potentially substantial, dilution to the net tangible book value of those shares of common stock that are issued and outstanding immediately prior to such transaction. Any future decrease in the net tangible book value of our issued and outstanding shares could have a material adverse effect on the market value of our shares.

We do not intend to pay cash dividends to our stockholders, so you will not receive any return on your investment in our Company prior to selling your interest in the Company.

The Company has never paid any cash dividends to our stockholders. We currently intend to retain any future earnings for funding growth and, therefore, do not expect to pay any cash dividends in the foreseeable future. As a result, you will not receive any return on your investment prior to selling your shares in our Company and, for the other reasons discussed in this “Risk Factors” section, you may not receive any return on your investment even when you sell your shares in our Company.

Certain shares of our common stock are restricted from immediate resale. The lapse of those restrictions, coupled with the sale of the related shares in the market, or the market’s expectation of such sales, could result in an immediate and substantial decline in the market price of our common stock.

Most of our shares of common stock are restricted from immediate resale in the public market. The restricted shares are restricted in accordance with Rule 144, which states that if unregistered, restricted securities are to be sold, a minimum of one year must elapse between the later of the date of acquisition of the securities from the issuer or from an affiliate of the issuer, and any resale of those securities in reliance on Rule 144. The Rule 144 restrictive legend remains on the stock until the holder of the stock holds the stock for longer than six months (unless an affiliate) and meets the other requirements of Rule 144 to have the restriction removed. The sale or resale of those shares in the public market, or the market’s expectation of such sales, may result in an immediate and substantial decline in the market price of our shares. Such a decline will adversely affect our investors, and make it more difficult for us to raise additional funds through equity offerings in the future.

Our common stock is subject to restrictions on sales by broker-dealers and penny stock rules, which may be detrimental to investors.

Our common stock is subject to Rules 15g-1 through 15g-9 under the Exchange Act, which imposes certain sales practice requirements on broker-dealers who sell our common stock to persons other than established customers and “accredited investors” (as defined in Rule 501(a) of the Securities Act). For transactions covered by this rule, a broker-dealer must make a special suitability determination for the purchaser and have received the purchaser’s written consent to the transaction prior to the sale. This rule adversely affects the ability of broker-dealers to sell our common stock and purchasers of our common stock to sell their shares of our common stock.

Additionally, our common stock is subject to SEC regulations applicable to “penny stocks.” Penny stocks include any non-Nasdaq equity security that has a market price of less than $5.00 per share, subject to certain exceptions. The regulations require that prior to any non-exempt buy/sell transaction in a penny stock; a disclosure schedule proscribed by the SEC relating to the penny stock market must be delivered by a broker-dealer to the purchaser of such penny stock. This disclosure must include the amount of commissions payable to both the broker-dealer and the registered representative and current price quotations for our common stock. The regulations also require that monthly statements be sent to holders of a penny stock that disclose recent price information for the penny stock and information of the limited market for penny stocks. These requirements adversely affect the market liquidity of our common stock.

Table of Contents -15-

Our Articles of Incorporation allow us to sell preferred stock without shareholder approval.

Our Board of Directors has the authority to issue up to 4,000,000 shares of preferred stock and to determine the price, rights, preferences, privileges and restrictions, including voting rights, of those shares without any additional vote or action by our shareholders. The rights of the holders of the common stock will be subject to, and could be materially adversely affected by, the rights of the holders of any preferred stock that may be issued in the future. For example we could issue preferred stock that has superior rights to dividends or is convertible into shares of common stock. This might adversely affect the market price of the common stock.

If we experience delays and/or defaults in customer payments, we could be unable to recover all expenditures.

Because of the nature of our contracts, at times we commit resources to projects prior to receiving payments from the customer in amounts sufficient to cover expenditures on projects as they are incurred. Delays in customer payments may require us to make a working capital investment. If a customer defaults in making their payments on a project in which we have devoted resources, it could have a material negative effect on our results of operations.

If we do not effectively manage our growth, our existing infrastructure may become strained, and we may be unable to increase revenue growth.

Our past growth that we have experienced, and in the future may experience, may provide challenges to our organization, requiring us to expand our personnel and our operations. Future growth may strain our infrastructure, operations and other managerial and operating resources. If our business resources become strained, our earnings may be adversely affected and we may be unable to increase revenue growth. Further, we may undertake contractual commitments that exceed our labor resources, which could also adversely affect our earnings and our ability to increase revenue growth.

SHOULD ONE OR MORE OF THE FOREGOING RISKS OR UNCERTAINTIES MATERIALIZE, OR SHOULD THE UNDERLYING ASSUMPTIONS PROVE INCORRECT, ACTUAL RESULTS MAY DIFFER SIGNIFICANTLY FROM THOSE ANTICIPATED, BELIEVED, ESTIMATED, EXPECTED, INTENDED OR PLANNED

ITEM 1B. UNRESOLVED STAFF COMMENTS

This Item is not applicable to us as we are not an accelerated filer, a large accelerated filer, or a well-seasoned issuer.

ITEM 2. PROPERTIES

Starting in January 2012, the Company began sharing an office with a shareholder at 1291 Galleria Drive, Suite 200, Henderson, Nevada 89014. The office is at no cost to the Company.

ITEM 3. LEGAL PROCEEDINGS

We are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations.

On July 5, 2013, the Company filed a complaint against Krooss Medical Management Systems, LLC, William F. Krooss and Marie W. Krooss ( the “Defendants”) in the United States District Court, District of Nevada Case No. 2013-CV-01187-ABG-VCF for the collection of approximately $200,000 of unpaid medical billing fees that were seriously delinquent.

After many attempts by the Company to begin collections, the Defendants refused to pay the outstanding balances, however they expected the Company to continue to bill for them. The Complaint includes causes of action for Breach of the Permanent Asset Transfer and Purchase Agreement (“PTAPA”), Breach of Billing and Collections Contracts, Negligence, Breach of the Duty of Good Faith and Fair Dealing, Tortious Interference with Business Relations, Fraud, and other causes of action.

Table of Contents -16-

On August 13, 2013, Krooss Medical Management Systems et al filed a Complaint in Chancery Court of Rankin County, Mississippi Case No. 13-1372 apparently as a strategy to keep the collection matter in Mississippi Chancery Court.

Case No. 13-1372 was remanded to the United States District Court, Southern District of Mississippi Jackson Division Case No. 3:13CV507-HTW-LRA.

This litigation is a collection matter of unpaid fees by the Defendants and the Company denies the allegations (Breach of the PTAPA, Rescission of the PTAPA, Breach of Billing and Collections Contracts, Negligence, Quantum Meruit, Restitution, and Estoppel, Breach of the Duty of Good Faith and Fair Dealing, Tortious Interference with Business Relations, and other causes of action) filed in Mississippi Chancery Court related to this collection matter. The Company does not expect the cost to litigate this matter to adversely affect the Company’s operations. However, the Company has discontinued operations in DNA-Cloud in Mississippi as the Company believes the Defendants have interfered with the billing contracts purchased which is one of the causes of action in the Complaint, among others. The Company believes many of the contracts have been terminated due to the interference by the Defendants, and DNA-Cloud has not been able to expand the business because of the reputation of the Defendants in Jackson, Mississippi and the surrounding area.

ITEM 4. REMOVED AND RESERVED

Table of Contents -17-

PART II

ITEM 5. MARKET FOR REGISTANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Cloud’s common stock is traded in the over-the-counter market, and quoted in the National Association of Securities Dealers Inter-dealer Quotation System (“Electronic Bulletin Board) and can be accessed on the Internet at OTCmarkets.com under the symbol “NSCT.”

At September 30, 2013, there were 214,624,216 shares of common stock of Cloud outstanding and there were in excess of 902 shareholders of record of the Company’s common stock.

The following table sets forth for the periods indicated the high and low bid quotations for Cloud’s common stock. These quotations represent inter-dealer quotations, without adjustment for retail markup, markdown or commission and may not represent actual transactions.

Periods	High		Low
Fiscal Year 2013
First Quarter (October – December  2012)	$	0.04	$	0.02
Second Quarter (January  – March 2013)	$	0.04	$	0.03
Third Quarter (April - June 2013)	$	0.04	$	0.02
Fourth Quarter (July – September  2013)	$	0.04	$	0.02
Fiscal Year 2012
First Quarter (October – December  2011)	$	0.01	$	0.01
Second Quarter (January  – March 2012)	$	0.01	$	0.01
Third Quarter (April - June 2012)	$	0.03	$	0.02
Fourth Quarter (July – September  2012)	$	0.03	$	0.03

On January 24, 2014, the closing bid price of our common stock was $0.029.

Dividends

We may never pay any dividends to our shareholders. We did not declare any dividends for the year ended September 30, 2013. Our Board of Directors does not intend to distribute dividends in the near future. The declaration, payment and amount of any future dividends will be made at the discretion of the Board of Directors, and will depend upon, among other things, the results of our operations, cash flows and financial condition, operating and capital requirements, and other factors as the Board of Directors considers relevant. There is no assurance that future dividends will be paid, and if dividends are paid, there is no assurance with respect to the amount of any such dividend.

Transfer Agent

Cloud’s Transfer Agent and Registrar for the common stock is Pacific Stock Transfer located in Las Vegas, Nevada.

Recent sales of Unregistered Securities

Fiscal Year Ending September 30, 2014

In October 2013, the Company issued 25,000 shares of common stock for net cash proceeds of $5,000.

In October 2013, the Company issued 200,000 shares of common stock for purchase of assets from Antree Systems Limited. These shares were valued at $6,000 based on the market price on the date of grant.

Table of Contents -18-

In November 2013, the Company issued 180,000 shares of common stock as replacement shares for the 160,000 shares of common stock issued to Antree Systems Limited and 20,000 shares of common stock to Kimberly Ilicerl. The Company intends to cancel the original shares because the shares were lost during delivery to Antree Systems. The Company replaced those lost shares and canceled the shares that were lost when delivered to Ireland at the office of Antree Systems.

On December 4, 2013, the Company issued 120,000 shares of common stock valued at $3,600 based on the market price on the date of grant, for the purchase of software in accordance with the software licensing and subscription agreements.

On January 12, 2014, the Company issued 10,000 shares of common stock for net cash proceeds of $10,000.

Fiscal Year Ended September 30, 2013

During the year ended September 30, 2013, the Company issued 217,500 shares of common stock for $143,000 in net cash proceeds as follows:

Date		Number of Shares		Proceeds
	October 14, 2012		20,000	$	20,000
	October 14, 2012		15,000		3,000
	October 14, 2012		18,750		2,500
	October 14, 2012		18,750		2,500
	December 6, 2012		15,000		3,000
	March 12, 2013		20,000		20,000
	March 12, 2013		20,000		20,000
	March 31, 2013		50,000		50,000
	April 17, 2013		20,000		20,000
	August 26, 2013		20,000		2,000
	Total		217,500	$	143,000

Stock Issued in Connection with Software Licensing and Subscription Agreements

During the year ended September 30, 2013, the Company issued 400,000 shares of common stock valued at $13,563 based on the market price on the date of grant, to customers, in regards to the purchase of software from the Company in accordance with the Software Licensing and Subscription Agreements. The fair values of the shares issued were recorded against software revenue recognized during the year ended September 30, 2013.

Date		Number of Shares		Fair Value
	October 14, 2012		50,000	$	1,300
	December 6, 2012		100,000		2,800
	March 12, 2013		50,000		1,750
	March 21, 2013		50,000		1,750
	March 21, 2013		50,000		1,750
	April 17, 2013		25,000		838
	April 17, 2013		50,000		1,675
	June 26, 2013		25,000		450
	September 30, 2013		50,000		1,250
	Total		400,000	$	13,563

Stock Issued for Services

During the year ended September 30, 2013, the Company issued 1,165,500 shares of common stock as compensation. The fair values of the shares were a total of $36,629 and were recorded at the market price on the date of grant. The issuances of stock were as follows:

Table of Contents -19-

Date		Number of Shares		Fair Value		Description of Services
	October 14, 2012		10,000	$	260	Commission
	December 6, 2012		100,000		2,800	Software Agreement
	March 12, 2013		50,000		1,750	Consulting
	March 21, 2013		167,000		5,845	Compensation
	March 21, 2013		500,000		17,500	Compensation
	April 17, 2013		78,500		2,630	Compensation
	May 1, 2013		20,000		522	Programming
	May 10, 2013		20,000		522	Programming
	August 26, 2013		100,000		1,800	Software Sales
	September 30, 2013		60,000		1,500	Programming
	September 30, 2013		60,000		1,500	Programming
	Total		1,165,500		36,629

Stock Issued for Assets Acquisition

On April 17, 2013, the Company issued 300,000 shares of common stock valued at $6,000, based on the market price on the date of grant, to Krooss Family Trust LLP for the acquisition of Doctors Network of America in Flowood, Mississippi and all of the assets of that company.

During year ended September 30, 2013, the Company issued 500,004 shares of common stock for the acquisition of CipherSmith software. Those shares were valued at $15,800 based on the market price on the dates of grant.

Fiscal Year Ended September 30, 2012

During year ended September 30, 2012, the Company issued 190,000 shares of common stock for proceeds of $68,000 as follows:

Date		Number of Shares		Proceeds
	October 15, 2011		25,000	$	5,000
	December 29, 2011		100,000		50,000
	June 21, 2012		65,000		13,000
	Total		190,000	$	68,000

Stock Issued in Connection with Software Licensing and Subscription Agreements

During the year ended September 30, 2012, the Company issued 941,333 shares of common stock valued at $19,301 based on the market price on the date of grant, to customers, in regards to the purchase of software from the Company in accordance with the Software Licensing and Subscription Agreements. The fair values of the shares issued were recorded against software revenue recognized during the year ended September 30, 2012.

Date		Number of Shares		Fair Value
	December 29, 2011		100,000	$	1,150
	May 29, 2012		25,000		400
	May 29, 2012		50,000		800
	May 29, 2012		100,000		1,600
	May 29, 2012		150,000		2,400
	May 29, 2012		181,333		2,901
	August 9, 2012		300,000		9,000
	August 9, 2012		35,000		1,050
	Total		941,333	$	19,301

Table of Contents -20-

Stock Issued for Services

During the year ended September 30, 2012, the Company issued 33,000 shares of common stock for compensation. The fair values of the shares were a total of $624 and were recorded at the market price on the date of grant. The issuances of stock were as follows:

Date		Number of Shares		Fair Value		Description of Services
	December 5, 2011		8,000	$	82	Legal services
	December 5, 2011		10,000		102	Advisory service
	June 21, 2012		1,000		20	Commission
	August 9, 2012		14,000		420	Commission
	Total		33,000	$	624

Stock Issued for Debt Settlement

On October 15, 2011, the Company issued 30,000,000 shares of common stock for the conversion of debt from our CEO in the principal amount of $1,200,106.

Stock Issued for Assets Acquisition

The Company issued 200,000 shares of common stock on June 21, 2012 to Krooss Medical Management in accordance with the acquisition agreement for Doctors Network of America and recorded it at the market price of the common shares of $0.020 and as an investment in Krooss Medical Management of $4,000.

The Company issued 100,000 shares of common stock to MediSouth LLC in accordance with the acquisition agreement and recorded it at the market price of the common shares of $0.025 and as an investment in MediSouth LLC of $2,500.

Common Stock

On April 11, 2011, the Company amended its articles of incorporation to increase the authorized shares to 650,000,000 shares, at $0.01 par value. There were 214,624,216 shares issued and outstanding as of September 30, 2013. The holders of our common stock are entitled to receive such dividends, if any, as may be declared by our board of directors from time to time out of legally available funds. The dividend rights of our common stock are junior to any preferential dividend rights of any outstanding shares of preferred stock. The holders of our common stock also are entitled to receive distributions upon our liquidation, dissolution or winding up of our assets that are legally available for distribution, after payment of all debt and other liabilities and distribution in full of preferential amounts, if any, to be distributed to holders of our preferred stock.

The holders of our common stock are not entitled to preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of any series of preferred stock that we may designate and issue in the future.

Preferred Stock

The Company has authorized 4,000,000 shares of preferred stock, at $0.01 par value and 4,000,000 are issued and outstanding as of September 30, 2013. Each share of the Preferred Stock has 150 votes on all matters presented to be voted by the holders of our common stock. All 4,000,000 shares of preferred stock have been granted to our CEO & CFO on November 30, 2010 and issued on April 11, 2012 which was valued at the trading price of the common stock of $0.0095 and recorded as an expense of $38,000.

Table of Contents -21-

The issuance of preferred stock by our board of directors could adversely affect the rights of holders of the common stock by, among other things, establishing preferential dividends, liquidation rights or voting powers. See “Risk Factors” above.

Warrants and Options

All warrants and options previously issued have expired.

Stock Option Plan

Our board of directors adopted the 2000 Stock Option Plan effective January 1, 2001. Our stockholders formally approved the 2000 Stock Option Plan on February 14, 2001. The 2000 Stock Option plan terminated in accordance with the term on December 1, 2010. The Current Board of Directors has not approved nor extended the Stock Option Plan; therefore, it is terminated.

ITEM 6. SELECTED FINANCIAL DATA

This is not required for smaller reporting companies and the company has elected to omit this information.

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following is management’s discussion and analysis of certain significant factors that have affected our financial position and operating results during the periods included in the accompanying financial statements, as well as information relating to the plans of our current management. This report includes forward-looking statements. Undue reliance should not be placed on these forward-looking statements which speak only as of the date hereof. We undertake no obligation to update these forward-looking statements.

The following discussion and analysis should be read in conjunction with our financial statements and the related notes thereto and other financial information contained elsewhere in this Form 10-K.

Business

The Company was incorporated in Texas on June 22, 1953 as American Mortgage Company. On May 16, 1996, the Company changed its name to National Scientific Corporation. On April 3, 2012, the Company changed its name to Cloud Medical Doctor Software Corporation. During 1996, the Company acquired the operations of Eden Systems, Inc. (Eden) as a wholly owned subsidiary. Eden was engaged in water treatment and the retailing of cleaning products. Eden’s operations were sold on October 1, 1997. From September 30, 1997 through the year ended September 30, 2001, we aimed our efforts in the research and development of semiconductor proprietary technology and processes and in raising capital to fund its operations and research. Beginning in calendar 2002, we focused our efforts on the development, acquisition, enhancement and marketing of location device technologies. Our revenue was derived from sales of electronic devices.

On February 4, 2010, the prior Board members, Mr. Michael Grollman and Mr. Greg Szabo, voted to discontinue and wind down the operation of the Company's Mobile DVR and Location Products business. These Company assets were transferred to a Limited Liability Company named NSC Labs, LLC controlled and owned by Mr. Grollman. Mr. Grollman and NSC Labs, LLC agreed to pay the Company 2% of future revenues and $100,000. However, neither Mr. Grollman nor NSC Labs, LLC have paid any consideration for this transaction. The Company discontinued these operations in 2011.

Table of Contents -22-

On November 19, 2010, the prior management of the Company was terminated and a new management team began working on operations related to the Company’s medical billing software. In fiscal 2011, the year of termination of prior management, the new management team deemed that the above transaction transferring prior operations to NSC Labs, LLC was transacted in full and final settlement of the liabilities owed to the former management. Since the transaction was related to the former management team, who had the ability to affect the terms and outcomes of the liabilities, the settlement of the liabilities has been subsequently recorded as an increase to additional paid in capital.

The Future for Cloud-MD™

Our business strategy includes the acquisition of successful billing companies in strategic markets, the acquisition or licensing of useful emerging technologies and the direct sale to physicians of Cloud-MD™ Office software licenses.

On the Medical Software and Billing Services side of the equation, Cloud-MD™ has already begun the sale of software licenses and the acquisition of billing companies with the purchase of Doctors Network of America, LLC and is currently in final negotiations with two others billing companies in Texas and we are currently in talks with another medical software company to acquire their software assets and customer base.

Our model is effective because we offer:

· Software For Life – Buy One Time

· Evergreen Product - Support, Maintenance and Upgrades Included With User License

· Physician Ownership Opportunity – Stock Award With Purchase Of License

· Cloud-MD™ is Publicly Traded NSCT.PK

· Patented Auto Post Feature - To Eliminate Need For Manual Posting of Electronic Remittance Advice (835) By Staff

· Multiple Opportunities to Recover Investment (Meaningful Use Dollars, Stock Award Option, IRS Section 179, Lower Employee and Maintenance Cost)

· State-Of-The-Art Claims Editing and Real-Time Eligibility - Increase Collections and Reduce Days in A/R

· Cloud Based Technology- IPAD, IPHONE, ANDROID, GOOGLE, WINDOWS for Anytime and Anywhere Availability and Eliminates Catastrophic Loss of Data

As we move forward building on our current platforms and strengths and gaining significant momentum in acquisitions, capabilities and revenue streams, it is important for Cloud-MD™ to augment its portfolio of capabilities with solutions that complement those offerings currently available. With the addition of a pending acquisition, we will add another dimension to our Cloud-MD™ Office and Billing Services offering that will offer a secure mechanism for providers to exchange patient PHI without the need to have all of the providers on a common EMR platform, but will integrate with our EMR in a manner that offers prospective large clients such as hospitals, ACO’s, etc. the functionality of an Electronic Health Interchange without the huge costs and overhead. In addition, we have recently developed enhanced capabilities within our Cloud-MD™ Office product offering that will offer superior solutions to hospitalists, nursing home practitioners and providers of home health services.

The Future for CipherLoc™

The digital cipher and encryption market offers seemingly endless opportunity. Our CipherLoc™ Polymorphic Cipher Engine is a ground-breaking; state-of-the-art Polymorphic Key Progression Algorithm (PKPA) based digital encryption solution that has wide-spread applicability throughout the commercial computer, communications and broadcasting industries as well as significant applicability in the government arena.

Table of Contents -23-

Critical Accounting Policies

Revenue Recognition

License revenue consists principally of revenue earned under software license agreements. The Company sells its software to a medical practitioner for direct payment or through a third party leasing company for direct payment to the Company. The third party lease agreement is a non-recourse debt and the Company is not responsible for the default of the medical practitioner. License revenue is generally recognized when a signed contract or other persuasive evidence of an arrangement exists, the software has been electronically delivered, the license fee is fixed or is measured on a paid user basis; and collection of the resulting receivable is probable. When contracts contain multiple elements wherein Vendor-Specific Objective Evidence (“VSOE”) exists for all undelivered elements, we account for the delivered elements in accordance with the “Residual Method.” VSOE of fair value for maintenance and support is established by a stated renewal rate, if substantive, included in the license arrangement or rates charged in stand-alone sales of maintenance and support. Revenue from subscription license agreements, which include software, rights to unspecified future products and maintenance, is recognized ratably over the term of the subscription period.

Provided all other revenue criteria are met, the upfront, minimum, non-refundable license fees from customers are generally recognized upon delivery and on-going royalty fees are generally recognized upon reports of new licenses issued. If there is significant uncertainty about the project completion or receipt of payment for professional services, revenue is deferred until the uncertainty is sufficiently resolved. VSOE of fair value of services is based upon stand-alone sales of those services.

Subscription revenue is generated from bandwidth and information storage. After the first year and each year thereafter, the software is purchased and installed the purchaser is required to pay an annual fee of $1,200, $1,500, $1,800, and $2,400, respectively. Subscription revenue is recognized ratably over the term of the agreement.

Transaction revenue is generated from the following services and recognized when the transaction occurs:

· Electronic Remittance Advise $0.35 Electronic remittance transaction fee;

· Paper Claims $1.00 Paper claim fee;

· Carrier Direct $0.16 Carrier direct fee;

· Fast Forward $0.35 Fast forward transaction fee; and,

· Patient Credit $2.50 Automatic Debit processing per transaction paid by the patient

The Company has not incurred any transaction revenue in the years ended September 30, 2013 or 2012.

Cost of License, and Subscriptions Revenues

Cost of license revenue is primarily comprised of the license-based royalties to third parties and production and distribution costs for initial product licenses. The Company has not incurred any costs of license revenue in the years ended September 30, 2013 or 2012.

Cost of subscription revenue is primarily comprised of the costs associated with the customer support personnel that provide maintenance, enhancement and support services to customers. The Company has not incurred any costs of subscription revenue in the years ended September 30, 2013 or 2012.

The amortization of acquired technology for products acquired through business combinations are considered as cost of revenues. The acquired technology is amortized using the straight-line method over 5 years. The Company recognized $243,470 and $181,739 during the years ended September 30, 2013 and 2012, respectively.

Table of Contents -24-

Accounts Receivable and Allowance for Uncollectible Accounts

Substantially all of the Company’s accounts receivable balance is related to trade receivables. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company will maintain allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments for services. Accounts with known financial issues are first reviewed and specific estimates are recorded. The remaining accounts receivable balances are then grouped in categories by the number of days the balance is past due, and the estimated loss is calculated as a percentage of the total category based upon past history. Account balances are charged against the allowance when it is probable the receivable will not be recovered.

During the year ended September 30, 2013, the Company wrote-off accounts receivable of approximately $200,000. These accounts receivable were from billing services performed in Doctors Network of America (“DNA”), subsequent to our acquisition of the company from Krooss Medical Management Systems, LLC (“Krooss”) during the year ended September 30, 2013. These amounts were deemed uncollectible due to our pending litigation with Krooss, and were recorded in loss from discontinued operations.

Share-Based Compensation

The Company measures the cost of services received in exchange for an award of an equity instrument based on the grant-date fair value of the award.  Compensation cost is recognized over the vesting or requisite service period. The Black-Scholes option-pricing model is used to estimate the fair value of options or warrants granted. There were no option or warrants issued by the Company during the years ended September 30, 2013 and 2012.

RESULTS OF OPERATIONS

Fiscal Year Ended September 30, 2013, Compared to Fiscal Year Ended September 30, 2012

Revenue increased to $516,868 from $487,703 for the years ended September 30, 2013 and 2012, respectively. On an annualized basis, our revenue decreased as a result of operation occurring for a full year in 2013 compared to operations from January 2012 through September 30, 2012. Sales in 2013 consisted of 10 software units compared to 12 software units in 2012.

Cost of revenue increased to $243,470 from $181,739 for the years ended September 30, 2013 and 2012, respectively. Our cost of services increased due to a full year amortization of the intangible assets compared to amortization from January 2102 through September 30, 2012.

General and administrative expenses increased to $714,266 from $223,211 for the years ended September 30, 2013 and 2012, respectively. The increase in general and administrative expenses are primarily related to the salaries of management and costs of accounting.

Research and development costs increased to $208,895 from $151,000 for the years ended September 30, 2013 and 2012, respectively. Our research and development increase is related to updates to our software required to be in compliance with the updated Affordable Care Act and other modifications to our software.

Impairment of assets increased to $6,000 from $4,000 for the years ended September 30, 2013 and 2012, respectively. We impaired the purchase of the DNA operations in Mississippi that was discontinued in 2013 due to the pending litigation with Krooss.

Interest expenses decreased to $392 from $1,488 for the years ended September 30, 2013 and 2012, respectively. Our interest expense decreased as a result of the lower outstanding principal balance of our line of credit.

Table of Contents -25-

We recorded a gain from discontinued operations for the year ended September 30, 2013 of $23,628 compared to $392,614 for the year ended September 30, 2012. The decrease in gain from discontinued operations is related to the Company writing off debt related to the Company’s previous GPS operations of $58,894 in the year ended September 30, 2013 compared to $410,482 for the year ended September 30, 2012. The Company wrote-off notes payable, accounts payable and accrued expenses previously classified as discontinued operations that was expired under the statute of limitations. Since the write off was related to debt incurred related to discontinued operations the gain has been recorded to discontinued operations. The Company discontinued its GPS operational device business in February 2010. The Company also discontinued its operations relating to DNA during the year ended September 30, 2013. As a result, the Company recorded a loss on discontinued operation from DNA of $35,266 during the year ended September 30, 2013. (See “Note 6 - Discontinued Operations” to the accompanying Financial Statements)

Liquidity and Capital Resources

We expect to incur substantial expenses and generate significant operating losses as we continue to grow our operations, as well as incur expenses related to operating as a public company and compliance with regulatory requirements.

The independent auditor’s report on our financial statements contains explanatory language that substantial doubt exists about our ability to continue as a going concern. We have an accumulated deficit at September 30, 2013 of $26,542,265 and need additional cash flows to maintain our operations. We depend on the continued contributions of our executive officers to finance our operations and need to obtain additional funding sources to explore potential strategic relationships and to provide capital and other resources for the further development and marketing of our products and business. We expect our cash needs for the next 12 months to be $850,000 to fund our operations. The ability of the Company to continue its operations is dependent on the successful execution of management’s plans, which include expectations of raising debt or equity based capital until such time that funds from operations are sufficient to fund working capital requirements. The Company may need to incur additional liabilities with related parties to sustain the Company’s existence. There is no assurance that such funding, if required will be available to us or, if available, will be available upon terms favorable to us.

The Company has a line of credit with Chase Bank with a balance of $9,796 at September 30, 2013. This line of credit allows us to borrow up to $50,000 as a revolving line of credit.

In November 2013, the Company entered into a revolving line of credit with Mutual of Omaha for a line of credit in the amount of $65,000 at 4.00% interest rate which renews annually. As of January 10, 2014 we have borrowed $36,500.

Cash flows from operations. Our cash (used in) provided by operating activities were ($136,711) and $150,317 for the years ended September 30, 2013 and 2012, respectively. The decrease in cash flows provided by operations was primarily attributable to the changes in operating assets and liabilities, the increase in depreciation and amortization for the year, and the decrease in gain from discontinued operations in the year ended September 30, 2013 as compared to the year ended September 30, 2012.

Cash flows from investing activities. Our cash used in investing activities were $11,500 and $0 for the years ended September 30, 2013 and 2012, respectively. The increase in cash flows used in) investing activities was attributable to the acquisition of intangible assets during 2013.

Cash flows from financing activities. Cash provided by (used in) financing activities were $105,442 and ($109,977) for the years ended September 30, 2013 and 2012, respectively. We received cash from sales of our common stock of $143,000 and $68,000 for the years ended September 30, 2013 and 2012, respectively. During the year ended September 30, 2013, we repaid our advances from our CEO of $31,000 and repaid our line of credit of $23,111. During the year ended September 30, 2013, our CEO advanced us $5,409 and we received proceeds from our line of credit of $11,144. During the year ended September 30, 2012, our CEO advanced us $7,969 and made payments of $25,236 directly on our line of credit. The Company made repayments on the advances from our CEO of $188,410 during the year ended September 30, 2012.

Table of Contents -26-

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We do not hold any derivative instruments and do not engage in any hedging activities.

ITEM 8. CONSOLIDATED FINANCIAL STATEMENTS

CLOUD MEDICAL DOCTOR SOFTWARE CORPORATION

TABLE OF CONTENTS	Page
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM	36
FINANCIAL STATEMENTS:
Consolidated Balance Sheets at September 30, 2013 and 2012	37
Consolidated Statements of Operations for the years ended September 30, 2013 and 2012	38
Consolidated Statements of Stockholders’ Equity for the years ended September 30, 2013 and 2012	39
Consolidated Statements of Cash Flows for the years ended September 30, 2013 and 2012	41
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS	42

Table of Contents -27-

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors of
Cloud Medical Doctor Software Corporation
(Formerly National Scientific Corporation)
Henderson, Nevada

We have audited the accompanying consolidated balance sheets of Cloud Medical Doctor Software Corporation as of September 30, 2013 and 2012, and the related consolidated statements of operations, stockholders’ equity, and cash flows for the years then ended. Cloud Medical Doctor Software Corporation’s management is responsible for these financial statements. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Cloud Medical Doctor Software Corporation as of September 30, 2013 and 2012, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

The accompanying consolidated financial statements have been prepared assuming that Cloud Medical Doctor Software Corporation will continue as a going concern. As discussed in Note 3 to the financial statements, Cloud Medical Doctor Software Corporation has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ GBH CPAs, PC

GBH CPAs, PC
www.gbhcpas.com
Houston, Texas
February 4, 2014

Table of Contents -28-

CLOUD MEDICAL DOCTOR SOFTWARE CORPORATION
(Formerly National Scientific Corporation)
CONSOLIDATED BALANCE SHEETS
	September 30,
	2013			2012
ASSETS
CURRENT ASSETS:
Cash	$	8,587		$	51,356
Accounts receivable		8,338			4,888
Total current assets		16,925			56,244
Proprietary technology, net		817,921			1,022,591
TOTAL ASSETS	$	834,846		$	1,078,835
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable and accrued liabilities	$	361,994		$	229,736
Liabilities attributable to discontinued operations		35,356			—
Advances from officers		—			25,591
Line of credit		9,796			21,763
Total current liabilities		407,146			277,090
TOTAL LIABILITIES		407,146			277,090
COMMITMENTS AND CONTINGENCIES		—			—
STOCKHOLDERS' EQUITY:
Preferred stock, $0.01 par value, 4,000,000 shares authorized; 4,000,000 issued and outstanding as of September 30, 2013 and 2012		40,000			40,000
Common stock, $0.01 par value, 650,000,000 shares authorized; 214,624,216 and 211,991,212 issued and outstanding as of September 30, 2013 and 2012, respectively		2,146,242			2,119,912
Additional paid-in capital		24,783,723			24,552,924
Accumulated deficit		(26,542,265	)		(25,911,091	)
Total stockholders' equity		427,700			801,745
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	834,846		$	1,078,835
The accompanying notes are an integral part of these financial statements.

Table of Contents -29-

CLOUD MEDICAL DOCTOR SOFTWARE CORPORATION
(Formerly National Scientific Corporation)
CONSOLIDATED STATEMENTS OF OPERATIONS
	Year Ended
	September 30,
	2013			2012
REVENUE	$	516,868		$	487,703
COST OF REVENUES		243,470			181,739
GROSS PROFIT		273,398			305,964
OPERATING EXPENSES:
General and administrative		714,266			223,211
Research and development		208,895			151,000
Impairment of assets		6,000			4,000
Total operating expenses		929,161			378,211
OPERATING LOSS		(655,763	)		(72,247	)
OTHER (INCOME) AND EXPENSES
Interest expense		392			1,488
Gain on the disposal of assets		(1,353	)		—
Total other (income) expenses		(961	)		1,488
LOSS FROM CONTINUING OPERATIONS		(654,802	)		(73,735	)
INCOME FROM DISCONTINUED OPERATIONS		23,628			392,614
NET INCOME (LOSS)	$	(631,174	)	$	318,879
NET INCOME (LOSS) PER COMMON SHARE - Basic and diluted:
Continuing operations	$	(0.00	)	$	(0.00	)
Discontinued operations	$	0.00		$	0.00
Total	$	0.00		$	0.00
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
Basic and diluted		212,798,744			210,463,497
The accompanying notes are an integral part of these financial statements.

Table of Contents -30-

CLOUD MEDICAL DOCTOR SOFTWARE CORPORATION
(Formerly National Scientific Corporation)
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
FOR THE YEARS ENDED SEPTEMBER 30, 2012 AND 2013
	Preferred Stock				Common Stock				Additional
		Shares		Amount		Shares		Amount		Paid-in Capital	Accumulated  Deficit				Total
SEPTEMBER 30, 2011		4,000,000	$	40,000		180,526,879	$	1,805,269	$	22,409,927	$	(26,229,970	)	$	(1,974,774	)
Common stock issued for settlement of debt		—		—		30,000,000		300,000		900,106					1,200,106
Common stock issued for investment						200,000		2,000		2,000					4,000
Common stock issued for purchase of software						100,000		1,000		1,500					2,500
Common stock issued for the purchase of billing software						941,333		9,413		9,888					19,301
Common stock issued for consulting services						33,000		330		294					624
Common stock issued for cash						190,000		1,900		66,100					68,000
Write-off of related party debt										1,163,109					1,163,109
Net loss												318,879			318,879
SEPTEMBER 30, 2012		4,000,000	$	40,000		211,991,212	$	2,119,912	$	24,552,924	$	(25,911,091	)	$	801,745
Common stock issued for investment						300,000		3,000		3,000					6,000
Common stock issued for purchase of software						500,004		5,000		10,800					15,800
Common stock issued for the purchase of billing software						450,000		4,500		9,063					13,563
Common stock issued for consulting services						1,165,500		11,655		24,974					36,629
Common stock issued for cash						217,500		2,175		140,825					143,000
Write-off of related party debt										42,137					42,137
Net loss												(631,174	)		(631,174	)
SEPTEMBER 30, 2013		4,000,000	$	40,000		214,624,216	$	2,146,242	$	24,783,723	$	(26,542,265	)	$	427,700
The accompanying notes are an integral part of these financial statements.

Table of Contents -31-

CLOUD MEDICAL DOCTOR SOFTWARE CORPORATION
(Formerly National Scientific Corporation)
CONSOLIDATED STATEMENTS OF CASH FLOWS
	Year Ended
	September 30,
	2013			2012
Net income (loss)	$	(631,174	)	$	318,879
Income from discontinued operations		(23,628	)		(392,614	)
Net loss from continuing operations		(654,802	)		(73,735	)
Adjustments to reconcile net loss from continuing operations to net cash (used in) provided by operating activities:
Depreciation and amortization		243,470			180,015
Impairment of assets		6,000			4,000
Stock issued for compensation		36,629			624
Stock issued with licensing agreements		13,563			19,301
Changes in operating assets and liabilities:
Accounts receivable		(3,450	)		(4,888	)
Accounts payable and accrued liabilities		221,879			25,000
Net cash (used) provided in operating activities		(136,711	)		150,317
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of intangible asset		(11,500	)		—
Net cash (used in) operating activities		(11,500	)		—
CASH FLOWS FROM FINANCING ACTIVITIES:
Advances from affiliates		5,409			7,969
Repayment of advances from officer		(31,000	)		(188,410	)
Proceeds from line of credit		11,144			2,464
Repayment of line of credit		(23,111	)		—
Common stock issued for cash		143,000			68,000
Net cash provided by (used in) financing activities		105,442			(109,977	)
(DECREASE) INCREASE IN CASH		(42,769	)		40,340
CASH, BEGINNING OF YEAR		51,356			11,016
CASH, END OF YEAR	$	8,587		$	51,356
CASH PAID FOR:
Interest paid	$	—		$	—
Taxes paid	$	—		$	—
SUPPLEMENTAL DISCLOSURE OF NONCASH OPERATING AND FINANCING ACTIVITIES:
Reclass from discontinued operations to accounts payable	$	—		$	204,736
Accrual of software acquisition costs	$	11,500		$	—
Write-off of debt - related parties	$	42,137		$	1,163,109
Common stock issued for investment in Doctors Network of America	$	6,000		$	4,000
Common stock issued for purchase of software	$	15,800		$	2,500
Transfer from line of credit to advance from officer	$	—		$	25,236
Common stock issued for settlement of debt	$	—		$	1,200,106
The accompanying notes are an integral part of these financial statements.

Table of Contents -32-

CLOUD MEDICAL DOCTOR SOFTWARE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED SEPTEMBER 30, 2013 AND 2012

NOTE 1 - DESCRIPTION OF BUSINESS

Cloud Medical Doctor Software Corporation (the “Company”, or “Cloud-MD”) was incorporated in Texas on June 22, 1953 as American Mortgage Company. On May 16, 1996, the Company changed its name to National Scientific Corporation. On April 3, 2012, the Company changed its name to Cloud Medical Doctor Software Corporation.

In the year ended September 30, 2011, Cloud-MD introduced the Cloud-MD Office, a “Cloud Based”, 5010 ready and ICD-10 compliant, fully integrated and interoperable suite of medical software and services, designed by experienced healthcare analysts and programmers for healthcare providers, that produces “Actionable Information” to help independent physician practices, New Care Delivery Models (ACO), healthcare systems and billing services optimize a wide range of business. The Company’s current software product offerings include Practice Management, Electronic Medical Records, Revenue Management, Patient Financial Solutions, Medical and Pharmaceutical Supply Management, Claims Management and Patient Health Information Exchange.

In the year ended September 30, 2012, Cloud-MD launched Cloud-MD Billing Services which provides management of medical claims from posting physician charges and payments into the Company’s medical billing software. The software uses a continuous insurance claim follow-up system to track and research all rejected or denied medical claims; a comprehensive reporting module that includes monthly financial statements and other detailed reports that are sent to the Company’s clients so they can see how their practice is performing, patient account inquiries and support to assist patients with their billing and insurance questions.

NOTE 2 - BASIS OF PRESENTATION

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net revenues and expenses recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates.

In managements’ opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.

NOTE 3 - GOING CONCERN ISSUES

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. However, the Company has an accumulated deficit at September 30, 2013 of $26,542,265 and needs additional cash to maintain its operations.

These factors raise doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s continued existence is dependent upon management’s ability to develop profitable operations, continued contributions from the Company’s executive officers to finance its operations and the ability to obtain additional funding sources to explore potential strategic relationships and to provide capital and other resources for the further development and marketing of the Company’s products and business.

Table of Contents -33-

NOTE 4 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. Significant accounting policies are as follows:

Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net revenues and expenses recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates. The Company’s most significant estimates relate to the valuation of its proprietary technology and the valuation of its common stock.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  At September 30, 2013 and 2012, cash and cash equivalents include cash on hand and cash in the bank. The FDIC insures these deposits up to $250,000.

Long-Lived Assets

Long-lived assets are evaluated for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows to the recorded value of the asset. If impairment is indicated, the asset is written down to its estimated fair value.

Fair Value of Financial Instruments

The Company's financial instruments consist primarily of cash, accounts payable and accrued expenses, and debt. The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments.  

Fair value is defined as an exit price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  Within the measurement of fair value, the use of market-based information is prioritized over entity specific information and a three-level hierarchy for fair value measurements is used, based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.

The three-level hierarchy for fair value measurements is defined as follows:

• Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets; liabilities in active markets;

• Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly, including inputs in markets that are not considered to be active; or directly or indirectly including inputs in markets that are not considered to be active;

• Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement

Table of Contents -34-

The following table summarizes fair value measurements by level at September 30, 2013 and 2012 for assets measured at fair value on a recurring basis:

	Level 1		Level 2		Level 3		Total
At September 30, 2013
Software development net of amortization	$	—	$	—	$	817,921	$	817,921
Total Proprietary Technology	$	—	$	—	$	817,921	$	817,921
At September 30, 2012
Software development net of amortization	$	—	$	—	$	1022,591	$	1,022,591
Total Proprietary Technology	$	—	$	—	$	1,022,591	$	1,022,591

Accounts Receivable and Allowance for Uncollectible Accounts

Substantially all of the Company’s accounts receivable balance is related to trade receivables. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company will maintain allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments for services. Accounts with known financial issues are first reviewed and specific estimates are recorded. The remaining accounts receivable balances are then grouped in categories by the number of days the balance is past due, and the estimated loss is calculated as a percentage of the total category based upon past history. Account balances are charged against the allowance when it is probable the receivable will not be recovered. As of September 30, 2013 and 2012, the Company had no valuation allowance for the Company’s accounts receivable.

During the year ended September 30, 2013, the Company wrote-off accounts receivable of approximately $200,000. These accounts receivable were from billing services performed in DNA, subsequent to our acquisition of the company from Krooss Medical Management Systems, LLC (“Krooss”) which was completed during the year ended September 30, 2013. These amounts were deemed uncollectible due to our pending litigation with Krooss, and were recorded in loss from discontinued operations.

Income Taxes

The Company utilizes the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for operating loss and tax credit carry-forwards and for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that the value of such assets will be realized.

The Company uses the two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. The Company considers many factors when evaluating and estimating the Company's tax positions and tax benefits, which may require periodic adjustments. At September 30, 2013, the Company did not record any liabilities for uncertain tax positions. 

Table of Contents -35-

Revenue Recognition

License revenue consists principally of revenue earned under software license agreements. The Company sells its software to a medical practitioner for direct payment or through a third party leasing company for direct payment to the Company. The third party lease agreement is a non-recourse debt and the Company is not responsible for the default of the medical practitioner. License revenue is generally recognized when a signed contract or other persuasive evidence of an arrangement exists, the software has been electronically delivered, the license fee is fixed or is measured on a paid user basis; and collection of the resulting receivable is probable. When contracts contain multiple elements wherein Vendor-Specific Objective Evidence (“VSOE”) exists for all undelivered elements, we account for the delivered elements in accordance with the “Residual Method.” VSOE of fair value for maintenance and support is established by a stated renewal rate, if substantive, included in the license arrangement or rates charged in stand-alone sales of maintenance and support. Revenue from subscription license agreements, which include software, rights to unspecified future products and maintenance, is recognized ratably over the term of the subscription period.

Provided all other revenue criteria are met, the upfront, minimum, non-refundable license fees from customers are generally recognized upon delivery and on-going royalty fees are generally recognized upon reports of new licenses issued. If there is significant uncertainty about the project completion or receipt of payment for professional services, revenue is deferred until the uncertainty is sufficiently resolved. VSOE of fair value of services is based upon stand-alone sales of those services.

Subscription revenue is generated from bandwidth and information storage. After the first year and each year thereafter that the software has been purchased and installed, the purchaser is required to pay an annual fee of $1,200, $1,500, $1,800, and $2,400, respectively. Subscription revenue is recognized ratably over the term of the agreement.

Transaction revenue is generated from the following services and recognized when transaction occurs:

· Electronic Remittance Advise $0.35 Electronic remittance transaction fee;

· Paper Claims $1.00 Paper claim fee;

· Carrier Direct $0.16 Carrier direct fee;

· Fast Forward $0.35 Fast forward transaction fee; and,

· Patient Credit $2.50 Automatic Debit processing per transaction paid by the patient

The Company has not incurred any transaction revenues in the year ended September 30, 2013.

Cost of License, and Subscription Revenues

Cost of license revenue is primarily comprised of the license-based royalties to third parties and production and distribution costs for initial product licenses. No costs were incurred for license revenue during the years ended September 30, 2013 and 2012.

Cost of subscription revenue is primarily comprised of the costs associated with the customer support personnel that provide maintenance, enhancement and support services to customers. No costs were incurred for subscription revenue or customer support during the years ended September 30, 2013 and 2012.

The amortization of acquired technology for products acquired through business combinations are considered as the cost of revenues. The acquired technology is amortized using the straight-line method over 5 years.

Sales Commissions

The Company pays commissions, including sales bonuses, to the direct sales force related to revenue transactions under sales compensation plans established annually. The commission payments are typically accrued on the date of sale and paid in the month following execution of the customer contracts. The Company paid commissions of $62,060 and $73,298 for the years ended September 30, 2013 and 2012, respectively.

Table of Contents -36-

Research and Development and Software Development Costs

Capitalization of certain software development costs are recorded after the determination of technological feasibility. Based on our product development process, technological feasibility is determined upon the completion of a working model. To date, costs incurred by us from the completion of the working model to the point at which the product is ready for general release have been insignificant. Accordingly, we have charged all such costs to research and development expense in the period incurred. Our research and development costs for the years ended September 30, 2013 and 2012 were $208,895 and $151,000, respectively.

Share-Based Compensation

The Company measures the cost of services received in exchange for an award of an equity instrument based on the grant-date fair value of the award.  Compensation cost is recognized over the vesting or requisite service period. The Black-Scholes option-pricing model is used to estimate the fair value of options or warrants granted. There were no options or warrants issued by the Company during the years ended September 30, 2013 and 2012.

Basic and Diluted Net Loss per Common Share

Basic income (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period. The weighted average number of shares is calculated by taking the number of shares outstanding and weighting them by the amount of time that they were outstanding.  Diluted earnings per share reflects the potential dilution that could occur if stock options, warrants, and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company. As of September 30, 2013 and 2012, the Company had no potentially dilutive instruments outstanding.

Diluted loss per share is the same as basic loss per share during periods where net losses are incurred since the inclusion of the potential common stock equivalents would be anti-dilutive as a result of the net loss.  

Concentration of Credit Risk

All of the Company’s cash and cash equivalents are maintained in regional and national financial institutions. The Company has exposure to credit risk to the extent that its cash and cash equivalents exceed amounts covered by the U.S. federal deposit insurance; however, the Company has not experienced any losses in such accounts. In management’s opinion, the capitalization and operating history of the financial institutions are such that the likelihood of material loss is remote.

Subsequent Events

The Company has evaluated all transactions occurring between the end of its fiscal year, September 30, 2013, through the date of issuance of the financial statements for subsequent event disclosure consideration.

Recent Accounting Pronouncements

No accounting standards or interpretations issued recently are expected to a have a material impact on the Company’s financial position, operations or cash flows.

Table of Contents -37-

NOTE 5 – SOFTWARE

The following is a detail of software at September 30, 2013 and 2012:

	2013			2012
Source Code License	$	2,500		$	2,500
Software License		1,200,106			1,200,106
EMR Certification		23,000			—
Encryption Software Code		15,800			—
Acquisition of Doctor’s Network of America		10,000			4,000
Total intangible assets		1,251,406			1,202,606
Accumulated amortization of intangible assets (charged to cost of sales)		(423,485	)		(180,015	)
Accumulated impairment of assets		(10,000	)		(4,000	)
Total proprietary technology, net	$	817,921		$	1,022,591

The Company impaired an investment of $10,000 and $4,000 for the years ended September 30, 2013 and 2012, respectively, directly related to the acquisition of Doctors Network of America (“DNA”) operating in Jackson Mississippi. The Company is currently in litigation with the sellers of DNA relating to the collection of certain medical billings owed to the Company. As a result of the litigation, the Company deemed the investment to be impaired. The amortization expense was $243,470 and $180,015 for the years ended September 30, 2013 and 2012, respectively. The Company’s proprietary technology was placed into service starting in the second quarter of fiscal 2012.

Source Code License

On August 14, 2012, the Company, through a comprehensive agreement (the “License Agreement”) with MediSouth, LLC, (“MediSouth”) has purchased a complete source code license (the “License”) and will integrate and enhance this feature set as part of its ever expanding Cloud-MD Office product suite.

The License Agreement requires the following:

a)	That MediSouth will provide the Companywith all software updates for the License within 5 working days of MediSouthimplementing those same software updates in its own production version of the License.
b)	The Company has the right to modify the software contained in the License to meet its operational needs.
c)	The Company shall provide to MediSouth, with the permission of each affected Companyclient, the de-identified purchasing data which is any data that would identify a patient such as social security numbers, date of birth, health condition, among others that it collects as a result of the Company’s clients utilizing the embedded Medical Supplies and Pharmaceutical Inventory Management functionality provided by the License.
e)	MediSouth shall receive 100,000 shares of the Company’s non-dilutable, commonstock with a one (1) year trading restriction.
f)	The Company may not sell the License, transfer the License, allow any other entity to use the License as part of that entity's software application or transfer any rights to another party to use the License separately from the Company’s products in which the License is embedded.

The fair value of the consideration and the assets acquired is based on the aggregate value of the 100,000 shares of common stock issued in exchange for the software. The total fair value on August 14, 2012 was $2,500.

Encryption Software Code

On November 21, 2012, the Company, through a purchase agreement with CipherSmith, LLC, purchased a complete source code, intellectual property rights, all computer software or algorithm licensed or sold under CipherSmith, and appropriate copy rights, patents, mask works, trademarks, service marks, internet domain names or world wide web URS. The Company issued 500,004 shares of its common stock as payment for the acquisition. The fair value of the consideration and the assets acquired is based on the aggregate fair value of the common stock issued in exchange for the software. The total fair value of the shares of common stock issued on the date of grant was $15,800.

Table of Contents -38-

Doctors Network of America

On June 22, 2012, the Company entered into an acquisition agreement that closed on March 16, 2013. The Company agreed to acquire DNA in Flowood, Mississippi from Krooss Medical Management Systems, LLC (“Krooss”) for 500,000 shares of common stock. As of September 30, 2012, only 200,000 shares of common stock were issued as a deposit, which was valued at $4,000 based on the market value on the date of grant. At the closing of the transaction on March 16, 2013, the Company issued an additional 300,000 shares of common stock which were valued at $6,000 based on the market value on the date of grant.

Subsequent to the transaction closing on March 16, 2013, the sellers refused to pay for medical billing process transaction fees in accordance with their contracts in the amount of approximately $200,000. The Company and the sellers are currently in litigation over the disputed transaction fees of $200,000. The Company has recorded an accumulated impairment of the acquired asset in the amount of $10,000 and $4,000 for the years ended September 30, 2013 and 2012, respectively.

NOTE 6 - DISCONTINUED OPERATIONS

The Company’s former Board of Directors believed that it was in the best interest of the Company to discontinue the business operations of the GPS operational device business. In 2011, the assets were transferred to National Scientific, LLC, a company owned by the Company’s prior CEO, by prior management in which the Company’s former CEO was to pay $100,000 plus 2% of revenues for that technology. The former officer never paid the required compensation.

Accordingly, the Company reclassified the assets, liabilities and operations related to its GPS operational device business as discontinued operations.  Consequently, the accompanying consolidated financial statements reflect the assets, liabilities and operations of the GPS operational device business as net assets of discontinued operations, net liabilities of discontinued operations and results from discontinued operations. As of September 30, 2013 and 2012, the Company did not have any net assets or net liabilities related to the GPS operational device business.

The Company closed the acquisition with the final payment for DNA on March 16, 2013. Subsequent to the transaction closing, the sellers refused to pay the transaction fees for medical billing contracts that were processed. The Company filed a law suit against the sellers for Breach of Contract among other things in June of 2013. During that time, the Company believe the sellers began contacting all billing contract holders and interfered with the acquisition of all the assets from the transaction. Consequently, the accompanying consolidated financial statements reflect the assets, liabilities and operations of DNA as net assets of discontinued operations, net liabilities of discontinued operations and results from discontinued operations. All of the assets that were acquired have been impaired and included in discontinued operations.

Details of the classifications for net liabilities and operations are shown below.

	September 30, 2013		September 30, 2012
Net liabilities of discontinued operations:
Accounts payable and accrued expenses		35,356		—
Net liabilities of discontinued operations	$	35,356	$	—

	Year ended September 30,
	2013			2012
Discontinued operations:
Revenues	$	431,400		$	—
Cost of sales		—			—
Operating expenses		(245,287	)		—
Bad debt		(221,469	)		—
Interest expense		—			(17,868	)
Gain from write-off of debt		58,984			410,482
Income from Discontinued Operations	$	23,628		$	392,614

Table of Contents -39-

Commitments and contingencies that were discontinued as a result of the transfer of the assets to National Scientific LLC as follows:

On November 1, 2005, the Company entered into a financing program with Strategic Working Capital Fund, LP. The terms of this program included a five-year note payable at maturity in November 2010 for $175,000, at an annual interest rate of 8%. Interest was due and payable semi-annually on May 1st and November 1st for each year in which the note is outstanding The transaction also included 1,200,000 restricted common shares and a conversion/exchange option to convert the principal amount and any unpaid interest of the Note into common shares at a per share conversion price of $0.0525. These shares included weighted average anti-dilution provisions, as well as piggyback registration rights. Additionally, the note had various put and call rights, and has a right to early payment under certain conditions after 2 years. The 1,200,000 restricted common shares were recorded at $0.043, which was the five-day average market closing price of our stock. The note and common stock were issued with a debt discount of $51,600 and a beneficial conversion feature of $9,933. The discount and beneficial conversion feature are being amortized to interest expense over the term of the note, which is approximately 60 months. The issuance of the shares resulted in deferred financing costs of $24,000. The deferred financing costs were amortized over term of the note, which is approximately 60 months, and are included in the statement of operations as offering costs. Management received a legal opinion and determined that this note is unenforceable and has been written off during fiscal year ended September 30, 2012 (See Note 7 – Debt Mitigation Program).

On February 24, 2005, March 28, 2005, May 2, 2005, and May 27, 2005 the Company’s former Chairman Michael Grollman made personal loans to the Company totaling $159,000 to assist it with working capital needs. The loans are evidenced by a demand note that provides for repayment within five business days of a demand notice from Mr. Grollman, with interest of 6% compounded annually from June 1, 2005. These loans were secured by an interest in the copyrights in the Company’s iBus software and designs.  During the three months ended September 30, 2007, these loans were paid down by $11,000. As of September 30, 2007, these loans had a balance outstanding of $148,000 and the interest rate going forward was adjusted to 8% compounded annually from October 1, 2007.  On September 30, 2007, the Company converted unpaid interest of $13,300 on demand notes payable to Michael Grollman into a new demand note of $13,300 that provided for repayment within five business days of a demand notice from Mr. Grollman, with interest of 8% compounded annually on October 1^st. Management received a legal opinion and determined this note is unenforceable and has been written off during fiscal year ended September 30, 2012 (See Note 7 – Debt Mitigation Program).

On April 27, 2006, the Company secured a short-term loan of $16,625 from a shareholder. The loan carries an origination/placement fee of $500 and has a perfectible security interest a) prior to delivery in any assets purchased for the fulfillment of a customer’s order dated March 16, 2006, and b) in any receivable resulting from the fulfillment of the customer’s purchase order. The interest rate on the loan was 12%. The transaction also included 100,000 warrants to purchase our common stock at $0.036 at any time before April 27, 2009 which have expired unexercised. The note had an approximate maturity date of June 15, 2006. Management received a legal opinion and determined this note is unenforceable and has been written off during fiscal year ended September 30, 2012 (See Note 7 – Debt Mitigation Program).

On May 31, 2006, we secured a short-term loan of $20,000 from a shareholder. The loan carried an origination/placement fee of $500 and has a perfectible security interest a) prior to delivery in any assets purchased for the fulfillment of Clover Park, WA’s order and b) in any receivable resulting from the fulfillment of the Clover Park purchase order. The interest rate on the loan was 12%. The transaction also included 100,000 warrants to purchase our common stock at $0.036 at any time before May 31, 2009 which expired unexercised. The note had a maturity date of July 10, 2006. Management received a legal opinion and determined this note is unenforceable and has been written off during fiscal year ended September 30, 2012 (See Note 7 – Debt Mitigation Program).

Table of Contents -40-

NOTE 7 – DEBT MITIGATION PROGRAM

The Company determined that the statute of limitations for certain of the Company’s creditors to enforce collection of any amounts they might be owed has now elapsed. Based on the determinations and findings, during the years ended September 30, 2013 and 2012, the Company wrote off $101,121 and $1,573,591, respectively, in creditor liabilities which were all previously included in current liabilities in the accompanying balance sheet. As a result of these write-offs, the Company recognized a gain on the write off of liabilities in the amount of $58,984 and $410,482 from third party liabilities, respectively, which was recorded in income from discontinued operations, and additional paid-in capital of $42,137 and $1,163,109 for related party liabilities, respectively. The Company will continue to conduct this analysis going forward and write-off obligations when such obligations are no longer enforceable based on applicable law.

The following liabilities, through the opinion of legal counsel, were determined by the Company as unenforceable.

	September 30,			September 30,
	2013			2012
Debt Mitigation Program:
Accounts payable and accrued expenses	$	58,984		$	66,281
Disputed salaries & vacation of former officers		—			968,645
Disputed salary – former employee		—			20,256
Disputed payroll taxes for back pay of former officers		—			84,701
Disputed interest		—			227,083
Accrued interest		42,137			—
Shareholders demand note payable at 12%		—			11,625
Shareholders demand note payable at 12%		—			20,000
Unsecured note payable at 8% interest due in November 2010, interest payments in default		—			175,000
Total debt mitigation program	$	101,121		$	1,573,591
Gain on write off of debt	$	(58,984	)	$	(410,483	)
Additional paid-in capital (1)	$	(42,137	)	$	(1,163,108	)

(1) All amounts that were owed to related parties in prior years were recorded to paid-in-capital.

NOTE 8– COMMITMENTS AND CONTINGENCIES

Rent expense for the years ended September 30, 2013 and 2012 was $0 for both years.

The Company entered into an agreement to purchase the assets of DNA in June 2012 and after due diligence by both parties the transaction closed on March 16, 2013. Subsequent to the transaction closing on March 16, 2013, the sellers refused to pay for medical billing process transaction fees in accordance with their contracts of approximately $200,000. In June 2013, the Company sued the sellers in federal court for breach of contract among other causes of action of unpaid medical billing transaction fees of approximately $200,000. The Company believes it will be successful in its litigation. However, if the Company is successful, the collectability of the judgment is highly questionable.

The Company has issued shares to new investors since January 2, 2011, that have an anti-reverse common stock split clause if the Company reverse splits the common stock. The reverse split of common stock is determined by management but must be approved by Financial Industry Regulation Authority (“FINRA”). Presently FINRA has denied the Company the right to reverse split the common stock until all Securities and Exchange Commission filings are current and at that point and time the Company will submit a request to FINRA to execute a reverse split of the common stock of the Company. The current investors holding anti-reverse split stock will have the right to hold the same number of shares of common stock as status quo after the reverse split. The anti-reverse split common stock protection is only for stock subject to reverse split and once the Company declares a reverse split and it is completed, the anti-reverse split protection will be terminate and shareholders that received anti-reverse split stock will be held with regular stockholders as the Company proceeds forward. In accordance with the anti-reverse split provision, no further shares will be issued to the anti-reverse split shareholders once the reverse split is approved and completed.

Table of Contents -41-

As discussed in Note 7, the Company has written off $101,121 and $1,573,591 in accounts payable, accrued liabilities and notes payable based on the opinion of legal counsel for years ended September 30, 2013 and 2012. However, the related creditors could make a claim in the future in regards to these liabilities.

NOTE 9– RELATED PARTY TRANSACTIONS

On October 15, 2011, the Company issued 30,000,000 common shares to the CEO for the conversion of the debt issued in the principal amount of $1,200,106.

During the years ended September 30, 2013 and 2012, the CEO advanced the Company cash of $5,409 and $7,969, respectively. In addition, during the year ended September 30, 2012, the CEO made payments on the Company’s behalf of $25,236 on the Company’s line of credit. The Company repaid $31,000 and $188,410 of the advances in the years ended September 30, 2013 and 2012, respectively. The advances from the CEO are due on demand and do not accrue interest. As of September 30, 2013 and 2012, the amount owed to the CEO for advances was $0 and $25,591, respectively.

Employment Agreements

The Company entered into an employment agreement with its Chief Executive Officer on January 1, 2013.  The employment agreement will expire on January 1, 2018 and shall automatically renew for another 5 years unless terminated in accordance with the provisions of the employment agreement. The employment agreement provides for:

i.	A monthly salary of $20,833 subject to an annual increase of 10% and consistent with the Company policy applicable to other senior executives and officers and approval by the Board of Directors.
ii.	A cash bonus of 25% of his annual base salary each year if the Company reaches the following milestones (none of which were attained in 2013):

a.	The Company posts annual gross revenues on a consolidated basis of at least $5,000,000;
b.	The Company's earnings before the deduction of income taxes and amortization expenses (“EBITA”), including cash extraordinary items but before officer's bonuses, on a consolidated basis for any year is at least $1,000,000; or the completion of the delinquent SEC filings for five (5) years through September 30, 2013 or the Company obtains FINRA approval for any reverse stock splits.

iii.	The issuance of shares equal to 1% of the then issued and outstanding shares of the Company annually which is approximately 2,146,242, to be issued in 2013.
iv.	The issuance of common stock on each anniversary date of the employment agreement of 5,000,000 shares and issuance of common stock for every acquisition granting 5,000,000 shares for DNA, 5,000,000 shares for CipherSmith, LLC, and 1,000,000 shares for MediSouth, LLC.
v.	An automobile allowance of $1,500 per month.
vi.	A medical insurance allowance of $1,500 per month.
vii.	In the event the Executive's employment is terminated without cause, he will receive the entire contract remaining on the agreement.

Table of Contents -42-

The Company entered into an employment agreement with its Chief Financial Officer on January 1, 2013.  The employment agreement will expire January 1, 2018 and shall automatically renew for another 5 years unless terminated in accordance with the provisions of the employment agreement. The employment agreement provides for:

i.	A monthly salary of $12,500 per month subject to an annual increase of 10% per year and consistent with the Company policy applicable to other senior executives and officers and approval by the Board of Directors.
ii.	A cash bonus of 25% of her annual base salary each year if the Company reaches the following milestones (none of which were attained in 2013):

a.	The Company posts annual gross revenues on a consolidated basis of at least $5,000,000;
b.	The Company's EBITA, including cash extraordinary items but before officer's bonuses, on a consolidated basis for any year is at least $1,000,000; or the completion of the delinquent SEC filings for five (5) years through September 30, 2013 or the Company obtains FINRA approval for any reverse stock splits.

iii.	The issuance of shares equal to 1% of the then issued and outstanding shares of the Company annually, which is approximately 2,146,242 to be issued in 2013
iv.	The issuance of common stock on each anniversary date of the employment agreement of 5,000,000 shares and issuance of common stock for every acquisition granting 3,000,000 shares for DNA, 3,000,000 shares for CipherSmith, LLC, and 750,000 shares for MediSouth, LLC.
v.	An automobile allowance of $1,000 per month.
vi.	A medical insurance allowance of $1,500 per month.
vii.	In the event the Executive's employment is terminated without cause he will receive the entire contract remaining on the agreement.

NOTE 10 - EQUITY

As of September 31, 2013, the Company was authorized to issue 650,000,000 common shares and 4,000,000 preferred shares at a par value of $0.01 per share.

Fiscal Year Ended September 30, 2013

Stock Issued for Cash

During the year ended September 30, 2013, the Company issued 217,500 shares of common stock for $143,000 in net proceeds as follows:

Date		Number of Shares		Proceeds
	October 14, 2012		20,000	$	20,000
	October 14, 2012		15,000		3,000
	October 14, 2012		18,750		2,500
	October 14, 2012		18,750		2,500
	December 6, 2012		15,000		3,000
	March 12, 2013		20,000		20,000
	March 12, 2013		20,000		20,000
	March 31, 2013		50,000		50,000
	April 17, 2013		20,000		20,000
	August 26, 2013		20,000		2,000
	Total		217,500	$	143,000

Table of Contents -43-

Stock Issued in Connection with Software Licensing and Subscription Agreements

During the year ended September 30, 2013, the Company issued 400,000 shares of common stock valued at $13,563 based on the market price on the date of grant, to customers, in regards to the purchase of software from the Company in accordance with the Software Licensing and Subscription Agreements. The fair values of the shares issued were recorded against software revenue recognized during the year ended September 30, 2013.

Date		Number of Shares		Fair Value
	October 14, 2012		50,000	$	1,300
	December 6, 2012		100,000		2,800
	March 12, 2013		50,000		1,750
	March 21, 2013		50,000		1,750
	March 21, 2013		50,000		1,750
	April 17, 2013		25,000		838
	April 17, 2013		50,000		1,675
	June 26, 2013		25,000		450
	September 30, 2013		50,000		1,250
	Total		400,000	$	13,563

Stock Issued for Services

During the year ended September 30, 2013, the Company issued 1,165,500 shares of common stock as compensation. The fair values of the shares were a total of $36,629 and were recorded at the market price on the date of grant. The issuances of stock were as follows:

Date		Number of Shares		Fair Value		Description of Services
	October 14, 2012		10,000	$	260	Commission
	December 6, 2012		100,000		2,800	Software Agreement
	March 12, 2013		50,000		1,750	Consulting
	March 21, 2013		167,000		5,845	Compensation
	March 21, 2013		500,000		17,500	Compensation
	April 17, 2013		78,500		2,630	Compensation
	May 1, 2013		20,000		522	Programming
	May 10, 2013		20,000		522	Programming
	August 26, 2013		100,000		1,800	Software Sales
	September 30, 2013		60,000		1,500	Programming
	September 30, 2013		60,000		1,500	Programming
	Total		1,165,500		36,629

Stock Issued for Assets Acquisition

On April 17, 2013, the Company issued 300,000 shares of common stock valued at $6,000, based on the market price on the date of grant, to Krooss Family Trust LLP for the acquisition of Doctors Network of America in Flowood, Mississippi and all of the assets of that company.

During year ended September 30, 2013, the Company issued 500,004 shares of common stock for the acquisition of CipherSmith software. Those shares were valued at $15,800 based on the market price on the dates of grant.

Table of Contents -44-

Fiscal Year Ended September 30, 2012

Stock Issued for Cash

During year ended September 30, 2012, the Company issued 190,000 shares of common stock for proceeds of $68,000 as follows:

Date		Number of Shares		Proceeds
	October 15, 2011		25,000	$	5,000
	December 29, 2011		100,000		50,000
	June 21, 2012		65,000		13,000
	Total		190,000	$	68,000

Stock Issued in Connection with Software Licensing and Subscription Agreements

During the year ended September 30, 2012, the Company issued 941,333 shares of common stock valued at $19,301 based on the market price on the date of grant, to customers, in regards to the purchase of software from the Company in accordance with the Software Licensing and Subscription Agreements. The fair values of the shares issued were recorded against software revenue recognized during the year ended September 30, 2012.

Date		Number of Shares		Fair Value
	December 29, 2011		100,000	$	1,150
	May 29, 2012		25,000		400
	May 29, 2012		50,000		800
	May 29, 2012		100,000		1,600
	May 29, 2012		150,000		2,400
	May 29, 2012		181,333		2,901
	August 9, 2012		300,000		9,000
	August 9, 2012		35,000		1,050
	Total		941,333	$	19,301

Stock Issued for Services

During the year ended September 30, 2012, the Company issued 33,000 shares of common stock for compensation. The fair values of the shares were a total of $624 and were recorded at the market price on the date of grant. The issuances of stock were as follows:

Date		Number of Shares		Fair Value		Description of Services
	December 5, 2011		8,000	$	82	Legal services
	December 5, 2011		10,000		102	Advisory service
	June 21, 2012		1,000		20	Commission
	August 9, 2012		14,000		420	Commission
	Total		33,000	$	624

Stock Issued for Debt Settlement

On October 15, 2011, the Company issued 30,000,000 shares of common stock for the conversion of debt from our CEO in the principal amount of $1,200,106.

Table of Contents -45-

Stock Issued for Assets Acquisition

The Company issued 200,000 shares of common stock on June 21, 2012 to Krooss Medical Management in accordance with the acquisition agreement for Doctors Network of America and recorded it at the market price of the common shares of $0.020 and as an investment in Krooss Medical Management of $4,000.

The Company issued 100,000 shares of common stock to MediSouth LLC in accordance with the acquisition agreement and recorded it at the market price of the common shares of $0.025 and as an investment in MediSouth LLC of $2,500.

Preferred Stock

The Company has authorized 4,000,000 shares of preferred stock, at $0.01 par value. The Corporation established and designates the rights and preferences of a Series A Preferred Stock, and reserve 4,000,000 shares of preferred stock against its issuance, such rights, preferences and designations. Each share of the Preferred Stock has 150 votes on all matters presented to be voted by the holders of our common stock. All 4,000,000 shares of preferred stock have been issued to our CEO & CFO on April 11, 2011.

NOTE 11 - INCOME TAXES

Deferred income taxes result from temporary differences in the recognition of income and expenses for the financial reporting purposes and for tax purposes. The Company has a net operating loss carryforward of approximately $25.9 million available to offset future taxable income through 2013. For income tax reporting purposes, the Company’s aggregate unused net operating losses are subject to limitations of Section 382 of the Internal Revenue Code, as amended. Under the Tax Reform Act of 1986, the benefits from net operating losses carried forward may be impaired or limited on certain circumstances. Events which may cause limitations in the amount of net operating losses that the Company may utilize in any one year include, but are not limited to, a cumulative ownership change of more than 50% over a three-year period. The consolidation of any limitations that may be imposed for future issuances of equity securities, including issuances with respect to acquisitions have not been determined. The Company has provided a valuation reserve against the full amount of the net operating loss benefit, because in the opinion of management based upon the earning history of the Company; it is more likely than not that the benefits will not be realized.

For the years ended September 30, 2013 and 2012, the difference between the amounts of income tax expense or benefit that would result from applying the statutory rates to pretax income to the reported income tax expense of $0 is the result of the net operation loss carryforward and the related valuation allowance.

The Company anticipates it will continue to record a valuation allowance against the losses of certain jurisdictions, primarily federal and state, until such time as it is able to determine it is “more-likely-than-not” the deferred tax asset will be realized. Such position is dependent on whether there will be sufficient future taxable income to realize such deferred tax assets. The Company’s effective tax rate may vary from period to period based on changes in estimated taxable income or loss by jurisdiction, changes to the valuation allowance, changes to federal, state or foreign tax laws, future expansion into areas with varying country, state, and local income tax rates, deductibility of certain costs and expenses by jurisdiction.

NOTE 12– SUBSEQUENT EVENTS

In October 2013, the Company through a purchase agreement with Antree Systems Limited has purchased a complete source code, intellectual property rights, all computer software, patents, or formulas, algorithm licensed or sold under a project known as Compass Rose and appropriate copyrights, patents, mask works, trademarks, service marks, internet domain names and world wide web uniform resource locators (“URLs”) from Antree Systems Limited. The Company issued 200,000 shares of its common stock as consideration for the purchase. The fair value of the consideration and the assets acquired is based on the fair value of the common stock issued in exchange for the software. The total fair value, based on the market price on the date of grant, was $6,000. The Company evaluated this acquisition and determined that it did not meet the definition of a significant business acquisition.

Table of Contents -46-

In November 2013, the Company entered into a revolving line of credit with Mutual of Omaha for a line of credit in the amount of $65,000 at 4.00% interest rate which renews annually. As of January 10, 2014 we have borrowed $36,500.

On December 17, 2013, the Company amended its Articles of Incorporation that gave the right to the holders of Preferred A shares to convert 1 share of Convertible Preferred A shares to 150 Common Shares of the Company. The holders of the Preferred A shares can convert the shares upon proper notice and approval of the Board of Directors. Presently, the holders of the Preferred A shares have not sent notice to the Board of Directors.

Stock issuances

Fiscal Year Ending September 30, 2014

In October 2013, the Company issued 25,000 shares of common stock for net cash proceeds of $5,000.

In October 2013, the Company issued 200,000 shares of common stock for purchase of assets from Antree Systems Limited. These shares were valued at $6,000 based on the market price on the date of grant.

In November 2013, the Company issued 180,000 shares of common stock as replacement shares for the 160,000 shares of common stock issued to Antree Systems Limited and 20,000 shares of common stock to Kimberly Ilicerl. The Company intends to cancel the original shares because the shares were lost during delivery to Antree Systems. The Company replaced those lost shares and canceled the shares that were lost when delivered to Ireland the office of Antree Systems.

On December 4, 2013, the Company issued 120,000 shares of common stock valued at $3,600 based on the market price on the date of grant, for the purchase of the software licensing and subscription agreements.

On January 12, 2014, the Company issued 10,000 shares of common stock for net cash proceeds of $10,000. 

Table of Contents -47-

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

Effective November 27, 2013, the Registrant engaged GBH CPAs, PC as its auditor. The previous auditor, S. E. Clark & Company, P.C., resigned on November 27, 2013.

During the period May 16, 2012 through November 27, 2013, there have been no disagreements with S. E. Clark & Company, P.C. (as defined in Item 304(a)(1)(iv) of Regulation S-K) on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of S. E. Clark & Company, P.C. would have caused them to make reference thereto in their report on financial statements for such years.

During the period May 16, 2012 through November 27, 2013 through the date of the resignation of S. E. Clark & Company, P.C., there were no reportable events as defined in Item 304(a)(1)(v) of Regulation S-K.

On November 27, 2013, on the recommendation of the Registrant’s Board of Directors, the Registrant engaged GBH CPAs, PC as its independent registered public accounting firm to audit the Registrant’s financial statements for the fiscal year ended September 30, 2013 and to perform procedures related to the financial statements included in the Registrant’s quarterly reports on Form 10-Q, beginning with the quarter ending March 31, 2012 through current.

Effective May 26, 2012, the Registrant engaged S. E. Clark & Company, P.C. The previous auditor Semple, Marchal & Cooper, LLP resigned as auditors on December 16, 2011.

During the period January 26, 2007 through December 16, 2011, there have been no disagreements with Semple, Marchal & Cooper, LLP (as defined in Item 304(a)(1)(iv) of Regulation S-K) on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Semple, Marchal & Cooper, LLP would have caused them to make reference thereto in their report on financial statements for such years.

During the period January 26, 2007 through December 16, 2011, there were no reportable events as defined in Item 304(a)(1)(v) of Regulation S-K. 

ITEM 9A. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures were designed to provide reasonable assurance that the controls and procedures would meet their objectives. As required by SEC Rule 13a-15(b), our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective at the reasonable assurance level.

Table of Contents -48-

Management’s Annual Report on Internal Control over Financial Reporting

Our Chief Executive Officer and Chief Financial Officer are responsible for establishing and maintaining adequate internal control over our financial reporting. In order to evaluate the effectiveness of internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act, management has conducted an assessment, including testing, using the criteria in Internal Control — Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Our system of internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Management has used the framework set forth in the report entitled Internal Control-Integrated Framework published by the Committee of Sponsoring Organizations of the Treadway Commission, known as COSO, to evaluate the effectiveness of our internal control over financial reporting. Based on this assessment, our Chief Executive Officer and Chief Financial Officer have concluded that our internal control over financial reporting was not effective as of September 30, 2013.

The Company’s material weaknesses in financial reporting were:

The inability of the Company to prepare and file its financial statements timely due to its limited financial and personnel resources and delays in the Company’s ability to respond to SEC inquiries regarding financial and accounting presentation. Further, the Company is delinquent in filings for fiscal year ended 2012 through and 2013. The Company also lacks segregation of duties and adequate documentation of our system of internal controls. The Company has implemented controls that the CEO would approve all transactions and the CFO would record and report these transactions which would implement segregation of duties weakness.

This annual report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by the Company's registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit the Company to provide only management's report in this annual report.

Changes in internal control over financial reporting

There were no changes in our internal control over financial reporting that occurred during the year ended September 30, 2013 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

It should be noted that any system of controls, however well designed and operated, can provide only reasonable and not absolute assurance that the objectives of the system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of certain events. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.

ITEM 9B. OTHER INFORMATION

There are no events required to be disclosed by the Item.

Table of Contents -49-

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE

Director and Executive Officer

Set forth below is information regarding the Company’s current directors and executive officers. There are no family relationships between any of our directors or executive officers. The directors are elected annually by stockholders. The executive officers serve at the pleasure of the Board of Directors.

Name	Age		Title
Michael De La Garza		55	Chairman, CEO,  President, Chairman
Pamela J. Thompson		50	Chief  Financial Officer, Secretary, Treasurer, Director

The chief executive officer and director and officer of the Company will hold office until additional members or officers are duly elected and qualified. The background and principal occupations of the sole officer and director of the Company is as follows:

Michael De La Garza

Cloud Medical Doctor Software Corporation – 2010-Present. President, CEO, Chairman of the Board,

Card Activation Technology Corporation. - President, CEO, Chairman of the Board a gift card technology company- 2008-2009

MedCom USA, Corporation. -President, CEO, Chairman of the Board of a medical software company - 2008-2009

PayMed USA, LLC President and co-founder of a medical software company -2003-2012

Providers Solution, Corporation. President and co-founder of a medical software company -2000-2012

Accident and Injury Medical Centers, Corporation, President and co-founder of a medical rehab company 1993-1999

Medical Synergies Corporation. COO, President, a medical billing company. 1991-1999

The Center’s for Diagnostic Medical Services, Corporation. COO and President, a medical imaging group company 1991-1999

Pamela Thompson

Cloud Medical Doctor Software Corporation; 2010-Present; Chief Financial Officer, Secretary, Treasurer, member of the Board of Directors,

Ms. Pamela J. Thompson, CPA, P.C. has been Chief Financial Officer, Treasurer, Secretary and Director of Cloud Medical Doctor Software Corporation since November 19, 2010. Ms. Thompson is the Founder of Pamela J. Thompson CPA PC and serves as its Principle Executive Officer.

Table of Contents -50-

Ms. Thompson formed Pamela J. Thompson, CPA, P.C. in 1990 and has over 20 years of experience in SEC compliance, tax and accounting for publicly traded companies. Her Sarbanes-Oxley Section compliance implementation experience is focused on assisting publicly traded companies with performing risk assessment on critical business process and documenting business process controls. She served as Chief Financial Officer, Secretary and Treasurer of several public companies. Ms. Thompson started her career in 1986 with the international accounting firm of Arthur Andersen and was subsequently with Pannell Kerr Forester, and one of the larger regional firms Eide, Bailey and Company. Ms. Thompson is featured in Arizona Republic, New Jersey Star, Arizona Women's Success Magazine, National Basketball Players Association Magazine, and Behind the Bench: National Basketball Wives Association Magazine and Wall Street Journal. She is a Certified Fraud Examiner Candidate. Ms. Thompson is also a Member of the Arizona Women's Society of Certified Public Accountants and Behind the Bench: National Basketball Wives Association. She is a Member of the American Institute of Certified Public Accountants. She is also a Member of the Association of Certified Fraud Examiners and Arizona Association of Certified Fraud Examiners. Ms. Thompson holds a Bachelor of Science from Minnesota State University - Moorhead in Accountancy in 1986 and holds her license as a Certified Public Accountant in the State of Arizona in 1993.

Audit Committee Financial Expert

The Company does not have an audit committee or a compensation committee of its board of directors. In addition, the Company’s board of directors has determined that the Company does not have an audit committee financial expert serving on the board. When the Company develops its operations, it will create an audit and a compensation committee and will seek an audit committee financial expert for its board and audit committee.

Conflicts of Interest

Members of our management are associated with other firms involved in a range of business activities. Consequently, there are potential inherent conflicts of interest in their acting as officers and directors of our company. Although the officers and directors are engaged in other business activities, we anticipate they will devote an important amount of time to our affairs.

Our officers and directors are now and may in the future become shareholders, officers or directors of other companies, which may be formed for the purpose of engaging in business activities similar to ours. Accordingly, additional direct conflicts of interest may arise in the future with respect to such individuals acting on behalf of us or other entities. Moreover, additional conflicts of interest may arise with respect to opportunities which come to the attention of such individuals in the performance of their duties or otherwise. Currently, we do not have a right of first refusal pertaining to opportunities that come to their attention and may relate to our business operations.

Our officers and directors are, so long as they are our officers or directors, subject to the restriction that all opportunities contemplated by our plan of operation which come to their attention, either in the performance of their duties or in any other manner, will be considered opportunities of, and be made available to us and the companies that they are affiliated with on an equal basis. A breach of this requirement will be a breach of the fiduciary duties of the officer or director. If we or the companies with which the officers and directors are affiliated both desire to take advantage of an opportunity, then said officers and directors would abstain from negotiating and voting upon the opportunity. However, all directors may still individually take advantage of opportunities if we should decline to do so. Except as set forth above, we have not adopted any other conflict of interest policy with respect to such transactions.

Compliance with Section 16(A) Of the Exchange Act 9.A. Directors and Executive Officers, Promoters, and Control Persons:

As of September 30, 2013, the Company is aware that all filings of Form 4 and 5 required of Section 16(a) of the Exchange Act of Directors, Officers or holders of 10% of the Company's prior management and board of directors have not filed the requirements timely. Current management needs to file Form 4 for the issuance of common shares as follows:

CFO January 2, 2011 5,000,000 common shares

CEO January 2, 2011 10,000,000 common shares

CEO October 2011 30,000,000 common shares

Table of Contents -51-

Code of Ethics

We have adopted a code of ethics that applies to all of our executive officers, directors and employees. Code of ethics codifies the business and ethical principles that govern all aspects of our business. This document will be made available in print, free of charge, to any shareholder requesting a copy in writing from the Company. A form of the code of conduct and ethics was filed as Exhibit 14.1 to the Annual Report on Form 10-K for the year ended September 30, 2004.

ITEM 11. EXECUTIVE COMPENSATION

Executive Officers and Directors

Summary Compensation Table

The following tables set forth certain information concerning all compensation paid, earned or accrued for service by (i) our Principal Executive Officer and Principal Financial Officer and (ii) all other executive officers who earned in excess of $100,000 in the fiscal years ended September 30, 2013, and each of the other two most highly compensated executive officers of the Company who served in such capacity at the end of the fiscal year whose total salary and bonus exceeded $100,000 (collectively, the “Named Executive Officer”):

2013 and 2012 SUMMARY COMPENSATION TABLE

Name and Principal Position	Year		Salary ($)		Bonus ($)		Stock Awards ($)		Option Awards ($)		Non-Equity Incentive Plan Compensation ($)		Change in Pension Value and Nonqualified Deferred Compensation Earnings ($)		All Other Compensation ($)		Total ($)
Michael De La Garza CEO, President & Chairman		2012		—		—		—		—		—		—		—		—
		2013		199,647		—		—		—		—		—		—		199,647
Pamela Thompson, CFO, Secretary, Treasurer & Director		2012		60,000		—		—		—		—		—		—		60,000
		2013		117,500		—		—		—		—		—		—		117,500

Table of Contents -52-

2013 and 2012 OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END TABLE

	Option Awards					Stock Awards
Name	Year	Number of Securities Underlying Unexercised Options (#)	Number of Securities Underlying Unexercised Options (#)	Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)	Option Exercise Price ($)	Option Expiration Date	Number of Shares or Units of Stock That Have Not Vested (#)	Market Value of Shares or Units of Stock That Have Not Vested ($)	Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#)	Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)
		Exercisable	Unexercisable
Michael De La Garza	2012	—	—	—	—	—	—	—	—	—
	2013	—	—	—	—	—	—	—	—	—
Pamela Thompson	2012	—	—	—	—	—	—	—	—	—
	2013	—	—	—	—	—	—	—	—	—

Compensation of Directors

Our current compensation policy for directors is to compensate them through options to purchase common stock or through common stock as consideration for their joining our board and/or providing continued services as a director. We do not currently provide our directors with cash compensation, although we do reimburse their expenses, with exception for a chairman of the board. No additional amounts are payable to the Company’s directors for committee participation or special assignments. There are no other arrangements pursuant to which any directors was compensated during the Company’s last completed fiscal year for any service provided except as follows:

On November 19, 2010, the Board of Directors appointed Michael De La Garza as the new Chief Executive Officer, President and Chairman of the Board of Directors.  

On November 19, 2010, the Board of Directors appointed Pamela Thompson as the new Chief Financial Officer, Secretary, Treasurer and member of the Board of Directors.

Table of Contents -53-

Employment Contracts

The Company entered into an employment agreement with its Chief Executive Officer on January 1, 2013.  The employment agreement will expire on January 1, 2018 and shall automatically renew for another 5 years unless terminated in accordance with the provisions of the employment agreement. The Employment Agreement provides for:

i.	A monthly salary of $20,833 per month subject to an annual increase of 10% per year and consistent with the Company policy applicable to other senior executives and officers and approval by the Board of Directors.
ii.	A cash bonus of 25% of his annual base salary each year if the Company reaches the following milestones (none of which were attained in 2013):

a.	The Company posts annual gross revenues on a consolidated basis of at least $5,000,000;
b.	The Company's earnings before the deduction of income taxes and amortization expenses (“EBITA”), including cash extraordinary items but before officer's bonuses, on a consolidated basis for any year is at least $1,000,000; or

iii.	The issuance of shares equal to 1% of the then issued and outstanding shares of the Company annually, which is approximately 2,146,242 to be issued in 2013.
iv.	The issuance of common stock on each anniversary date of the employment agreement of 5,000,000 shares and issuance of common stock for every acquisition granting 5,000,000 shares for DNA, 5,000,000 shares for CipherSmith, LLC, and 1,000,000 shares for MediSouth, LLC.
v.	An automobile allowance of $1,500 per month.
vi.	A medical insurance allowance of $1,500 per month.
vii.	In the event the executive's employment is terminated without cause he will receive the entire contract remaining on the agreement.

The Company entered into an employment agreement with its Chief Financial Officer on January 1, 2013.  The employment agreement will expire January 1, 2018 and shall automatically renew for another 5 years unless terminated in accordance with the provisions of the employment agreement. The employment agreement provides for:

i.	A monthly salary of $12,500 per month subject to an annual increase of 10% per year and consistent with the Company policy applicable to other senior executives and officers and approval by the Board of Directors.
ii.	A cash bonus of 25% of her annual base salary each year if the Company reaches the following milestones (none of which were attained in 2013):

a.	The Company posts annual gross revenues on a consolidated basis of at least $5,000,000;
b.	The Company's earnings before the deduction of income taxes and amortization expenses (“EBITA”), including cash extraordinary items but before officer's bonuses, on a consolidated basis for any year is at least $1,000,000; or

iii.	The issuance of shares equal to 1% of the then issued and outstanding shares of the Company annually, which is approximately 2,146,242 to be issued in 2013.
iv.	The issuance of common stock on each anniversary date of the employment agreement of 5,000,000 shares and issuance of common stock for every acquisition granting 3,000,000 shares for DNA, 3,000,000 shares for CipherSmith, LLC, and 750,000 shares for MediSouth, LLC.
v.	An automobile allowance of $1,000 per month.
vi.	A medical insurance allowance of $1,500 per month.
vii.	In the event the executive's employment is terminated without cause he will receive the entire contract remaining on the agreement.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The following table lists stock ownership of our Common Stock as of January 24, 2013 based on 215,159,216 shares of common stock issued and outstanding on a fully diluted basis. The information includes beneficial ownership by (i) holders of more than 5% of our Common Stock, (ii) each of our directors and executive officers and (iii) all of our directors and executive officers as a group. Except as noted below, to our knowledge, each person named in the table has sole voting and investment power with respect to all shares of our Common Stock beneficially owned by them.

Table of Contents -54-

Name and Address of Owner	Title of Class	Number of Shares Owned (1)		Percentage of Class
Michael De La Garza(1) c/o Cloud 1291 Galleria Drive, Suite 200 Henderson, NV 89014	Common Stock		40,000,000		18.86	%
Pamela Thompson(2) c/o Cloud 1291 Galleria Drive, Suite 200 Henderson, NV 89014	Common Stock		5,000,000		2.35	%
All Officers and Directors As a Group (2 persons)	Common Stock		45,000,000		21.21	%

(1)	Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and generally includes voting or investment power with respect to securities.
(2)	Pamela Thompson does not have beneficial ownership to the stock issued to her; those shares are held in an irrevocable trust for the benefit of her minor children, that she does not have control or voting control of those shares.

Changes in Control

We are not aware of any arrangements that may result in a change in control of the Company.

DESCRIPTION OF SECURITIES

General

On April 11, 2011 the Company amended its articles of incorporation to increase the authorized common shares to 650,000,000 shares, at $0.01 par value. There were 214,624,216 shares issued and outstanding as of September 30, 2013.

Common Stock

The holders of our common stock are entitled to receive such dividends, if any, as may be declared by our board of directors from time to time out of legally available funds. The dividend rights of our common stock are junior to any preferential dividend rights of any outstanding shares of preferred stock. The holders of our common stock also are entitled to receive distributions upon our liquidation, dissolution or winding up of our assets that are legally available for distribution, after payment of all debt and other liabilities and distribution in full of preferential amounts, if any, to be distributed to holders of our preferred stock.

The holders of our common stock are not entitled to preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of any series of preferred stock that we may designate and issue in the future.

Preferred Stock

The Company has authorized 4,000,000 shares of preferred stock, at $0.01 par value and 4,000,000 are issued and outstanding as of September 30, 2013. The Corporation established and designates the rights and preferences of a Series A Convertible Preferred Stock, and reserves 4,000,000 shares of preferred stock against its issuance, such rights, preferences and designations. Each share of the Preferred Stock shall have 150 votes on all matters presented to be voted by the holders of our common stock. All 4,000,000 shares of preferred stock that have been issued to our CEO & CFO on April 11, 2011 valued at the trading price of the common stock of $0.0095 and recorded as an expense of $38,000.

Table of Contents -55-

The issuance of preferred stock by our board of directors could adversely affect the rights of holders of the common stock by, among other things, establishing preferential dividends, liquidation rights or voting powers. See “Risk Factors” above.

Warrants and Options

All warrants and options issued have expired.

Voting Rights 

Each holder of Common Stock is entitled to one vote for each share of Common Stock held on all matters submitted to a vote of stockholders.

Dividends 

Subject to preferences that may be applicable to any then-outstanding shares of Preferred Stock, if any, and any other restrictions, holders of Common Stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by the Company’s board of directors out of legally available funds. The Company and its predecessors have not declared any dividends in the past. Further, the Company does not presently contemplate that there will be any future payment of any dividends on Common Stock.

Convertible Securities

The Company has no convertible securities as of September 30, 2013.

Amendment of our Bylaws

Our bylaws may be adopted, amended or repealed by the affirmative vote of a majority of our outstanding shares. Subject to applicable law, our bylaws also may be adopted, amended or repealed by our board of directors.

Transfer Agent

On August 31, 2011, the Company engaged Pacific Stock Transfer to serve in the capacity of transfer agent. Their mailing address and telephone number are as follows: Pacific Stock Transfer, 4045 South Spencer #403, Las Vegas, NV 89119 - (702) 361-3033.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

On October 15, 2011, the Company issued 30,000,000 common shares to the CEO to convert the debt in the principal amount of $1,200,106 in principal.

During the years ended September 30, 2013 and 2012, the CEO advanced the Company cash proceeds of $0 and $7,969, respectively. In addition, during the year ended September 30, 2012, the CEO made payments on the Company’s behalf of $25,236 on the Company’s line of credit. The Company repaid $25,591 and $188,410 of the advances in the years ended September 30, 2013 and 2012, respectively. The advances from the CEO are due on demand and do not accrue interest. As of September 30, 2013 and 2012, the amount owed to the CEO for advances was $0 and $25,591, respectively.

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

Audit Fees. The aggregate fees billed by GBH CPAs, PC for the audit of the Company’s annual financial statements for fiscal years ended September 30, 2013 and 2012 were approximately $32,000 and $32,000, respectively.

Audit-Related Fees. The aggregate fees billed by GBH CPAs, PC for assurance and related services that are reasonably related to the performance of the audit or review of the Company’s financial statements for the fiscal years ended September 30, 2013 and 2012, and that are not disclosed in the paragraph captioned “Audit Fees” above, were $0 and $0, respectively.

Table of Contents -56-

Tax Fees. The aggregate fees billed by GBH CPAs, PC for professional services rendered for tax compliance, tax advice and tax planning for the fiscal years ended September 30, 2013 and 2012 were $0 and $0, respectively.

All Other Fees. The aggregate fees billed by GBH CPAs, PC for products and services, other than the services described in the paragraphs “Audit Fees,” “Audit-Related Fees,” and “Tax Fees” above for the fiscal years ended September 30, 2013 and 2012 were $0 and $0, respectively.

The Board of Directors has received and reviewed the written disclosures and the letter from the independent registered public accounting firm required by Independence Standards Board Standard No. 1 (Independence Discussions with Audit Committees), and has discussed with its auditors its independence from the Company. The Board of Directors has considered whether the provision of services other than audit services is compatible with maintaining auditor independence.

Based on the review and discussions referred to above, the Board of Directors approved the inclusion of the audited financial statements be included in the Company’s Annual Report on Form 10-K for its 2013 fiscal year for filing with the SEC.

The Board of Directors pre-approved all fees described above.

Table of Contents -57-

PART IV

ITEM 15. EXHIBITS AND REPORTS

Exhibits

3.1	Articles of Incorporation(1)
3.2	Bylaws(2)
3.3	Amendment to Preferred Shares (9)
10.1	Employment Agreement between National Scientific Corporation and Michael A. Grollman dated January 2001(4)
10.2	Employment Agreement between National Scientific Corporation and Graham L. Clark dated January 2003(6)
10.3	NSC Consulting Agreement dated August 2001, and Amendments dated August 2002 and July 2003, with Dr. El-Badawy El-Sharawy(6)
10.4	Amended and Restated 2000 Stock Option Plan(3)
10.5	Form of 2004 Stock Retainage Plan Agreement(6)
10.6	Agreement Regarding Management Consulting Services with Stanton Walker of New York dated May 2003(6)
10.7	Agreement Regarding Distribution and Marketing of Gotcha!® Child Safety Product and other products dated December 2002 with FutureCom Global, Inc. (6)
10.8	Purchase Order from Verify Systems, Inc., dated March 2003 for IBUS™ School Child Tracking Systems(5)
10.9	Letter of Understanding and Agreement dated April 2004 Regarding Sales and Distribution of Verify School safety products, and an Unlimited Software License with Anthony Grosso and CIS Services, LLC(6)
10.10	Letter of Intent from Positus, Inc. dba Bike & Cycle Trak, dated February 2003 for Design of Power Sports Tracking System(6)
10.11	Purchase Order from Positus, Inc. dba Bike & Cycle Trak, for Design of Power Sports Tracking System dated March 2003(6)
10.12	Employment agreement of Michael De La Garza(8)
10.13	Employment agreement of Pamela Thompson(8)
14	Code of Ethics(7)
31.1	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act(9)
31.2	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act(9)
32.1	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act(9)
32.2	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act(9)

____________

(1)	Incorporated by reference to the Registrant’s Form 10-SB filed on or about January 3, 2000.
(2)	Incorporated by reference to the Registrant’s Form 10-QSB for the quarter ended March 31, 2001 and filed on or about May 15, 2001.
(3)	Incorporated by reference to the Registrant’s Form 10-QSB for the quarter ended December 31, 2000 and filed on or about February 14, 2001.
(4)	Incorporated by reference to the Registrant’s Form 10-KSB for the year ended September 30, 2000 and filed on or about December 19, 2000.
(5)	Incorporated by reference to the Registrant’s Form S-8 filed on or around June 3, 2003.
(6)	Incorporated by reference to the Registrant’s Form SB-2 filed on or around June 24, 2004.
(7)	Incorporated by reference to the Registrant’s Form 10-QSB for the quarter ended June 30, 2004 and filed on or about August 16, 2004.
(8)	Incorporated by reference to the Registrant’s Form 10-K for the year ended September 30, 2011 and filed on October 10, 2013.
(9)	Incorporated herein

Table of Contents -58-

 SIGNATURES

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, there unto duly authorized.

Registrant Date: February 5, 2014	Cloud Medical Doctor Software Corporation By: /s/ Michael De La Garza
	Michael De La Garza
	Chairman, Chief Executive Officer (Principal Executive Officer), President
Date: February 5, 2014	By: /s/ Pamela Thompson
	Pamela Thompson
	Chief Financial Officer (Principal Accounting Officer), Secretary, Treasurer

In accordance with the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Company and in the capacities and on the dates indicated.

Date: February 5, 2014	By: /s/ Michael De La Garza
	Michael De La Garza
	Chairman
Date: February 5, 2014	By: /s/ Pamela Thompson
	Pamela Thompson
	Director

Table of Contents -59-

EX-31.2

EXHIBIT 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO RULES 13A-14 AND 15D-14

OF THE SECURITIES EXCHANGE ACT OF 1934

I, Pamela Thompson, certify that:

1.	I have reviewed this annual report on Form 10-K of Cloud Medical Doctor Software Corporation;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and have:

a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By /s/ Pamela Thompson

Pamela Thompson

Chief Financial Officer, Secretary, Treasurer

February 5, 2014

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Cloud Medical Doctor Software Corporation (the “Company”) on Form 10-K for the period ended September 30, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael De La Garza, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, That to the best of my knowledge:

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By /s/ Michael De La Garza

Michael De La Garza

Chairmen, Chief Executive Officer, President

February 5, 2014

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Cloud Medical Doctor Software Corporation (the “Company”) on Form 10-K for the period ended September 30, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Pamela Thompson, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, That to the best of my knowledge:

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By /s/ Pamela Thompson

Pamela Thompson

Chief Financial officer, Secretary, Treasurer

February 5, 2014

XML

NOTE 8. COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
COMMITMENTS AND CONTINGENCIES
Rent Expense	$ 0	$ 0
Litigation Reserve	200,000
Write Offs	$ 101,121	$ 1,573,591

XML

NOTE 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurements by Level (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2012
Software Development, Net of Amortization	$ 817,921	$ 1,022,591
Total Proprietary Technology	817,921	1,022,591
Level 1
Software Development, Net of Amortization
Total Proprietary Technology
Level 2
Software Development, Net of Amortization
Total Proprietary Technology
Level 3
Software Development, Net of Amortization	817,921	1,022,591
Total Proprietary Technology	$ 817,921	$ 1,022,591

XML

NOTE 12. SUBSEQUENT EVENTS (Details Narrative) (USD $)	3 Months Ended	12 Months Ended
	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012	Jan. 10, 2014	Nov. 30, 2013	Oct. 31, 2013
Acquisition of Software, Fair Value			$ 10,000	$ 4,000			$ 6,000
Shares Issued in Acquisition	200,000			500,000
Line of Credit, Amount						65,000
Line of Credit, Interest Rate						4.00%
Line of Credit, Amount Outstanding					36,500
Preferred Stock Conversion Rights	1 shares of Convertible Preferred A Shares to 150 Common Shares of the Company
Stock Issued for Cash, Shares		68,000	217,500	190,000
Stock Issued for Cash, Value			143,000	68,000
Stock Issued for Software Purchase, Shares			500,004	100,000
Stock Issued for Software Purchase, Value		2,500	15,800	2,500
Stock Issued for Software Purchase 2, Shares			400,000	941,333
Stock Issued for Software Purchase 2, Value		19,301	15,800	19,301
Subsequent Event [Member]
Stock Issued for Cash, Shares		35,000
Stock Issued for Cash, Value		15,000
Stock Issued for Software Purchase, Shares		200,000
Stock Issued for Software Purchase, Value		6,000
Stock Issued as Replacement Shares, Shares		180,000
Stock Issued for Software Purchase 2, Shares		120,000
Stock Issued for Software Purchase 2, Value		$ 3,600
Antree Systems Limited
Stock Issued as Replacement Shares, Shares		160,000
Kimberly Ilicerl
Stock Issued as Replacement Shares, Shares		20,000

XML

NOTE 3. GOING CONCERN ISSUES

12 Months Ended

Sep. 30, 2013

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NOTE 3. GOING CONCERN ISSUES

NOTE 3 - GOING CONCERN ISSUES

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. However, the Company has an accumulated deficit at September 30, 2013 of $26,542,265 and needs additional cash to maintain its operations.

These factors raise doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s continued existence is dependent upon management’s ability to develop profitable operations, continued contributions from the Company’s executive officers to finance its operations and the ability to obtain additional funding sources to explore potential strategic relationships and to provide capital and other resources for the further development and marketing of the Company’s products and business.

XML

NOTE 6. DISCONTINUED OPERATIONS - Discontinued Operations (Details) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Revenues	$ 516,868	$ 487,703
Cost of sales	243,470	181,739
Operating expenses	929,161	378,211
Interest expense	392	1,488
Gain from write-off of debt	(58,984)	(410,483)
Discontinued Operations
Accounts payable and accrued expenses	35,356
Net liabilities of discontinued operations	35,356
Revenues	431,400
Cost of sales
Operating expenses	(245,287)
Bad debt	(221,469)
Interest expense		(17,868)
Gain from write-off of debt	58,984	410,482
Income from Discontinued Operations	$ 23,628	$ 392,614

XML

NOTE 5. SOFTWARE (Details Narrative) (USD $)	3 Months Ended	12 Months Ended
	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012
Research and Development [Abstract]
Investment Impairment			$ 10,000	$ 4,000
Amortization Expense			243,470	180,015
Stock Issued for Software Purchase, Shares			500,004	100,000
Stock Issued During Period for Software Acquisition, Value				2,500
Stock Issued During Period for Software Acquisition 2, Shares			400,000	941,333
Stock Issued for Software Purchase 2, Value		19,301	15,800	19,301
Stock issued for Acquisition, Shares	200,000			500,000
Stock Issued During Period for Investment, Shares			300,000	200,000
Stock Issued Investment, Value		4,000	6,000	4,000
Accumulated Impairmnt of the Acquired Asset		$ 4,000	$ 6,000	$ 4,000

XML

NOTE 6. DISCONTINUED OPERATIONS (Details Narrative) (USD $)	3 Months Ended	12 Months Ended
	Sep. 30, 2007	Sep. 30, 2011	Sep. 30, 2006	Sep. 30, 2005	Sep. 30, 2013	Sep. 30, 2012	May 31, 2006	Apr. 27, 2006	Nov. 01, 2005	May 27, 2005
Discontinued Operations and Disposal Groups [Abstract]
Sale of Assets, Purchase Price		$ 100,000
Note Payable							20,000	16,625	175,000
Note Payable, Interest Rate	8.00%						1200.00%	1200.00%	800.00%	6.00%
Shares Issued, Financing Program				1,200,000
Per Share Conversion Price									$ 0.0525
Shares Issued, Price Per Share									$ 0.043
Debt Discount									51,600
Beneficial Conversion Feature				9,933
Deferred Financing Costs, Issuance of Shares									24,000
Related Party Payable	13,300					25,591				159,000
Proceeds from Repayment of Related Party Debt	11,000	0
Due to Related Party	148,000				0	25,591
Interest Payable	13,300
Origination/Placement Fee			500
Warrants Issued			$ 100,000
Purchase Price Per Share							$ 0.036	$ 0.036

XML

NOTE 7. DEBT MITIGATION PROGRAM - Debt Mitigation Program (Details) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Debt mitigation program	$ 101,121	$ 1,573,591
Gain on write off of debt	(58,984)	(410,483)
Additional paid-in capital	42,137	1,163,109	[1]
Accounts Payable and Accrued Expenses
Debt mitigation program	58,984	66,281
Disputed Salaries & Vacations of Former Officers
Debt mitigation program		968,645
Disputed Salaries of Former Employees
Debt mitigation program		20,256
Disputed Payroll Taxes for Back Pay of Former Officers
Debt mitigation program		84,701
Disputed Interest
Debt mitigation program		227,083
Accrued Interest
Debt mitigation program	42,137
Shareholders Demand Note 1
Debt mitigation program		11,625
Shareholders Demand Note 2
Debt mitigation program		20,000
Unsecured Note
Debt mitigation program		$ 175,000

[1] All amounts that were owed to related parties in prior years were recorded to paid-in-capital.

XML

NOTE 2. BASIS OF PRESENTATION

12 Months Ended

Sep. 30, 2013

Notes to Financial Statements

NOTE 2. BASIS OF PRESENTATION

NOTE 2 - BASIS OF PRESENTATION

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net revenues and expenses recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates.

In managements’ opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.

XML

NOTE 7. DEBT MITIGATION PROGRAM (Details Narrative) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
OTHER (INCOME) AND EXPENSES
Creditor Liabilities, Write Off	$ 101,121	$ 1,573,591
Gain on the Write Off of Liabilities	58,984	410,482
Additional Paid-In Capital for Related Party Liabilities	$ 42,137	$ 1,163,109	[1]

[1] All amounts that were owed to related parties in prior years were recorded to paid-in-capital.

XML

Balance Sheets (USD $)	Sep. 30, 2013	Sep. 30, 2012
CURRENT ASSETS:
Cash	$ 8,587	$ 51,356
Accounts receivable	8,338	4,888
Total current assets	16,925	56,244
Proprietary technology, net	817,921	1,022,591
TOTAL ASSETS	834,846	1,078,835
CURRENT LIABILITIES:
Accounts payable and accrued liabilities	361,994	229,736
Liabilities attributable to discontinued operations	35,356
Advances from officers		25,591
Line of credit	9,796	21,763
Total current liabilities	407,146	277,090
TOTAL LIABILITIES	407,146	277,090
STOCKHOLDERS' EQUITY:
Preferred stock, $0.10 par value, 4,000,000 shares authorized; 4,000,000 issued and outstanding as of September 30, 2013 and 2012	40,000	40,000
Common stock, $0.01 par value, 650,000,000 shares authorized; 214,624,216 and 211,991,212 issued and outstanding as of September 30, 2013 and 2012, respectively	2,146,242	2,119,912
Additional paid-in capital	24,783,723	24,552,924
Accumulated deficit	(26,542,265)	(25,911,091)
Total stockholders' equity	427,700	801,745
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 834,846	$ 1,078,835

XML

Statements of Cash Flows (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Statement of Cash Flows [Abstract]
Net income (loss)	$ 318,879	$ (631,174)
Income from discontinued operations	392,614	23,628
Net loss from continuing operations	(73,735)	(654,802)
Adjustments to reconcile net loss from continuing operations to net cash (used in) provided by operating activities:
Depreciation and amortization	180,015	243,470
Impairment of assets	4,000	6,000
Stock issued for compensation	624	36,629
Stock Issued for Software Purchase, Value	19,301	15,800
Changes in operating assets and liabilities:
Accounts receivable	(4,888)	(3,450)
Accounts payable and accrued liabilities	25,000	221,879
Net cash (used) provided in operating activities	150,317	(136,711)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of intangible asset		(11,500)
Net cash (used in) operating activities		(11,500)
CASH FLOWS FROM FINANCING ACTIVITIES:
Advances from affiliates	7,969	5,409
Repayment of advances from officer	(188,410)	(31,000)
Proceeds from line of credit	2,464	11,144
Repayment of line of credit		(23,111)
Stock Issued for Cash, Shares	68,000	217,500
Net cash provided by (used in) financing activities	(109,977)	105,442
(DECREASE) INCREASE IN CASH	40,340	(42,769)
CASH, BEGINNING OF YEAR	8,587	51,356
CASH, END OF YEAR	51,356	8,587
CASH PAID FOR:
Interest paid
Taxes paid
SUPPLEMENTAL DISCLOSURE OF NONCASH OPERATING AND FINANCING ACTIVITIES:
Reclass from discontinued operations to accounts payable	204,736
Accrual of software acquisition costs		11,500
Write-off of debt - related parties	1,163,109	42,137
Stock Issued Investment, Value	4,000	6,000
Stock Issued for Software Purchase, Value	2,500	15,800
Transfer from line of credit to advance from officer	25,236
Common stock issued for settlement of debt	$ 1,200,106

XML

NOTE 10. EQUITY (Details Narrative) (USD $)	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012	Jun. 21, 2012
Equity [Abstract]
Common Stock, Shares Authorized		650,000,000	650,000,000
Preferred Stock, Shares Authorized		4,000,000	4,000,000
Preferred Stock, Par Value		$ 0.01	$ 0.01
Stock Issued for Cash, Shares	68,000	217,500	190,000
Stock Issued During Period for Cash, Value		$ 143,000	$ 68,000
Stock Issued for Software Purchase 2, Shares		400,000	941,333
Stock Issued for Software Purchase 2, Value	19,301	15,800	19,301
Stock Issued Compensation, Shares		1,165,500	33,000
Stock Issued Compensation, Value	624	36,629	624
Stock Issued Investment, Shares		300,000	200,000
Stock Issued Investment, Value	4,000	6,000	4,000
Stock Issued for Software Purchase, Shares		500,004	100,000
Stock Issued for Software Purchase, Value	2,500	15,800	2,500
Stock Issued Conversion of Debt, Shares			30,000,000
Stock Issued Conversion of Shares, Value	$ 1,200,106		$ 1,200,106
Stock Issued, Price Per Share			$ 0.025	$ 0.020
Preferred Stock, Shares Reserved		4,000,000
Preferred Stock, Voting Rights		150

XML

NOTE 6. DISCONTINUED OPERATIONS (Tables)

12 Months Ended

Sep. 30, 2013

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

	September 30, 2013		September 30, 2012
Net liabilities of discontinued operations:
Accounts payable and accrued expenses		35,356		—
Net liabilities of discontinued operations	$	35,356	$	—

	Year ended September 30,
	2013			2012
Discontinued operations:
Revenues	$	431,400		$	—
Cost of sales		—			—
Operating expenses		(245,287	)		—
Bad debt		(221,469	)		—
Interest expense		—			(17,868	)
Gain from write-off of debt		58,984			410,482
Income from Discontinued Operations	$	23,628		$	392,614

XML

NOTE 11. INCOME TAXES (Details Narrative) (USD $)	12 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]
Net Operating Loss Carryforward	$ 25,900,000
Income Tax Expense	$ 0

XML

NOTE 3. GOING CONCERN ISSUES (Details Narrative) (USD $)	Sep. 30, 2013	Sep. 30, 2012
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated Deficit	$ (26,542,265)	$ (25,911,091)

XML

NOTE 1. DESCRIPTION OF BUSINESS

12 Months Ended

Sep. 30, 2013

Notes to Financial Statements

NOTE 1. DESCRIPTION OF BUSINESS

NOTE 1 - DESCRIPTION OF BUSINESS

Cloud Medical Doctor Software Corporation (the “Company”, or “Cloud-MD”) was incorporated in Texas on June 22, 1953 as American Mortgage Company. On May 16, 1996, the Company changed its name to National Scientific Corporation. On April 3, 2012, the Company changed its name to Cloud Medical Doctor Software Corporation.

In the year ended September 30, 2011, Cloud-MD introduced the Cloud-MD Office, a “Cloud Based”, 5010 ready and ICD-10 compliant, fully integrated and interoperable suite of medical software and services, designed by experienced healthcare analysts and programmers for healthcare providers, that produces “Actionable Information” to help independent physician practices, New Care Delivery Models (ACO), healthcare systems and billing services optimize a wide range of business. The Company’s current software product offerings include Practice Management, Electronic Medical Records, Revenue Management, Patient Financial Solutions, Medical and Pharmaceutical Supply Management, Claims Management and Patient Health Information Exchange.

In the year ended September 30, 2012, Cloud-MD launched Cloud-MD Billing Services which provides management of medical claims from posting physician charges and payments into the Company’s medical billing software. The software uses a continuous insurance claim follow-up system to track and research all rejected or denied medical claims; a comprehensive reporting module that includes monthly financial statements and other detailed reports that are sent to the Company’s clients so they can see how their practice is performing, patient account inquiries and support to assist patients with their billing and insurance questions.

XML

Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Sep. 30, 2012
Statement of Financial Position [Abstract]
Preferred Stock, Par Value	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	4,000,000	4,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstandng	0	0
Common Stock, Par Value	$ 0.01	$ 0.01
Common Stock, Shares Authorized	650,000,000	650,000,000
Common Stock, Shares Issued	211,542,212	180,526,879
Common Stock, Shares Outstanding	211,542,212	180,526,879

XML

NOTE 11. INCOME TAXES

12 Months Ended

Sep. 30, 2013

Income Tax Disclosure [Abstract]

NOTE 11. INCOME TAXES

NOTE 11 - INCOME TAXES

Deferred income taxes result from temporary differences in the recognition of income and expenses for the financial reporting purposes and for tax purposes. The Company has a net operating loss carryforward of approximately $25.9 million available to offset future taxable income through 2013. For income tax reporting purposes, the Company’s aggregate unused net operating losses are subject to limitations of Section 382 of the Internal Revenue Code, as amended. Under the Tax Reform Act of 1986, the benefits from net operating losses carried forward may be impaired or limited on certain circumstances. Events which may cause limitations in the amount of net operating losses that the Company may utilize in any one year include, but are not limited to, a cumulative ownership change of more than 50% over a three-year period. The consolidation of any limitations that may be imposed for future issuances of equity securities, including issuances with respect to acquisitions have not been determined. The Company has provided a valuation reserve against the full amount of the net operating loss benefit, because in the opinion of management based upon the earning history of the Company; it is more likely than not that the benefits will not be realized.

For the years ended September 30, 2013 and 2012, the difference between the amounts of income tax expense or benefit that would result from applying the statutory rates to pretax income to the reported income tax expense of $0 is the result of the net operation loss carryforward and the related valuation allowance.

The Company anticipates it will continue to record a valuation allowance against the losses of certain jurisdictions, primarily federal and state, until such time as it is able to determine it is “more-likely-than-not” the deferred tax asset will be realized. Such position is dependent on whether there will be sufficient future taxable income to realize such deferred tax assets. The Company’s effective tax rate may vary from period to period based on changes in estimated taxable income or loss by jurisdiction, changes to the valuation allowance, changes to federal, state or foreign tax laws, future expansion into areas with varying country, state, and local income tax rates, deductibility of certain costs and expenses by jurisdiction.

XML

Document and Entity Information (USD $)	12 Months Ended
	Sep. 30, 2013	Mar. 30, 2013	Jan. 31, 2014 Common Stock	Jan. 31, 2014 Preferred Stock
Entity Registrant Name	NATIONAL SCIENTIFIC CORP/AZ
Entity Central Index Key	0001022505
Document Type	10-K
Document Period End Date	Sep. 30, 2013
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	No
Entity Filer Category	Smaller Reporting Company
Entity Public Float		$ 5,219,871
Entity Common Stock, Shares Outstanding			215,159,216	4,000,000
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2013

XML

NOTE 12. SUBSEQUENT EVENTS

12 Months Ended

Sep. 30, 2013

Subsequent Events [Abstract]

NOTE 12. SUBSEQUENT EVENTS

NOTE 12– SUBSEQUENT EVENTS

In October 2013, the Company through a purchase agreement with Antree Systems Limited has purchased a complete source code, intellectual property rights, all computer software, patents, or formulas, algorithm licensed or sold under a project known as Compass Rose and appropriate copyrights, patents, mask works, trademarks, service marks, internet domain names and world wide web uniform resource locators (“URLs”) from Antree Systems Limited. The Company issued 200,000 shares of its common stock as consideration for the purchase. The fair value of the consideration and the assets acquired is based on the fair value of the common stock issued in exchange for the software. The total fair value, based on the market price on the date of grant, was $6,000. The Company evaluated this acquisition and determined that it did not meet the definition of a significant business acquisition.

In November 2013, the Company entered into a revolving line of credit with Mutual of Omaha for a line of credit in the amount of $65,000 at 4.00% interest rate which renews annually. As of January 10, 2014 we have borrowed $36,500.

On December 17, 2013, the Company amended its Articles of Incorporation that gave the right to the holders of Preferred A shares to convert 1 share of Convertible Preferred A shares to 150 Common Shares of the Company. The holders of the Preferred A shares can convert the shares upon proper notice and approval of the Board of Directors. Presently, the holders of the Preferred A shares have not sent notice to the Board of Directors.

Stock issuances

Fiscal Year Ending September 30, 2014

In October 2013, the Company issued 25,000 shares of common stock for net cash proceeds of $5,000.

In October 2013, the Company issued 200,000 shares of common stock for purchase of assets from Antree Systems Limited. These shares were valued at $6,000 based on the market price on the date of grant.

In November 2013, the Company issued 180,000 shares of common stock as replacement shares for the 160,000 shares of common stock issued to Antree Systems Limited and 20,000 shares of common stock to Kimberly Ilicerl. The Company intends to cancel the original shares because the shares were lost during delivery to Antree Systems. The Company replaced those lost shares and canceled the shares that were lost when delivered to Ireland the office of Antree Systems.

On December 4, 2013, the Company issued 120,000 shares of common stock valued at $3,600 based on the market price on the date of grant, for the purchase of our software licensing and subscription agreements.

On January 12, 2014, the Company issued 10,000 shares of common stock for net cash proceeds of $10,000. 

XML

Statements of Operations (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Income Statement [Abstract]
REVENUE	$ 516,868	$ 487,703
COST OF REVENUES	243,470	181,739
GROSS PROFIT	273,398	305,964
OPERATING EXPENSES:
General and administrative	714,266	223,211
Research and development	208,895	151,000
Impairment of assets	6,000	4,000
Total operating expenses	929,161	378,211
OPERATING LOSS	(655,763)	(72,247)
OTHER (INCOME) AND EXPENSES
Interest expense	392	1,488
Gain on the disposal of assets	(1,353)
Total other (income) expenses	(961)	1,488
LOSS FROM CONTINUING OPERATIONS	(654,802)	(73,735)
INCOME FROM DISCONTINUED OPERATIONS	23,628	392,614
NET INCOME (LOSS)	$ (631,174)	$ 318,879
NET INCOME (LOSS) PER COMMON SHARE - Basic and diluted:
Continuing operations	$ 0.00	$ 0.00
Discontinued operations	$ 0.00	$ 0.00
Total	$ 0.00	$ 0.00
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic and diluted	212,798,744	210,463,497

XML

NOTE 6. DISCONTINUED OPERATIONS

12 Months Ended

Sep. 30, 2013

Discontinued Operations and Disposal Groups [Abstract]

NOTE 6. DISCONTINUED OPERATIONS

NOTE 6 - DISCONTINUED OPERATIONS

The Company’s former Board of Directors believed that it was in the best interest of the Company to discontinue the business operations of the GPS operational device business. In 2011, the assets were transferred to National Scientific, LLC, a company owned by the Company’s prior CEO, by prior management in which the Company’s former CEO was to pay $100,000 plus 2% of revenues for that technology. The former officer never paid the required compensation.

Accordingly, the Company reclassified the assets, liabilities and operations related to its GPS operational device business as discontinued operations.  Consequently, the accompanying consolidated financial statements reflect the assets, liabilities and operations of the GPS operational device business as net assets of discontinued operations, net liabilities of discontinued operations and results from discontinued operations. As of September 30, 2013 and 2012, the Company did not have any net assets or net liabilities related to the GPS operational device business.

The Company closed the acquisition with the final payment for DNA on March 16, 2013. Subsequent to the transaction closing, the sellers refused to pay the transaction fees for medical billing contracts that were processed. The Company filed a law suit against the sellers for Breach of Contract among other things in June of 2013. During that time, the Company believe the sellers began contacting all billing contract holders and interfered with the acquisition of all the assets from the transaction. Consequently, the accompanying consolidated financial statements reflect the assets, liabilities and operations of DNA as net assets of discontinued operations, net liabilities of discontinued operations and results from discontinued operations. All of the assets that were acquired have been impaired and included in discontinued operations.

Details of the classifications for net liabilities and operations are shown below.

	September 30, 2013		September 30, 2012
Net liabilities of discontinued operations:
Accounts payable and accrued expenses		35,356		—
Net liabilities of discontinued operations	$	35,356	$	—

	Year ended September 30,
	2013			2012
Discontinued operations:
Revenues	$	431,400		$	—
Cost of sales		—			—
Operating expenses		(245,287	)		—
Bad debt		(221,469	)		—
Interest expense		—			(17,868	)
Gain from write-off of debt		58,984			410,482
Income from Discontinued Operations	$	23,628		$	392,614

Commitments and contingencies that were discontinued as a result of the transfer of the assets to National Scientific LLC as follows:

On November 1, 2005, the Company entered into a financing program with Strategic Working Capital Fund, LP. The terms of this program included a five-year note payable at maturity in November 2010 for $175,000, at an annual interest rate of 8%. Interest was due and payable semi-annually on May 1st and November 1st for each year in which the note is outstanding The transaction also included 1,200,000 restricted common shares and a conversion/exchange option to convert the principal amount and any unpaid interest of the Note into common shares at a per share conversion price of $0.0525. These shares included weighted average anti-dilution provisions, as well as piggyback registration rights. Additionally, the note had various put and call rights, and has a right to early payment under certain conditions after 2 years. The 1,200,000 restricted common shares were recorded at $0.043, which was the five-day average market closing price of our stock. The note and common stock were issued with a debt discount of $51,600 and a beneficial conversion feature of $9,933. The discount and beneficial conversion feature are being amortized to interest expense over the term of the note, which is approximately 60 months. The issuance of the shares resulted in deferred financing costs of $24,000. The deferred financing costs were amortized over term of the note, which is approximately 60 months, and are included in the statement of operations as offering costs. Management received a legal opinion and determined that this note is unenforceable and has been written off during fiscal year ended September 30, 2012 (See Note 7 – Debt Mitigation Program).

On February 24, 2005, March 28, 2005, May 2, 2005, and May 27, 2005 the Company’s former Chairman Michael Grollman made personal loans to the Company totaling $159,000 to assist it with working capital needs. The loans are evidenced by a demand note that provides for repayment within five business days of a demand notice from Mr. Grollman, with interest of 6% compounded annually from June 1, 2005. These loans were secured by an interest in the copyrights in the Company’s iBus software and designs.  During the three months ended September 30, 2007, these loans were paid down by $11,000. As of September 30, 2007, these loans had a balance outstanding of $148,000 and the interest rate going forward was adjusted to 8% compounded annually from October 1, 2007.  On September 30, 2007, the Company converted unpaid interest of $13,300 on demand notes payable to Michael Grollman into a new demand note of $13,300 that provided for repayment within five business days of a demand notice from Mr. Grollman, with interest of 8% compounded annually on October 1^st. Management received a legal opinion and determined this note is unenforceable and has been written off during fiscal year ended September 30, 2012 (See Note 7 – Debt Mitigation Program).

On April 27, 2006, the Company secured a short-term loan of $16,625 from a shareholder. The loan carries an origination/placement fee of $500 and has a perfectible security interest a) prior to delivery in any assets purchased for the fulfillment of a customer’s order dated March 16, 2006, and b) in any receivable resulting from the fulfillment of the customer’s purchase order. The interest rate on the loan was 12%. The transaction also included 100,000 warrants to purchase our common stock at $0.036 at any time before April 27, 2009 which have expired unexercised. The note had an approximate maturity date of June 15, 2006. Management received a legal opinion and determined this note is unenforceable and has been written off during fiscal year ended September 30, 2012 (See Note 7 – Debt Mitigation Program).

On May 31, 2006, we secured a short-term loan of $20,000 from a shareholder. The loan carried an origination/placement fee of $500 and has a perfectible security interest a) prior to delivery in any assets purchased for the fulfillment of Clover Park, WA’s order and b) in any receivable resulting from the fulfillment of the Clover Park purchase order. The interest rate on the loan was 12%. The transaction also included 100,000 warrants to purchase our common stock at $0.036 at any time before May 31, 2009 which expired unexercised. The note had a maturity date of July 10, 2006. Management received a legal opinion and determined this note is unenforceable and has been written off during fiscal year ended September 30, 2012 (See Note 7 – Debt Mitigation Program).

XML

NOTE 5. SOFTWARE

12 Months Ended

Sep. 30, 2013

Research and Development [Abstract]

NOTE 5. SOFTWARE

NOTE 5 – SOFTWARE

The following is a detail of software at September 30, 2013 and 2012:

	2013			2012
Source Code License	$	2,500		$	2,500
Software License		1,200,106			1,200,106
EMR Certification		23,000			—
Encryption Software Code		15,800			—
Acquisition of Doctor’s Network of America		10,000			4,000
Total intangible assets		1,251,406			1,202,606
Accumulated amortization of intangible assets (charged to cost of sales)		(423,485	)		(180,015	)
Accumulated impairment of assets		(10,000	)		(4,000	)
Total proprietary technology, net	$	817,921		$	1,022,591

The Company impaired an investment of $10,000 and $4,000 for the years ended September 30, 2013 and 2012, respectively, directly related to the acquisition of Doctors Network of America (“DNA”) operating in Jackson Mississippi. The Company is currently in litigation with the sellers of DNA relating to the collection of certain medical billings owed to the Company. As a result of the litigation, the Company deemed the investment to be impaired. The amortization expense was $243,470 and $180,015 for the years ended September 30, 2013 and 2012, respectively. The Company’s proprietary technology was placed into service starting in the second quarter of fiscal 2012.

Source Code License

On August 14, 2012, the Company, through a comprehensive agreement (the “License Agreement”) with MediSouth, LLC, (“MediSouth”) has purchased a complete source code license (the “License”) and will integrate and enhance this feature set as part of its ever expanding Cloud-MD Office product suite.

The License Agreement requires the following:

a)	That MediSouth will provide the Companywith all software updates for the License within 5 working days of MediSouthimplementing those same software updates in its own production version of the License.
b)	The Company has the right to modify the software contained in the License to meet its operational needs.
c)	The Company shall provide to MediSouth, with the permission of each affected Companyclient, the de-identified purchasing data which is any data that would identify a patient such as social security numbers, date of birth, health condition, among others that it collects as a result of the Company’s clients utilizing the embedded Medical Supplies and Pharmaceutical Inventory Management functionality provided by the License.
e)	MediSouth shall receive 100,000 shares of the Company’s non-dilutable, commonstock with a one (1) year trading restriction.
f)	The Company may not sell the License, transfer the License, allow any other entity to use the License as part of that entity's software application or transfer any rights to another party to use the License separately from the Company’s products in which the License is embedded.

The fair value of the consideration and the assets acquired is based on the aggregate value of the 100,000 shares of common stock issued in exchange for the software. The total fair value on August 14, 2012 was $2,500.

Encryption Software Code

On November 21, 2012, the Company, through a purchase agreement with CipherSmith, LLC, purchased a complete source code, intellectual property rights, all computer software or algorithm licensed or sold under CipherSmith, and appropriate copy rights, patents, mask works, trademarks, service marks, internet domain names or world wide web URS. The Company issued 500,004 shares of its common stock as payment for the acquisition. The fair value of the consideration and the assets acquired is based on the aggregate fair value of the common stock issued in exchange for the software. The total fair value of the shares of common stock issued on the date of grant was $15,800.

Doctors Network of America

On June 22, 2012, the Company entered into an acquisition agreement that closed on March 16, 2013. The Company agreed to acquire DNA in Flowood, Mississippi from Krooss Medical Management Systems, LLC (“Krooss”) for 500,000 shares of common stock. As of September 30, 2012, only 200,000 shares of common stock were issued as a deposit, which was valued at $4,000 based on the market value on the date of grant. At the closing of the transaction on March 16, 2013, the Company issued an additional 300,000 shares of common stock which were valued at $6,000 based on the market value on the date of grant.

Subsequent to the transaction closing on March 16, 2013, the sellers refused to pay for medical billing process transaction fees in accordance with their contracts in the amount of approximately $200,000. The Company and the sellers are currently in litigation over the disputed transaction fees of $200,000. The Company has recorded an accumulated impairment of the acquired asset in the amount of $10,000 and $4,000 for the years ended September 30, 2013 and 2012, respectively.

XML

NOTE 7. DEBT MITIGATION PROGRAM (Tables)

12 Months Ended

Sep. 30, 2013

OTHER (INCOME) AND EXPENSES

Debt Mitigation Program

	September 30,			September 30,
	2013			2012
Debt Mitigation Program:
Accounts payable and accrued expenses	$	58,984		$	66,281
Disputed salaries & vacation of former officers		—			968,645
Disputed salary – former employee		—			20,256
Disputed payroll taxes for back pay of former officers		—			84,701
Disputed interest		—			227,083
Accrued interest		42,137			—
Shareholders demand note payable at 12%		—			11,625
Shareholders demand note payable at 12%		—			20,000
Unsecured note payable at 8% interest due in November 2010, interest payments in default		—			175,000
Total debt mitigation program	$	101,121		$	1,573,591
Gain on write off of debt	$	(58,984	)	$	(410,483	)
Additional paid-in capital (1)	$	(42,137	)	$	(1,163,108	)

XML

NOTE 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Sep. 30, 2013

Accounting Policies [Abstract]

Use of Estimates and Assumptions

Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net revenues and expenses recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates. The Company’s most significant estimates relate to the valuation of its proprietary technology and the valuation of its common stock.

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  At September 30, 2013 and 2012, cash and cash equivalents include cash on hand and cash in the bank. The FDIC insures these deposits up to $250,000.

Long-Lived Assets

Long-Lived Assets

Long-lived assets are evaluated for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows to the recorded value of the asset. If impairment is indicated, the asset is written down to its estimated fair value.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The Company's financial instruments consist primarily of cash, accounts payable and accrued expenses, and debt. The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments.  

Fair value is defined as an exit price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  Within the measurement of fair value, the use of market-based information is prioritized over entity specific information and a three-level hierarchy for fair value measurements is used, based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.

The three-level hierarchy for fair value measurements is defined as follows:

• Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets; liabilities in active markets;

• Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly, including inputs in markets that are not considered to be active; or directly or indirectly including inputs in markets that are not considered to be active;

• Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement

The following table summarizes fair value measurements by level at September 30, 2013 and 2012 for assets measured at fair value on a recurring basis:

	Level 1		Level 2		Level 3		Total
At September 30, 2013
Software development net of amortization	$	—	$	—	$	817,921	$	817,921
Total Proprietary Technology	$	—	$	—	$	817,921	$	817,921
At September 30, 2012
Software development net of amortization	$	—	$	—	$	1022,591	$	1,022,591
Total Proprietary Technology	$	—	$	—	$	1,022,591	$	1,022,591

Accounts Receivable and Allowance for Uncollectible Accounts

Accounts Receivable and Allowance for Uncollectible Accounts

Substantially all of the Company’s accounts receivable balance is related to trade receivables. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company will maintain allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments for services. Accounts with known financial issues are first reviewed and specific estimates are recorded. The remaining accounts receivable balances are then grouped in categories by the number of days the balance is past due, and the estimated loss is calculated as a percentage of the total category based upon past history. Account balances are charged against the allowance when it is probable the receivable will not be recovered. As of September 30, 2013 and 2012, the Company had no valuation allowance for the Company’s accounts receivable.

During the year ended September 30, 2013, the Company wrote-off accounts receivable of approximately $200,000. These accounts receivable were from billing services performed in DNA, subsequent to our acquisition of the company from Krooss Medical Management Systems, LLC (“Krooss”) which was completed during the year ended September 30, 2013. These amounts were deemed uncollectible due to our pending litigation with Krooss, and were recorded in loss from discontinued operations.

Income Taxes

Income Taxes

The Company utilizes the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for operating loss and tax credit carry-forwards and for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that the value of such assets will be realized.

The Company uses the two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. The Company considers many factors when evaluating and estimating the Company's tax positions and tax benefits, which may require periodic adjustments. At September 30, 2013, the Company did not record any liabilities for uncertain tax positions.

Revenue Recognition

Revenue Recognition

License revenue consists principally of revenue earned under software license agreements. The Company sells its software to a medical practitioner for direct payment or through a third party leasing company for direct payment to the Company. The third party lease agreement is a non-recourse debt and the Company is not responsible for the default of the medical practitioner. License revenue is generally recognized when a signed contract or other persuasive evidence of an arrangement exists, the software has been electronically delivered, the license fee is fixed or is measured on a paid user basis; and collection of the resulting receivable is probable. When contracts contain multiple elements wherein Vendor-Specific Objective Evidence (“VSOE”) exists for all undelivered elements, we account for the delivered elements in accordance with the “Residual Method.” VSOE of fair value for maintenance and support is established by a stated renewal rate, if substantive, included in the license arrangement or rates charged in stand-alone sales of maintenance and support. Revenue from subscription license agreements, which include software, rights to unspecified future products and maintenance, is recognized ratably over the term of the subscription period.

Provided all other revenue criteria are met, the upfront, minimum, non-refundable license fees from customers are generally recognized upon delivery and on-going royalty fees are generally recognized upon reports of new licenses issued. If there is significant uncertainty about the project completion or receipt of payment for professional services, revenue is deferred until the uncertainty is sufficiently resolved. VSOE of fair value of services is based upon stand-alone sales of those services.

Subscription revenue is generated from bandwidth and information storage. After the first year and each year thereafter that the software has been purchased and installed, the purchaser is required to pay an annual fee of $1,200, $1,500, $1,800, and $2,400, respectively. Subscription revenue is recognized ratably over the term of the agreement.

Transaction revenue is generated from the following services and recognized when transaction occurs:

· Electronic Remittance Advise $0.35 Electronic remittance transaction fee;

· Paper Claims $1.00 Paper claim fee;

· Carrier Direct $0.16 Carrier direct fee;

· Fast Forward $0.35 Fast forward transaction fee; and,

· Patient Credit $2.50 Automatic Debit processing per transaction paid by the patient

The Company has not incurred any transaction revenues in the year ended September 30, 2013.

Cost of License, and Subscription Revenues

Cost of License, and Subscription Revenues

Cost of license revenue is primarily comprised of the license-based royalties to third parties and production and distribution costs for initial product licenses. No costs were incurred for license revenue during the years ended September 30, 2013 and 2012.

Cost of subscription revenue is primarily comprised of the costs associated with the customer support personnel that provide maintenance, enhancement and support services to customers. No costs were incurred for subscription revenue or customer support during the years ended September 30, 2013 and 2012.

The amortization of acquired technology for products acquired through business combinations are considered as the cost of revenues. The acquired technology is amortized using the straight-line method over 5 years.

Sales Commissions

Sales Commissions

The Company pays commissions, including sales bonuses, to the direct sales force related to revenue transactions under sales compensation plans established annually. The commission payments are typically accrued on the date of sale and paid in the month following execution of the customer contracts. The Company paid commissions of $62,060 and $73,298 for the years ended September 30, 2013 and 2012, respectively.

Research and Development and Software Development Costs

Research and Development and Software Development Costs

Capitalization of certain software development costs are recorded after the determination of technological feasibility. Based on our product development process, technological feasibility is determined upon the completion of a working model. To date, costs incurred by us from the completion of the working model to the point at which the product is ready for general release have been insignificant. Accordingly, we have charged all such costs to research and development expense in the period incurred. Our research and development costs for the years ended September 30, 2013 and 2012 were $208,895 and $151,000, respectively.

Share-Based Compensation

Share-Based Compensation

The Company measures the cost of services received in exchange for an award of an equity instrument based on the grant-date fair value of the award.  Compensation cost is recognized over the vesting or requisite service period. The Black-Scholes option-pricing model is used to estimate the fair value of options or warrants granted. There were no options or warrants issued by the Company during the years ended September 30, 2013 and 2012.

Basic and Diluted Net Loss per Common Share

Basic and Diluted Net Loss per Common Share

Basic income (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period. The weighted average number of shares is calculated by taking the number of shares outstanding and weighting them by the amount of time that they were outstanding.  Diluted earnings per share reflects the potential dilution that could occur if stock options, warrants, and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company. As of September 30, 2013 and 2012, the Company had no potentially dilutive instruments outstanding.

Diluted loss per share is the same as basic loss per share during periods where net losses are incurred since the inclusion of the potential common stock equivalents would be anti-dilutive as a result of the net loss.  

Concentration of Credit Risk

Concentration of Credit Risk

All of the Company’s cash and cash equivalents are maintained in regional and national financial institutions. The Company has exposure to credit risk to the extent that its cash and cash equivalents exceed amounts covered by the U.S. federal deposit insurance; however, the Company has not experienced any losses in such accounts. In management’s opinion, the capitalization and operating history of the financial institutions are such that the likelihood of material loss is remote.

Subsequent Events

Subsequent Events

The Company has evaluated all transactions occurring between the end of its fiscal year, September 30, 2013, through the date of issuance of the financial statements for subsequent event disclosure consideration.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

No accounting standards or interpretations issued recently are expected to a have a material impact on the Company’s financial position, operations or cash flows.

XML

NOTE 9. RELATED PARTY TRANSACTIONS

12 Months Ended

Sep. 30, 2013

Related Party Transactions [Abstract]

NOTE 9. RELATED PARTY TRANSACTIONS

NOTE 9– RELATED PARTY TRANSACTIONS

On October 15, 2011, the Company issued 30,000,000 common shares to the CEO for the conversion of the debt issued in the principal amount of $1,200,106.

During the years ended September 30, 2013 and 2012, the CEO advanced the Company cash of $5,409 and $7,969, respectively. In addition, during the year ended September 30, 2012, the CEO made payments on the Company’s behalf of $25,236 on the Company’s line of credit. The Company repaid $31,000 and $188,410 of the advances in the years ended September 30, 2013 and 2012, respectively. The advances from the CEO are due on demand and do not accrue interest. As of September 30, 2013 and 2012, the amount owed to the CEO for advances was $0 and $25,591, respectively.

Employment Agreements

The Company entered into an employment agreement with its Chief Executive Officer on January 1, 2013.  The employment agreement will expire on January 1, 2018 and shall automatically renew for another 5 years unless terminated in accordance with the provisions of the employment agreement. The employment agreement provides for:

i.	A monthly salary of $20,833 subject to an annual increase of 10% and consistent with the Company policy applicable to other senior executives and officers and approval by the Board of Directors.
ii.	A cash bonus of 25% of his annual base salary each year if the Company reaches the following milestones (none of which were attained in 2013):

a.	The Company posts annual gross revenues on a consolidated basis of at least $5,000,000;
b.	The Company's earnings before the deduction of income taxes and amortization expenses (“EBITA”), including cash extraordinary items but before officer's bonuses, on a consolidated basis for any year is at least $1,000,000; or the completion of the delinquent SEC filings for five (5) years through September 30, 2013 or the Company obtains FINRA approval for any reverse stock splits.

iii.	The issuance of shares equal to 1% of the then issued and outstanding shares of the Company annually which is approximately 2,146,242, to be issued in 2013.
iv.	The issuance of common stock on each anniversary date of the employment agreement of 5,000,000 shares and issuance of common stock for every acquisition granting 5,000,000 shares for DNA, 5,000,000 shares for CipherSmith, LLC, and 1,000,000 shares for MediSouth, LLC.
v.	An automobile allowance of $1,500 per month.
vi.	A medical insurance allowance of $1,500 per month.
vii.	In the event the Executive's employment is terminated without cause, he will receive the entire contract remaining on the agreement.

The Company entered into an employment agreement with its Chief Financial Officer on January 1, 2013.  The employment agreement will expire January 1, 2018 and shall automatically renew for another 5 years unless terminated in accordance with the provisions of the employment agreement. The employment agreement provides for:

i.	A monthly salary of $12,500 per month subject to an annual increase of 10% per year and consistent with the Company policy applicable to other senior executives and officers and approval by the Board of Directors.
ii.	A cash bonus of 25% of her annual base salary each year if the Company reaches the following milestones (none of which were attained in 2013):

a.	The Company posts annual gross revenues on a consolidated basis of at least $5,000,000;
b.	The Company's EBITA, including cash extraordinary items but before officer's bonuses, on a consolidated basis for any year is at least $1,000,000; or the completion of the delinquent SEC filings for five (5) years through September 30, 2013 or the Company obtains FINRA approval for any reverse stock splits.

iii.	The issuance of shares equal to 1% of the then issued and outstanding shares of the Company annually, which is approximately 2,146,242 to be issued in 2013
iv.	The issuance of common stock on each anniversary date of the employment agreement of 5,000,000 shares and issuance of common stock for every acquisition granting 3,000,000 shares for DNA, 3,000,000 shares for CipherSmith, LLC, and 750,000 shares for MediSouth, LLC.
v.	An automobile allowance of $1,000 per month.
vi.	A medical insurance allowance of $1,500 per month.
vii.	In the event the Executive's employment is terminated without cause he will receive the entire contract remaining on the agreement.

XML

NOTE 7. DEBT MITIGATION PROGRAM

12 Months Ended

Sep. 30, 2013

OTHER (INCOME) AND EXPENSES

NOTE 7. DEBT MITIGATION PROGRAM

NOTE 7 – DEBT MITIGATION PROGRAM

The Company determined that the statute of limitations for certain of the Company’s creditors to enforce collection of any amounts they might be owed has now elapsed. Based on the determinations and findings, during the years ended September 30, 2013 and 2012, the Company wrote off $101,121 and $1,573,591, respectively, in creditor liabilities which were all previously included in current liabilities in the accompanying balance sheet. As a result of these write-offs, the Company recognized a gain on the write off of liabilities in the amount of $58,984 and $410,482 from third party liabilities, respectively, which was recorded in income from discontinued operations, and additional paid-in capital of $42,137 and $1,163,109 for related party liabilities, respectively. The Company will continue to conduct this analysis going forward and write-off obligations when such obligations are no longer enforceable based on applicable law.

The following liabilities, through the opinion of legal counsel, were determined by the Company as unenforceable.

	September 30,			September 30,
	2013			2012
Debt Mitigation Program:
Accounts payable and accrued expenses	$	58,984		$	66,281
Disputed salaries & vacation of former officers		—			968,645
Disputed salary – former employee		—			20,256
Disputed payroll taxes for back pay of former officers		—			84,701
Disputed interest		—			227,083
Accrued interest		42,137			—
Shareholders demand note payable at 12%		—			11,625
Shareholders demand note payable at 12%		—			20,000
Unsecured note payable at 8% interest due in November 2010, interest payments in default		—			175,000
Total debt mitigation program	$	101,121		$	1,573,591
Gain on write off of debt	$	(58,984	)	$	(410,483	)
Additional paid-in capital (1)	$	(42,137	)	$	(1,163,108	)

(1) All amounts that were owed to related parties in prior years were recorded to paid-in-capital.

XML

NOTE 8. COMMITMENTS AND CONTINGENCIES

12 Months Ended

Sep. 30, 2013

COMMITMENTS AND CONTINGENCIES

NOTE 8. COMMITMENTS AND CONTINGENCIES

NOTE 8– COMMITMENTS AND CONTINGENCIES

Rent expense for the years ended September 30, 2013 and 2012 was $0 for both years.

The Company entered into an agreement to purchase the assets of DNA in June 2012 and after due diligence by both parties the transaction closed on March 16, 2013. Subsequent to the transaction closing on March 16, 2013, the sellers refused to pay for medical billing process transaction fees in accordance with their contracts of approximately $200,000. In June 2013, the Company sued the sellers in federal court for breach of contract among other causes of action of unpaid medical billing transaction fees of approximately $200,000. The Company believes it will be successful in its litigation. However, if the Company is successful, the collectability of the judgment is highly questionable.

The Company has issued shares to new investors since January 2, 2011, that have an anti-reverse common stock split clause if the Company reverse splits the common stock. The reverse split of common stock is determined by management but must be approved by Financial Industry Regulation Authority (“FINRA”). Presently FINRA has denied the Company the right to reverse split the common stock until all Securities and Exchange Commission filings are current and at that point and time the Company will submit a request to FINRA to execute a reverse split of the common stock of the Company. The current investors holding anti-reverse split stock will have the right to hold the same number of shares of common stock as status quo after the reverse split. The anti-reverse split common stock protection is only for stock subject to reverse split and once the Company declares a reverse split and it is completed, the anti-reverse split protection will be terminate and shareholders that received anti-reverse split stock will be held with regular stockholders as the Company proceeds forward. In accordance with the anti-reverse split provision, no further shares will be issued to the anti-reverse split shareholders once the reverse split is approved and completed.

As discussed in Note 7, the Company has written off $101,121 and $1,573,591 in accounts payable, accrued liabilities and notes payable based on the opinion of legal counsel for years ended September 30, 2013 and 2012. However, the related creditors could make a claim in the future in regards to these liabilities.

XML

NOTE 10. EQUITY

12 Months Ended

Sep. 30, 2013

Equity [Abstract]

NOTE 10. EQUITY

NOTE 10 - EQUITY

As of September 31, 2013, the Company was authorized to issue 650,000,000 common shares and 4,000,000 preferred shares at a par value of $0.01 per share.

Fiscal Year Ended September 30, 2013

Stock Issued for Cash

During the year ended September 30, 2013, the Company issued 217,500 shares of common stock for $143,000 in net proceeds as follows:

Date		Number of Shares		Proceeds
	October 14, 2012		20,000	$	20,000
	October 14, 2012		15,000		3,000
	October 14, 2012		18,750		2,500
	October 14, 2012		18,750		2,500
	December 6, 2012		15,000		3,000
	March 12, 2013		20,000		20,000
	March 12, 2013		20,000		20,000
	March 31, 2013		50,000		50,000
	April 17, 2013		20,000		20,000
	August 26, 2013		20,000		2,000
	Total		217,500	$	143,000

Stock Issued in Connection with Software Licensing and Subscription Agreements

During the year ended September 30, 2013, the Company issued 400,000 shares of common stock valued at $13,563 based on the market price on the date of grant, to customers, in regards to the purchase of software from the Company in accordance with the Software Licensing and Subscription Agreements. The fair values of the shares issued were recorded against software revenue recognized during the year ended September 30, 2013.

Date		Number of Shares		Fair Value
	October 14, 2012		50,000	$	1,300
	December 6, 2012		100,000		2,800
	March 12, 2013		50,000		1,750
	March 21, 2013		50,000		1,750
	March 21, 2013		50,000		1,750
	April 17, 2013		25,000		838
	April 17, 2013		50,000		1,675
	June 26, 2013		25,000		450
	September 30, 2013		50,000		1,250
	Total		400,000	$	13,563

Stock Issued for Services

During the year ended September 30, 2013, the Company issued 1,165,500 shares of common stock as compensation. The fair values of the shares were a total of $36,629 and were recorded at the market price on the date of grant. The issuances of stock were as follows:

Date		Number of Shares		Fair Value		Description of Services
	October 14, 2012		10,000	$	260	Commission
	December 6, 2012		100,000		2,800	Software Agreement
	March 12, 2013		50,000		1,750	Consulting
	March 21, 2013		167,000		5,845	Compensation
	March 21, 2013		500,000		17,500	Compensation
	April 17, 2013		78,500		2,630	Compensation
	May 1, 2013		20,000		522	Programming
	May 10, 2013		20,000		522	Programming
	August 26, 2013		100,000		1,800	Software Sales
	September 30, 2013		60,000		1,500	Programming
	September 30, 2013		60,000		1,500	Programming
	Total		1,165,500		36,629

Stock Issued for Assets Acquisition

On April 17, 2013, the Company issued 300,000 shares of common stock valued at $6,000, based on the market price on the date of grant, to Krooss Family Trust LLP for the acquisition of Doctors Network of America in Flowood, Mississippi and all of the assets of that company.

During year ended September 30, 2013, the Company issued 500,004 shares of common stock for the acquisition of CipherSmith software. Those shares were valued at $15,800 based on the market price on the dates of grant.

Fiscal Year Ended September 30, 2012

Stock Issued for Cash

During year ended September 30, 2012, the Company issued 190,000 shares of common stock for $68,000 as follows:

Date		Number of Shares		Proceeds
	October 15, 2011		25,000	$	5,000
	December 29, 2011		100,000		50,000
	June 21, 2012		65,000		13,000
	Total		190,000	$	68,000

Stock Issued in Connection with Software Licensing and Subscription Agreements

During the year ended September 30, 2012, the Company issued 941,333 shares of common stock valued at $19,301based on the market price on the date of grant, to customers, in regards to the purchase of software from the Company in accordance with the Software Licensing and Subscription Agreements. The fair values of the shares issued were recorded against software revenue recognized during the year ended September 30, 2012.

Date		Number of Shares		Fair Value
	December 29, 2011		100,000	$	1,150
	May 29, 2012		25,000		400
	May 29, 2012		50,000		800
	May 29, 2012		100,000		1,600
	May 29, 2012		150,000		2,400
	May 29, 2012		181,333		2,901
	August 9, 2012		300,000		9,000
	August 9, 2012		35,000		1,050
	Total		941,333	$	19,301

Stock Issued for Services

During the year ended September 30, 2012, the Company issued 33,000 shares of common stock for compensation. The fair values of the shares were a total of $624 and were recorded at the market price on the date of grant. The issuances of stock were as follows:

Date		Number of Shares		Fair Value		Description of Services
	December 5, 2011		8,000	$	82	Legal services
	December 5, 2011		10,000		102	Advisory service
	June 21, 2012		1,000		20	Commission
	August 9, 2012		14,000		420	Commission
	Total		33,000	$	624

Stock Issued for Debt Settlement

On October 15, 2011, the Company issued 30,000,000 shares of common stock for the conversion of debt from our CEO in the principal amount of $1,200,106.

Stock Issued for Assets Acquisition

The Company issued 200,000 shares of common stock on June 21, 2012 to Krooss Medical Management in accordance with the acquisition agreement for Doctors Network of America and recorded it at the market price of the common shares of $0.020 and as an investment in Krooss Medical Management of $4,000.

The Company issued 100,000 shares of common stock to MediSouth LLC in accordance with the acquisition agreement and recorded it at the market price of the common shares of $0.025 and as an investment in MediSouth LLC of $2,500.

Preferred Stock

The Company has authorized 4,000,000 shares of preferred stock, at $0.01 par value. The Corporation established and designates the rights and preferences of a Series A Preferred Stock, and reserve 4,000,000 shares of preferred stock against its issuance, such rights, preferences and designations. Each share of the Preferred Stock has 150 votes on all matters presented to be voted by the holders of our common stock. All 4,000,000 shares of preferred stock have been issued to our CEO & CFO on April 11, 2011.

XML

NOTE 9. RELATED PARTY TRANSACTIONS (Details Narrative) (USD $)

12 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2007

Related Party Transactions [Abstract]

Stock Issued during Period for Conversion of Debt, Shares

30,000,000

Stock Issued During Period Conversion of Debt, Value

$ 1,200,106

Related Party, Cash Advances

5,409

7,969

Related Party, Payments Made on Behalf of Compay

25,236

Repayment of Related Party Debt

(188,410)

(31,000)

(188,410)

Due to Related Party

$ 0

$ 25,591

$ 148,000

Employment Agreements

Employment Agreements

The Company entered into an employment agreement with its Chief Executive Officer on January 1, 2013.  The employment agreement will expire on January 1, 2018 and shall automatically renew for another 5 years unless terminated in accordance with the provisions of the employment agreement. The employment agreement provides for:

i.	A monthly salary of $20,833 subject to an annual increase of 10% and consistent with the Company policy applicable to other senior executives and officers and approval by the Board of Directors.
ii.	A cash bonus of 25% of his annual base salary each year if the Company reaches the following milestones (none of which were attained in 2013):

a.	The Company posts annual gross revenues on a consolidated basis of at least $5,000,000;
b.	The Company's earnings before the deduction of income taxes and amortization expenses (“EBITA”), including cash extraordinary items but before officer's bonuses, on a consolidated basis for any year is at least $1,000,000; or the completion of the delinquent SEC filings for five (5) years through September 30, 2013 or the Company obtains FINRA approval for any reverse stock splits.

iii.	The issuance of shares equal to 1% of the then issued and outstanding shares of the Company annually which is approximately 2,146,242, to be issued in 2013.
iv.	The issuance of common stock on each anniversary date of the employment agreement of 5,000,000 shares and issuance of common stock for every acquisition granting 5,000,000 shares for DNA, 5,000,000 shares for CipherSmith, LLC, and 1,000,000 shares for MediSouth, LLC.
v.	An automobile allowance of $1,500 per month.
vi.	A medical insurance allowance of $1,500 per month.
vii.	In the event the Executive's employment is terminated without cause, he will receive the entire contract remaining on the agreement.

The Company entered into an employment agreement with its Chief Financial Officer on January 1, 2013.  The employment agreement will expire January 1, 2018 and shall automatically renew for another 5 years unless terminated in accordance with the provisions of the employment agreement. The employment agreement provides for:

i.	A monthly salary of $12,500 per month subject to an annual increase of 10% per year and consistent with the Company policy applicable to other senior executives and officers and approval by the Board of Directors.
ii.	A cash bonus of 25% of her annual base salary each year if the Company reaches the following milestones (none of which were attained in 2013):

a.	The Company posts annual gross revenues on a consolidated basis of at least $5,000,000;
b.	The Company's EBITA, including cash extraordinary items but before officer's bonuses, on a consolidated basis for any year is at least $1,000,000; or the completion of the delinquent SEC filings for five (5) years through September 30, 2013 or the Company obtains FINRA approval for any reverse stock splits.

iii.	The issuance of shares equal to 1% of the then issued and outstanding shares of the Company annually, which is approximately 2,146,242 to be issued in 2013
iv.	The issuance of common stock on each anniversary date of the employment agreement of 5,000,000 shares and issuance of common stock for every acquisition granting 3,000,000 shares for DNA, 3,000,000 shares for CipherSmith, LLC, and 750,000 shares for MediSouth, LLC.
v.	An automobile allowance of $1,000 per month.
vi.	A medical insurance allowance of $1,500 per month.
vii.	In the event the Executive's employment is terminated without cause he will receive the entire contract remaining on the agreement.

XML

NOTE 5. SOFTWARE (Tables)

12 Months Ended

Sep. 30, 2013

Research and Development [Abstract]

Software Detail

	2013			2012
Source Code License	$	2,500		$	2,500
Software License		1,200,106			1,200,106
EMR Certification		23,000			—
Encryption Software Code		15,800			—
Acquisition of Doctor’s Network of America		10,000			4,000
Total intangible assets		1,251,406			1,202,606
Accumulated amortization of intangible assets (charged to cost of sales)		(423,485	)		(180,015	)
Accumulated impairment of assets		(10,000	)		(4,000	)
Total proprietary technology, net	$	817,921		$	1,022,591

XML

NOTE 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $)	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Accounting Policies [Abstract]
FDIC Insured Deposits	$ 250,000
Accounts Receivable, Write-Offs	200,000
Commissions	62,060	73,298
Research and Development Costs	208,895	151,000
Subscription Revenue in Year One	1,200
Subscription Revenue in Year Two	1,500
Subscription Revenue in Year Three	1,800
Subscription Revenue in Year Four	$ 2,400

XML

Shareholders Equity (USD $)	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning Balance, Amount at Sep. 30, 2011	$ 40,000	$ 1,805,269	$ 22,409,927	$ (26,229,970)	$ (1,974,774)
Beginning Balance, Shares at Sep. 30, 2011	4,000,000	180,526,879
Common stock issued for settlement of debt, Shares	0	30,000,000			30,000,000
Common stock issued for settlement of debt, Amount	0	300,000	900,106		1,200,106
Common stock issued for investment, Shares		200,000			200,000
Common stock issued for investment, Amount		2,000	2,000		4,000
Common stock issued for purchase of software, Shares		100,000			100,000
Common stock issued for purchase of software, Amount		1,000	1,500		2,500
Common stock issued for the purchase of billing software, Shares		941,333			941,333
Stock Issued for Software Purchase two, Value		9,413	9,888		19,301
Common stock issued for consulting services, Shares		33,000
Common stock issued for consulting services, Amount		330	294		624
Common stock issued for cash, Shares		190,000			190,000
Common stock issued for cash, Amount		1,900	66,100		68,000
Write-off of related party debt			1,163,109		1,163,109
Net loss				318,879	318,879
Ending Balance, Amount at Sep. 30, 2012	40,000	2,119,912	24,552,924	(25,911,091)	801,745
Ending Balance, Shares at Sep. 30, 2012	4,000,000	211,991,212
Common stock issued for settlement of debt, Amount
Common stock issued for investment, Shares		300,000			300,000
Common stock issued for investment, Amount		3,000	3,000		6,000
Common stock issued for purchase of software, Shares		500,004			500,004
Common stock issued for purchase of software, Amount		5,000	10,800		15,800
Common stock issued for the purchase of billing software, Shares		450,000			400,000
Stock Issued for Software Purchase two, Value		4,500	9,063		15,800
Common stock issued for consulting services, Shares		1,165,500
Common stock issued for consulting services, Amount		11,655	24,974		36,629
Common stock issued for cash, Shares		217,500			217,500
Common stock issued for cash, Amount		2,175	140,825		143,000
Write-off of related party debt			42,137		42,137
Net loss				(631,174)	(631,174)
Ending Balance, Amount at Sep. 30, 2013	$ 40,000	$ 2,146,242	$ 24,783,723	$ (26,542,265)	$ 427,700
Ending Balance, Shares at Sep. 30, 2013	4,000,000	214,624,216

XML

NOTE 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Sep. 30, 2013

Accounting Policies [Abstract]

NOTE 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 4 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. Significant accounting policies are as follows:

Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net revenues and expenses recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates. The Company’s most significant estimates relate to the valuation of its proprietary technology and the valuation of its common stock.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  At September 30, 2013 and 2012, cash and cash equivalents include cash on hand and cash in the bank. The FDIC insures these deposits up to $250,000.

Long-Lived Assets

Long-lived assets are evaluated for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows to the recorded value of the asset. If impairment is indicated, the asset is written down to its estimated fair value.

Fair Value of Financial Instruments

The Company's financial instruments consist primarily of cash, accounts payable and accrued expenses, and debt. The carrying amounts of such financial instruments approximate their respective estimated fair value due to the short-term maturities and approximate market interest rates of these instruments.  

Fair value is defined as an exit price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  Within the measurement of fair value, the use of market-based information is prioritized over entity specific information and a three-level hierarchy for fair value measurements is used, based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.

The three-level hierarchy for fair value measurements is defined as follows:

• Level 1 – inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets; liabilities in active markets;

• Level 2 – inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability other than quoted prices, either directly or indirectly, including inputs in markets that are not considered to be active; or directly or indirectly including inputs in markets that are not considered to be active;

• Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement

The following table summarizes fair value measurements by level at September 30, 2013 and 2012 for assets measured at fair value on a recurring basis:

	Level 1		Level 2		Level 3		Total
At September 30, 2013
Software development net of amortization	$	—	$	—	$	817,921	$	817,921
Total Proprietary Technology	$	—	$	—	$	817,921	$	817,921
At September 30, 2012
Software development net of amortization	$	—	$	—	$	1022,591	$	1,022,591
Total Proprietary Technology	$	—	$	—	$	1,022,591	$	1,022,591

Accounts Receivable and Allowance for Uncollectible Accounts

Substantially all of the Company’s accounts receivable balance is related to trade receivables. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company will maintain allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments for services. Accounts with known financial issues are first reviewed and specific estimates are recorded. The remaining accounts receivable balances are then grouped in categories by the number of days the balance is past due, and the estimated loss is calculated as a percentage of the total category based upon past history. Account balances are charged against the allowance when it is probable the receivable will not be recovered. As of September 30, 2013 and 2012, the Company had no valuation allowance for the Company’s accounts receivable.

During the year ended September 30, 2013, the Company wrote-off accounts receivable of approximately $200,000. These accounts receivable were from billing services performed in DNA, subsequent to our acquisition of the company from Krooss Medical Management Systems, LLC (“Krooss”) which was completed during the year ended September 30, 2013. These amounts were deemed uncollectible due to our pending litigation with Krooss, and were recorded in loss from discontinued operations.

Income Taxes

The Company utilizes the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for operating loss and tax credit carry-forwards and for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that the value of such assets will be realized.

The Company uses the two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. The Company considers many factors when evaluating and estimating the Company's tax positions and tax benefits, which may require periodic adjustments. At September 30, 2013, the Company did not record any liabilities for uncertain tax positions.

Revenue Recognition

License revenue consists principally of revenue earned under software license agreements. The Company sells its software to a medical practitioner for direct payment or through a third party leasing company for direct payment to the Company. The third party lease agreement is a non-recourse debt and the Company is not responsible for the default of the medical practitioner. License revenue is generally recognized when a signed contract or other persuasive evidence of an arrangement exists, the software has been electronically delivered, the license fee is fixed or is measured on a paid user basis; and collection of the resulting receivable is probable. When contracts contain multiple elements wherein Vendor-Specific Objective Evidence (“VSOE”) exists for all undelivered elements, we account for the delivered elements in accordance with the “Residual Method.” VSOE of fair value for maintenance and support is established by a stated renewal rate, if substantive, included in the license arrangement or rates charged in stand-alone sales of maintenance and support. Revenue from subscription license agreements, which include software, rights to unspecified future products and maintenance, is recognized ratably over the term of the subscription period.

Provided all other revenue criteria are met, the upfront, minimum, non-refundable license fees from customers are generally recognized upon delivery and on-going royalty fees are generally recognized upon reports of new licenses issued. If there is significant uncertainty about the project completion or receipt of payment for professional services, revenue is deferred until the uncertainty is sufficiently resolved. VSOE of fair value of services is based upon stand-alone sales of those services.

Subscription revenue is generated from bandwidth and information storage. After the first year and each year thereafter that the software has been purchased and installed, the purchaser is required to pay an annual fee of $1,200, $1,500, $1,800, and $2,400, respectively. Subscription revenue is recognized ratably over the term of the agreement.

Transaction revenue is generated from the following services and recognized when transaction occurs:

· Electronic Remittance Advise $0.35 Electronic remittance transaction fee;

· Paper Claims $1.00 Paper claim fee;

· Carrier Direct $0.16 Carrier direct fee;

· Fast Forward $0.35 Fast forward transaction fee; and,

· Patient Credit $2.50 Automatic Debit processing per transaction paid by the patient

The Company has not incurred any transaction revenues in the year ended September 30, 2013.

Cost of License, and Subscription Revenues

Cost of license revenue is primarily comprised of the license-based royalties to third parties and production and distribution costs for initial product licenses. No costs were incurred for license revenue during the years ended September 30, 2013 and 2012.

Cost of subscription revenue is primarily comprised of the costs associated with the customer support personnel that provide maintenance, enhancement and support services to customers. No costs were incurred for subscription revenue or customer support during the years ended September 30, 2013 and 2012.

The amortization of acquired technology for products acquired through business combinations are considered as the cost of revenues. The acquired technology is amortized using the straight-line method over 5 years.

Sales Commissions

The Company pays commissions, including sales bonuses, to the direct sales force related to revenue transactions under sales compensation plans established annually. The commission payments are typically accrued on the date of sale and paid in the month following execution of the customer contracts. The Company paid commissions of $62,060 and $73,298 for the years ended September 30, 2013 and 2012, respectively.

Research and Development and Software Development Costs

Capitalization of certain software development costs are recorded after the determination of technological feasibility. Based on our product development process, technological feasibility is determined upon the completion of a working model. To date, costs incurred by us from the completion of the working model to the point at which the product is ready for general release have been insignificant. Accordingly, we have charged all such costs to research and development expense in the period incurred. Our research and development costs for the years ended September 30, 2013 and 2012 were $208,895 and $151,000, respectively.

Share-Based Compensation

The Company measures the cost of services received in exchange for an award of an equity instrument based on the grant-date fair value of the award.  Compensation cost is recognized over the vesting or requisite service period. The Black-Scholes option-pricing model is used to estimate the fair value of options or warrants granted. There were no options or warrants issued by the Company during the years ended September 30, 2013 and 2012.

Basic and Diluted Net Loss per Common Share

Basic income (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period. The weighted average number of shares is calculated by taking the number of shares outstanding and weighting them by the amount of time that they were outstanding.  Diluted earnings per share reflects the potential dilution that could occur if stock options, warrants, and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company. As of September 30, 2013 and 2012, the Company had no potentially dilutive instruments outstanding.

Diluted loss per share is the same as basic loss per share during periods where net losses are incurred since the inclusion of the potential common stock equivalents would be anti-dilutive as a result of the net loss.  

Concentration of Credit Risk

All of the Company’s cash and cash equivalents are maintained in regional and national financial institutions. The Company has exposure to credit risk to the extent that its cash and cash equivalents exceed amounts covered by the U.S. federal deposit insurance; however, the Company has not experienced any losses in such accounts. In management’s opinion, the capitalization and operating history of the financial institutions are such that the likelihood of material loss is remote.

Subsequent Events

The Company has evaluated all transactions occurring between the end of its fiscal year, September 30, 2013, through the date of issuance of the financial statements for subsequent event disclosure consideration.

Recent Accounting Pronouncements

No accounting standards or interpretations issued recently are expected to a have a material impact on the Company’s financial position, operations or cash flows.

XML

NOTE 5. SOFTWARE - Software Detail (Details) (USD $)	Oct. 31, 2013	Sep. 30, 2013	Sep. 30, 2012
Acquisition of Doctors Network of America	$ 6,000	$ 10,000	$ 4,000
Total intangible assets		1,251,406	1,202,606
Accumulated amortization of intangible assets		(423,485)	(180,015)
Impairment of assets		(10,000)	(4,000)
Total intangible assets		817,921	1,022,591
Source Code License
Source Code License		2,500	2,500
Software License
Source Code License		1,200,106	1,200,106
EMR Certification
Source Code License		23,000
Encryption Software Code
Source Code License		$ 15,800

XML

NOTE 4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Sep. 30, 2013

Accounting Policies [Abstract]

Fair Value Measurements by Level

	Level 1		Level 2		Level 3		Total
At September 30, 2013
Software development net of amortization	$	—	$	—	$	817,921	$	817,921
Total Proprietary Technology	$	—	$	—	$	817,921	$	817,921
At September 30, 2012
Software development net of amortization	$	—	$	—	$	1022,591	$	1,022,591
Total Proprietary Technology	$	—	$	—	$	1,022,591	$	1,022,591